WO2016121908A1 - 抗alk2抗体 - Google Patents
抗alk2抗体 Download PDFInfo
- Publication number
- WO2016121908A1 WO2016121908A1 PCT/JP2016/052602 JP2016052602W WO2016121908A1 WO 2016121908 A1 WO2016121908 A1 WO 2016121908A1 JP 2016052602 W JP2016052602 W JP 2016052602W WO 2016121908 A1 WO2016121908 A1 WO 2016121908A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- nucleotide sequence
- Prior art date
Links
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims abstract description 162
- 102100034111 Activin receptor type-1 Human genes 0.000 claims abstract description 142
- 208000034970 Heterotopic Ossification Diseases 0.000 claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 208000007502 anemia Diseases 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims abstract 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 642
- 239000002773 nucleotide Substances 0.000 claims description 638
- 125000000539 amino acid group Chemical group 0.000 claims description 396
- 150000001413 amino acids Chemical class 0.000 claims description 389
- 235000001014 amino acid Nutrition 0.000 claims description 167
- 229940024606 amino acid Drugs 0.000 claims description 163
- 239000000427 antigen Substances 0.000 claims description 141
- 108091007433 antigens Proteins 0.000 claims description 141
- 102000036639 antigens Human genes 0.000 claims description 141
- 230000027455 binding Effects 0.000 claims description 140
- 239000012634 fragment Substances 0.000 claims description 136
- 102000040430 polynucleotide Human genes 0.000 claims description 109
- 108091033319 polynucleotide Proteins 0.000 claims description 109
- 239000002157 polynucleotide Substances 0.000 claims description 109
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 96
- 206010049811 Extraskeletal ossification Diseases 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 60
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 48
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 43
- 239000004471 Glycine Substances 0.000 claims description 40
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 38
- 235000004279 alanine Nutrition 0.000 claims description 38
- 229960003767 alanine Drugs 0.000 claims description 37
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 36
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 36
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 36
- 235000009582 asparagine Nutrition 0.000 claims description 32
- 229960001230 asparagine Drugs 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 29
- 239000004473 Threonine Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 28
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 28
- 239000004474 valine Substances 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 27
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 23
- 230000011164 ossification Effects 0.000 claims description 22
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 21
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 21
- 235000004554 glutamine Nutrition 0.000 claims description 21
- 230000000750 progressive effect Effects 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 235000003704 aspartic acid Nutrition 0.000 claims description 19
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 19
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 208000013558 Developmental Bone disease Diseases 0.000 claims description 17
- 206010072610 Skeletal dysplasia Diseases 0.000 claims description 17
- 230000011664 signaling Effects 0.000 claims description 17
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 15
- 229960000310 isoleucine Drugs 0.000 claims description 15
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000003449 preventive effect Effects 0.000 claims description 9
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 9
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 230000000472 traumatic effect Effects 0.000 claims description 7
- 229940122361 Bisphosphonate Drugs 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 150000004663 bisphosphonates Chemical class 0.000 claims description 6
- 239000003158 myorelaxant agent Substances 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims description 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 206010031240 Osteodystrophy Diseases 0.000 abstract 1
- 230000007941 heterotopic ossification Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 683
- 210000004027 cell Anatomy 0.000 description 113
- 239000002299 complementary DNA Substances 0.000 description 99
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 61
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 61
- 229940112869 bone morphogenetic protein Drugs 0.000 description 61
- 108090000623 proteins and genes Proteins 0.000 description 57
- 210000004408 hybridoma Anatomy 0.000 description 45
- 239000003814 drug Substances 0.000 description 43
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 35
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 32
- 229960002449 glycine Drugs 0.000 description 32
- 239000004475 Arginine Substances 0.000 description 27
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 27
- 235000009697 arginine Nutrition 0.000 description 27
- 229960003121 arginine Drugs 0.000 description 27
- 229940124597 therapeutic agent Drugs 0.000 description 27
- 108010076504 Protein Sorting Signals Proteins 0.000 description 26
- 239000013604 expression vector Substances 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 210000000988 bone and bone Anatomy 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 22
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 21
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 19
- 230000035772 mutation Effects 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 17
- 102000054953 human ACVR1 Human genes 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- 239000004472 Lysine Substances 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 15
- 235000018977 lysine Nutrition 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 14
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 11
- 101100490443 Mus musculus Acvr1 gene Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000012197 amplification kit Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 210000002027 skeletal muscle Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 102100029177 PDZ and LIM domain protein 3 Human genes 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 4
- 239000012097 Lipofectamine 2000 Substances 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000031146 intracellular signal transduction Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000004072 osteoblast differentiation Effects 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- -1 simadronate Chemical compound 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 201000005671 spondyloarthropathy Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 150000001483 arginine derivatives Chemical group 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 102000018511 hepcidin Human genes 0.000 description 3
- 108060003558 hepcidin Proteins 0.000 description 3
- 229940066919 hepcidin Drugs 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000000302 molecular modelling Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000003720 plasmablast Anatomy 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710105225 Activin receptor type-1 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 2
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108091006976 SLC40A1 Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000047644 human ACVRL1 Human genes 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 238000012004 kinetic exclusion assay Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150062697 ALK2 gene Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101710170231 Antimicrobial peptide 2 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- DWGWCWDDNTVOGF-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.Cl Chemical compound Cl.Cl.Cl.Cl.Cl.Cl DWGWCWDDNTVOGF-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- YTFHCXIPDIHOIA-DHZHZOJOSA-N Palovarotene Chemical compound C1=CC=NN1CC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 YTFHCXIPDIHOIA-DHZHZOJOSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 229940122954 Transcription factor inhibitor Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000000242 childhood brain stem neoplasm Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 150000002308 glutamine derivatives Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 229940034008 mannitol / sorbitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229950000473 palovarotene Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to a substance useful as a therapeutic and / or prophylactic agent for ectopic ossification and / or bone dysplasia, and a method for treating and / or preventing ectopic ossification and / or bone dysplasia.
- Non-Patent Documents 1-3 Progressive ossifying fibrodysplasia (Fibrodysplasia ossificans prostiva (FOP)) is an ectopic formation of cartilage or bone tissue in soft tissues such as skeletal muscles, tendons, and ligaments that normally do not form bone tissue. It is a hereditary disease (Non-Patent Documents 1-3). In this disease, ectopic ossification occurs throughout the body, including the face, and the ectopic bone tissue and existing bone tissue coalesce to significantly reduce the range of motion of the joint or cause body deformation (non- Patent Documents 1-3).
- Ectopic ossification in FOP is known to be acute ectopic ossification that progresses with a symptom called flare-up caused by muscle damage or viral infection in addition to chronic progression with growth (Non-Patent Document 1). Flare-up is an swelling mainly caused by an inflammatory reaction or long-term pain. In addition to being induced by bruises, falls, or intramuscular injections that cause muscle damage, there are sudden cases where the cause is not clear. It has been.
- ectopic bone tissue is formed after flare-up, so invasive medical practices such as biopsy and surgery are contraindicated, and ectopic bone tissue cannot be removed surgically.
- the ectopic bone tissue formed by FOP is formed by normal chondrocytes and osteoblasts and is metabolized in the same manner as normal bone tissue. It is not possible to remove only bone tissue.
- ALK2 Activin Like Kinase 2
- BMP bone morphogenetic protein
- Human and mouse ALK2 is a single-transmembrane protein having a signal peptide consisting of 509 amino acids, and functions as a transmembrane serine / threonine kinase receptor that binds to BMP (Non-patent Documents 1-3).
- BMP is bound in the extracellular region on the N-terminal side, and a downstream intracellular signal transduction system is activated by intracellular serine, threonine kinase.
- BMP receptors are classified into two types according to their structure and function: type I receptors including ALK2 and type II receptors (Non-Patent Documents 1-3).
- Type II receptors are constitutively active enzymes that exhibit kinase activity without binding BMP.
- type I receptor containing ALK2 is an inactive enzyme in a state where it does not bind to BMP, and exhibits kinase activity depending on the binding to BMP. This is considered to be because the kinase of type II receptor is phosphorylated using the intracellular domain of type I receptor as a substrate by binding to BMP, and the three-dimensional structure is changed to activate type I receptor.
- Non-Patent Documents 1-3 Non-Patent Documents 1-3.
- Non-patent Documents 1-3 Non-patent Documents 1-3.
- this constitutively active mutant of type I receptor is overexpressed, the intracellular signal transduction system is activated without applying BMP stimulation. Therefore, it is considered that the type I receptor is a responsible molecule that transmits BMP information from outside the cell to inside the cell.
- Non-patent Document 4 The mutation of ALK2 identified from familial and typical sporadic FOP cases was R206H mutant in which Arg206 was replaced with His. So far, all the gene mutations identified from FOP cases have been found to cause amino acid mutations in the intracellular region of ALK2. Many of these mutations in FOP cases are concentrated in the vicinity of the ATP-binding region in the intracellular region of ALK2 (Non-patent Document 5).
- Non-patent Document 6 When the ALK2 mutant identified by FOP is overexpressed in cultured cells, the intracellular signal transduction system of BMP is activated without applying BMP stimulation (Non-patent Document 6). Therefore, as a therapeutic agent for FOP, a small molecule inhibitor for ALK2 kinase, RNAi or exon skip method that specifically suppresses the expression of genetically mutated ALK2, a transcription factor inhibitor downstream of ALK2 receptor, and An osteoblast differentiation inhibitor by BMP signal has been developed (Patent Document 1 and Non-Patent Document 1-3).
- the currently developed low molecular weight compounds and nucleic acid FOP therapeutic agents are all expected to permeate the cell membrane and inhibit the ALK2 signal in the cell.
- an effective drug delivery method has not been established for nucleic acid drugs, and problems remain such that kinase inhibitors have low specificity for other ALK receptor families having high identity to ALK2. Therefore, development of a new therapeutic agent having high specificity for ALK2 with respect to FOP is desired.
- Antibody drugs that act on the extracellular domain of ALK2 to inhibit signals are highly safe treatments that utilize the physiological immune system. An antibody drug is easy to deliver a stable drug via the bloodstream, and does not act on other ALK receptor families with high identity, and can exhibit specificity that inhibits only ALK2. .
- an inhibitory action can be expected for various mutants in the intracellular region including ALK2 wild-type and novel mutants.
- ALK2 wild-type and novel mutants since it does not inhibit ALK3 that is expressed in cells throughout the body, a specific inhibitory antibody against ALK2 is different from a general osteoblast differentiation inhibitor in the growth, maintenance, and regeneration of normal skeletal tissue. Can be expected to be a drug with little impact.
- antibodies that specifically bind to ALK2 and have a therapeutic effect on FOP have not been known so far.
- An object of the present invention is to provide a substance useful as a therapeutic and / or prophylactic agent for ectopic ossification and / or bone dysplasia, and a method for treating and / or preventing ectopic ossification and / or dysplasia. There is to do.
- the present inventors diligently studied to solve the above-mentioned problems. As a result, the present inventors specifically bind to ALK2, and have a novel effect of treating and / or preventing ectopic ossification and / or bone dysplasia. The present invention was completed by successfully obtaining a novel antibody.
- the present invention includes the following inventions.
- A amino acid sequence shown in SEQ ID NO: 84
- B amino acid sequence consisting of amino acid residues 21 to 123 of the amino acid sequence shown in SEQ ID NO: 84
- c amino acid sequence shown in SEQ ID NO: 86
- a BMP signal that specifically binds to a polypeptide sequence consisting of at least 7 amino acids in the amino acid sequence encoded by the nucleotide sequence described in any one of (f) to (j) below and that is mediated by ALK2
- An antibody or antigen-binding fragment of the antibody that suppresses transmission An antibody or antigen-binding fragment of the antibody that suppresses transmission.
- nucleotide sequence shown in SEQ ID NO: 85 (g) nucleotide sequence consisting of nucleotide residues 728 to 1036 of the nucleotide sequence shown in SEQ ID NO: 85 (h) nucleotide sequence (i) sequence shown in SEQ ID NO: 87 (A polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence according to any one of nucleotide sequences (j) (f) to (i) consisting of nucleotide residues 728 to 1036 of the nucleotide sequence shown in No. 87 Sequence of polynucleotides that hybridize with stringent conditions
- any of (1) to (5), wherein the antibody and the antigen-binding fragment are a chimeric antibody, a humanized antibody, a human antibody, a single chain antibody, a bispecific antibody, or a multispecific antibody. Or an antigen-binding fragment thereof.
- At least one selected from the group consisting of an antibody comprising a region, a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 14, and an antibody comprising a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 16 The antibody according to any one of (1) to (6), which cross-competes for binding to two antibodies and the polypeptide, Antigen-binding fragment of the body.
- At least one selected from the group consisting of an antibody comprising a region, a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 14, and an antibody comprising a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 16 The antibody according to any one of (1) to (6), which binds to an epitope to which two antibodies bind, or antigen binding of the antibody Pieces.
- the heavy chain sequence includes a variable region having CDRH1, CDRH2, CDRH3, the CDRH1 is composed of an amino acid sequence represented by SEQ ID NO: 72, the CDRH2 is composed of an amino acid sequence represented by SEQ ID NO: 73, and the CDRH3 Consists of an amino acid sequence shown in SEQ ID NO: 74; and a light chain sequence comprising a variable region having CDRL1, CDRL2, CDRL3, said CDRL1 consisting of an amino acid sequence shown in SEQ ID NO: 75, Said CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 76, and said CDRL3 consists of the amino acid sequence shown in SEQ ID NO: 77;
- the antibody or antigen-binding fragment of the antibody according to any one of (1) to (8), wherein
- the antibody according to (15), comprising a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 4.
- An antigen-binding fragment of the antibody comprising a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 4.
- the heavy chain sequence includes a variable region having CDRH1, CDRH2, CDRH3, the CDRH1 is composed of an amino acid sequence represented by SEQ ID NO: 59, the CDRH2 is composed of an amino acid sequence represented by SEQ ID NO: 60, and the CDRH3 Consists of an amino acid sequence shown in SEQ ID NO: 61; and a light chain sequence comprising a variable region having CDRL1, CDRL2, CDRL3, said CDRL1 consisting of an amino acid sequence shown in SEQ ID NO: 62,
- the CDRL2 comprises an amino acid sequence represented by SEQ ID NO: 63 or 71, and the CDRL3 comprises an amino acid sequence represented by SEQ ID NO: 64;
- the antibody or antigen-binding fragment of the antibody according to any one of (1) to (8), wherein
- a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 6 and a light chain variable consisting of the 21st to 133rd amino acid residues of the amino acid sequence shown in SEQ ID NO: 8 or the amino acid sequence shown in SEQ ID NO: 36
- the heavy chain sequence includes a variable region having CDRH1, CDRH2, CDRH3, the CDRH1 is composed of an amino acid sequence represented by SEQ ID NO: 78, the CDRH2 is composed of an amino acid sequence represented by SEQ ID NO: 79, and the CDRH3 Consists of an amino acid sequence shown in SEQ ID NO: 80; and a light chain sequence comprising a variable region having CDRL1, CDRL2, CDRL3, said CDRL1 consisting of an amino acid sequence shown in SEQ ID NO: 81, Said CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 82, and said CDRL3 consists of the amino acid sequence shown in SEQ ID NO: 83;
- the antibody or antigen-binding fragment of the antibody according to any one of (1) to (10) and (13) to (14),
- the antibody according to (19), comprising a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 10 and a light chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 12.
- An antigen-binding fragment of the antibody comprising a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 10 and a light chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 12.
- the heavy chain sequence includes a variable region having CDRH1, CDRH2, CDRH3, the CDRH1 is composed of an amino acid sequence represented by SEQ ID NO: 65, the CDRH2 is composed of an amino acid sequence represented by SEQ ID NO: 66, and the CDRH3 Consists of the amino acid sequence shown in SEQ ID NO: 67; and the light chain sequence comprises a variable region having CDRL1, CDRL2, CDRL3, said CDRL1 consists of the amino acid sequence shown in SEQ ID NO: 68, The CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 69, and the CDRL3 consists of the amino acid sequence shown in SEQ ID NO: 70;
- the antibody or antigen-binding fragment of the antibody according to any one of (1) to (8) and (11) to (14),
- the antibody according to (21), comprising a heavy chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 14 and a light chain variable region sequence consisting of the amino acid sequence shown in SEQ ID NO: 16. An antigen-binding fragment of the antibody.
- the heavy chain comprises a constant region of a human immunoglobulin G1 heavy chain, a human immunoglobulin G2 heavy chain, or a human immunoglobulin G4 heavy chain
- the light chain comprises a constant region of a human immunoglobulin kappa light chain (1 ) To (24).
- A a heavy chain variable region sequence selected from the group consisting of the following amino acid sequences: a1) an amino acid sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 28; a2) an amino acid sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 30; a3) an amino acid sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 105; a4) an amino acid sequence having at least 95% identity with the amino acid sequence of a1) to a3); a5) an amino acid sequence having at least 99% identity with the amino acid sequence of a1) to a3); a6) an amino acid sequence in which one to several amino acid residues are substituted, deleted or added to the amino acid sequence of a1) to a3); and
- a heavy chain comprising an amino acid sequence comprising amino acid residues 20 to 472 of the amino acid sequence represented by SEQ ID NO: 30 and an amino acid sequence comprising amino acid residues 21 to 238 of the amino acid sequence represented by SEQ ID NO: 36
- a heavy chain comprising an amino acid sequence consisting of amino acid residues 20 to 468 of the amino acid sequence shown in SEQ ID NO: 105 and amino acids 21 to 238 of the amino acid sequence shown in SEQ ID NO: 36
- the antibody according to (33) which is an antibody consisting of a light chain comprising an amino acid sequence consisting of residues.
- a heavy chain comprising an amino acid sequence comprising amino acid residues 20 to 468 of the amino acid sequence represented by SEQ ID NO: 105 and an amino acid sequence comprising amino acid residues 21 to 238 of the amino acid sequence represented by SEQ ID NO: 36
- a heavy chain variable region sequence selected from the group consisting of the following amino acid sequences: a1) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 40; a2) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 42; a3) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 44; a4) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 46; a5) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 48; a6) an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 107;
- a heavy chain comprising an amino acid sequence consisting of amino acid residues 20 to 470 of the amino acid sequence shown in SEQ ID NO: 109 and amino acids 21 to 234 of the amino acid sequence shown in SEQ ID NO: 56
- the antibody according to (37) which is an antibody consisting of a light chain comprising an amino acid sequence consisting of residues.
- a heavy chain variable region sequence selected from the group consisting of the following amino acid sequences: a1) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 111; a2) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 113; a3) an amino acid sequence having at least 95% identity with the amino acid sequence of a1) or a2); a4) an amino acid sequence having at least 99% identity with the amino acid sequence of a1) or a2); a5) an amino acid sequence in which one to several amino acid residues are substituted, deleted or added to the amino acid sequence of a1) or a2); and (b) a light chain variable region selected from the group consisting of the following amino acid sequences: Array: b1) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 111; a2) an amino acid sequence consisting of amino acid residues 20 to
- a heavy chain variable region sequence selected from the group consisting of the following amino acid sequences: a1) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 121; a2) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 123; a3) an amino acid sequence having at least 95% identity with the amino acid sequence of a1) or a2); a4) an amino acid sequence having at least 99% identity with the amino acid sequence of a1) or a2); a5) an amino acid sequence in which one to several amino acid residues are substituted, deleted or added to the amino acid sequence of a1) or a2); and (b) a light chain variable region selected from the group consisting of the following amino acid sequences: Array: b1) an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 121; a2) an amino acid sequence consisting of amino acid residues 20 to
- a pharmaceutical composition comprising at least one of the antibody according to any one of (1) to (44) or an antigen-binding fragment of the antibody.
- At least one of the antibody or antigen-binding fragment of the antibody according to any one of (1) to (44), an anti-inflammatory agent, a steroid agent, a bisphosphonate, a muscle relaxant, and retinoin A pharmaceutical composition for treating and / or preventing ectopic ossification, comprising at least one selected from the group consisting of acid receptor (RAR) ⁇ agonists.
- RAR acid receptor
- Ectopic ossification is progressive ossification fibrosis (FOP), progressive bone dysplasia (POH), traumatic ectopic ossification, or ectopic after artificial joint replacement
- FOP progressive ossification fibrosis
- POH progressive bone dysplasia
- traumatic ectopic ossification or ectopic after artificial joint replacement
- composition according to (45) which is a therapeutic and / or prophylactic agent for anemia.
- DIPG diffuse bridge glioma
- a method of treating and / or preventing ectopic ossification characterized by comprising:
- RAR retinoic acid receptor
- Ectopic ossification is progressive ossification fibrosis (FOP), progressive bone dysplasia (POH), traumatic ectopic ossification, or ectopic after artificial joint replacement
- FOP progressive ossification fibrosis
- POH progressive bone dysplasia
- traumatic ectopic ossification or ectopic after artificial joint replacement
- the treatment and / or prevention method according to (52) or (53), wherein the method is sexual ossification.
- (59) (a) a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 27; a2) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 29; a3) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 104; a4) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) to a3); a5) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) to a3); a6) a nucleotide sequence possessed by a polynucleotide that hybridizes under stringent
- a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 39; a2) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 41; a3) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 43; a4) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 45; a5) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 47; a6) a nucleotide sequence consisting of nucleotide sequence consisting of
- (61) (a) a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 110; a2) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 112; a3) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) or a2); a4) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) or a2); a5) a nucleotide sequence possessed by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of a1) or a2); a6)
- (62) (a) a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 120; a2) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 122; a3) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) or a2); a4) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) or a2); a5) a nucleotide sequence possessed by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of a1) or a2); a6)
- a vector comprising any one of the polynucleotides according to any one of (58) to (62).
- a transformed host cell comprising any one of the polynucleotides according to any one of (58) to (62).
- a transformed host cell comprising the vector according to (63).
- a therapeutic agent and / or a preventive agent for ectopic ossification and / or abnormal bone formation can be obtained.
- FIG. 2 is a graph showing recognition of monoclonal antibodies produced by hybridomas A2-11E, A2-15A, A2-25C, and A2-27D to mouse ALK2-His & Fc (“mALK2-Fc”) and binding to human Fc. Medium was used as a control (“Control medium”). It is the graph which showed that the monoclonal antibody which hybridoma A2-11E, A2-15A, A2-25C, and A2-27D produce does not recognize the fluorescent protein EGFP expression cell.
- FIG. 5 is a graph showing that monoclonal antibodies produced by hybridomas A2-11E, A2-15A, A2-25C, and A2-27D recognize wild-type mouse ALK2-expressing cells (mALK2 (WT) -EGFP).
- FIG. 5 is a graph showing that monoclonal antibodies produced by hybridomas A2-11E, A2-15A, A2-25C, and A2-27D recognize wild-type human ALK2-expressing cells (hALK2 (WT) -EGFP).
- a graph showing that the monoclonal antibodies produced by the hybridomas A2-11E, A2-15A, A2-25C, and A2-27D specifically recognize only ALK2-expressing cells and not ALK1, ALK3, ALK6-expressing cells. It is.
- Monoclonal antibodies produced by hybridomas A2-11E, A2-15A, A2-25C, and A2-27D recognize wild-type ALK2-expressing cells and 12 types of ALK2 mutant-expressing cells identified by FOP. It is the graph which showed.
- BMP7-induced luciferase induced by BMP7 in HEK293A cells in which monoclonal antibodies produced by the hybridomas A2-11E, A2-15A, A2-25C, and A2-27D overexpress the wild-type and R206H mutants of ALK2 ( luc) is a graph showing that the activity is suppressed in a dose-dependent manner.
- FIG. 3 is a graph showing that chimerized antibodies cA2-15A and cA2-27D inhibit the differentiation of C2C12 cells induced by BMP into osteoblast-like cells in a dose-dependent manner.
- FIG. 5 shows the amino acid sequence of each CDR sequence of the A2-15A antibody. It is the figure which showed the amino acid sequence of each CDR arrangement
- FIG. 10 shows the amino acid sequence of each CDR sequence of the A2-11E antibody.
- FIG. 3 shows the amino acid sequence of each CDR sequence of the A2-25C antibody.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-15A-H1.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-15A-H4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-15A-L1.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-15A-L4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-15A-L6.
- FIG. 3 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-15A-L7.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H1.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H2.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H3.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H5.
- FIG. 3 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-27D-L1.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-27D-L2.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-27D-L3.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-27D-L4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of a DNA fragment containing a sequence encoding humanized hA2-27D-L5.
- FIG. 5 is a graph showing that humanized A2-15A antibody (IgG1) and humanized A2-27D antibody (IgG1) suppress BMP7-induced BMP-specific luciferase (luc) activity in a dose-dependent manner.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-15A-H4 IgG2 type.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H2-LALA.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-27D-H3-LALA.
- FIG. 3 is a graph showing that humanized A2-15A antibody (IgG2) and humanized A2-27D antibody (LALA) inhibit BMP7-induced BMP-specific luciferase (luc) activity in a dose-dependent manner.
- FIG. 3 shows that humanized A2-15A antibody (IgG2) and humanized A2-27D antibody (LALA) suppress ectopic bone induction in mouse skeletal muscle tissue induced by BMP7.
- FIG. 3 is a view showing an X-ray crystal structure of a complex of human ALK2-ECD and human chimeric cA2-27D-Fab.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-11E-H3.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-11E-H4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-11E-L2.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-11E-L3. It is the figure which showed the nucleotide sequence and amino acid sequence of humanized hA2-11E-L4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-25C-H3.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-25C-H4.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-25C-L1.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-25C-L2.
- FIG. 2 shows the nucleotide sequence and amino acid sequence of humanized hA2-25C-L3.
- Humanized A2-11E antibody (IgG1) and humanized A2-25C antibody (IgG1) showed dose-dependent inhibition of BMP-induced differentiation of C2C12 cells into osteoblast-like cells It is a graph.
- FIG. 3 is a diagram showing an X-ray crystal structure of a complex of human ALK2-ECD and human chimeric cA2-25C-Fab.
- the term “gene” includes not only DNA but also mRNA, cDNA, and cRNA.
- polynucleotide is used in the same meaning as a nucleic acid, and includes DNA, RNA, probes, oligonucleotides, and primers.
- polypeptide and “protein” are used without distinction.
- RNA fraction refers to a fraction containing RNA.
- cell includes cells in an individual animal and cultured cells.
- ALK2 is used in the same meaning as the ALK2 protein, and includes a wild type and a mutant (also referred to as a mutant).
- the “antigen-binding fragment of an antibody” is also referred to as “functional fragment of an antibody” and means a partial fragment of an antibody having binding activity with an antigen.
- Fab ′ which is a monovalent fragment of the variable region of an antibody obtained by treating F (ab ′) 2 under reducing conditions, is also included in the antigen-binding fragment of an antibody.
- the molecule is not limited to these molecules as long as it has the ability to bind to an antigen.
- These antigen-binding fragments include not only those obtained by treating full-length antibody protein molecules with appropriate enzymes, but also proteins produced in appropriate host cells using genetically engineered antibody genes. It is.
- epitope is also referred to as “antigen-binding site” and generally refers to an antigen site to which an antibody binds, consisting of at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, or at least 10 amino acids of an antigen.
- it means a partial peptide or partial tertiary structure of ALK2 to which a specific anti-ALK2 antibody binds.
- the epitope which is a partial peptide of ALK2 can be determined by a method well known to those skilled in the art such as an immunoassay. For example, it can be performed by the following method.
- Various partial structures of ALK2 are prepared.
- a known oligopeptide synthesis technique can be used. For example, after preparing a series of polypeptides sequentially shortened from the C-terminus or N-terminus of ALK2 by an appropriate length using a gene recombination technique well known to those skilled in the art, the reactivity of the antibody against them is examined. After determining the recognition site, the epitope can be determined by synthesizing shorter peptides and examining their reactivity with those peptides. In addition, an epitope that is a partial three-dimensional structure of ALK2 to which a specific ALK2 antibody binds can be determined by specifying an amino acid residue of ALK2 adjacent to the antibody by X-ray crystal structure analysis.
- the second anti-ALK2 antibody binds to the partial peptide or partial three-dimensional structure to which the first anti-ALK2 antibody binds, it can be determined that the first antibody and the second antibody have a common epitope. Also, confirm that the second anti-ALK2 antibody (cross) competes for binding of the first anti-ALK2 antibody to ALK2 (ie, the second antibody prevents binding of the first antibody to ALK2). Thus, even if the sequence or structure of a specific epitope is not determined, it can be determined that the first antibody and the second antibody have a common epitope. Further, when the first antibody and the second antibody bind to a common epitope and the first antibody has an activity such as an inhibitory activity of BMP signal via ALK2, the second antibody also has the same activity. I can expect that.
- CDRs complementarity determining regions
- the complementarity-determining region is also called a hypervariable domain, and is located in the variable region of the heavy and light chains of the antibody and has a particularly high primary structure variability.
- the polypeptide chains are separated at three locations on the primary structure of the polypeptide chain.
- the complementarity determining region of an antibody is expressed as CDRH1, CDRH2, CDRH3 from the amino terminal side of the heavy chain amino acid sequence, and the complementarity determining region of the light chain is lightly expressed.
- CDRL1, CDRL2, and CDRL3 are represented from the amino terminal side of the chain amino acid sequence. These sites are close to each other on the three-dimensional structure and determine the specificity for the antigen to be bound.
- hybridize under stringent conditions means to hybridize at about 50-70 ° C. (for example, 68 ° C.) in a commercially available hybridization solution ExpressHyb Hybridization Solution (Clontech), or After hybridization at about 50-70 ° C. (eg, 68 ° C.) in the presence of about 0.7-1.0 M NaCl using a filter on which DNA is immobilized, about 0.1-2 times the concentration of SSC Use a solution (single-concentration SSC consists of 150 mM NaCl, 15 mM sodium citrate. If necessary, the solution may contain about 0.1-0.5% SDS). Conditions that can be identified by washing at about 50-70 ° C. (eg 68 ° C.) At the same say that hybridizes under the same conditions.
- “several” when there are descriptions “1 to several” and “one or several” means 2 to 10. Preferably, it is 10 or less, more preferably 5 or 6 or less, and still more preferably 2 or 3.
- ALK2 The ALK2 gene is a responsible gene of FOP that encodes a kind of BMP receptor that induces ectopic bone formation in soft tissues including skeletal muscle tissues. Mutant ALK2 with amino acid substitutions has been found in familial and sporadic FOP cases.
- the mutant forms of human ALK2 include L196P (mutation in which 196th leucine is replaced by proline), delP197_F198insL (mutation in which 197th proline and 198th phenylalanine are deleted, and leucine is inserted), R202I (202 Arginine substituted with isoleucine), R206H (206th arginine substituted with histidine), Q207E (207th glutamine substituted with glutamic acid), R258S (258th arginine substituted with serine) ), R258G (mutation in which the 258th arginine is substituted with glycine), G325A (mutation in which the 325th glycine is substituted with alanine), G328E (variation in which the 328th glycine is substituted with glutamic acid) ), G328R (mutation in which the 328th glycine is replaced with arginine), G328W (mutation in which the 328
- ALK2 used in the present invention can be obtained by synthesis in vitro or by producing it in a host cell by genetic manipulation. Specifically, ALK2 cDNA is incorporated into a vector that can be expressed and then synthesized in a solution containing enzymes, substrates and energy substances necessary for transcription and translation, or other prokaryotic or eukaryotic host cells. The protein can be obtained by expressing ALK2 by transforming.
- ALK2 used in the present invention is ALK2 derived from mammals including humans and mice.
- the amino acid sequence and nucleotide sequence of human ALK2 can be obtained by referring to GenBank accession number NM-001105.
- SEQ ID NO: 84 the nucleotide sequence is also disclosed herein as SEQ ID NO: 85.
- the amino acid sequence and nucleotide sequence of mouse ALK2 is available by reference to GenBank accession number NP-0011033674, the amino acid sequence is also disclosed herein as SEQ ID NO: 86, and the nucleotide sequence is also disclosed herein as SEQ ID NO: 87.
- ALK2 is sometimes called ACVR1 (Activin A type I Receptor 1) or ACTR1 (Activin Receptor Type 1), which all indicate the same molecule.
- ALK2 cDNA can be obtained by, for example, polymerase chain reaction (hereinafter referred to as “PCR”) using a cDNA library expressing ALK2 cDNA as a template and a primer that specifically amplifies ALK2 cDNA (Saiki, R. et al. K., et al., Science, (1988) 239, 487-49).
- PCR polymerase chain reaction
- a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence encoding human or mouse ALK2, and that encodes a protein having a biological activity equivalent to ALK2, is also ALK2.
- a polynucleotide that is a splicing variant transcribed from a human or mouse ALK2 locus or a polynucleotide that hybridizes under stringent conditions thereto, and that encodes a protein having a biological activity equivalent to that of ALK2, is also ALK2. contained in cDNA.
- ALK2 It consists of an amino acid sequence of human or mouse ALK2, or an amino acid sequence obtained by subtracting, deleting, or adding one or several amino acids in the amino acid sequence obtained by removing the signal sequence from these sequences, and is equivalent to ALK2. Proteins having the biological activity of ALK2 are also included in ALK2. Furthermore, the amino acid sequence encoded by the splicing variant transcribed from the human or mouse ALK2 locus, or an amino acid sequence in which one or several amino acids are substituted, deleted or added, and ALK2 ALK2 also includes a protein having a biological activity equivalent to that of ALK2.
- Ectopic ossification means that a bone is formed in a site where bone is not originally present, and “abnormal bone formation” means that there is an abnormality in the shape and quality of existing bone.
- Ectopic ossification includes progressive ossification fibrodysplasia (FOP), progressive bone dysplasia (POH), traumatic ectopic ossification, ectopic nature after artificial joint replacement
- FOP progressive ossification fibrodysplasia
- POH progressive bone dysplasia
- traumatic ectopic ossification ectopic nature after artificial joint replacement
- Examples of “bone dysplasia” as ossification include spondyloarthritis (SpA) and ankylosing spondylitis (AS), but are not limited thereto.
- ALK2 is a transmembrane serine / threonine kinase receptor that binds BMP, binds BMP in the extracellular region on the N-terminal side, and is downstream in the intracellular signal transduction system by serine / threonine kinase in the cell.
- BMP Bone morphogenetic protein
- TGF- ⁇ transforming growth factor ⁇
- BMP-2 and BMP-4 are considered to have higher affinity for ALK3 than ALK2.
- ALK3 is expressed more ubiquitously than ALK2, it is considered that BMP-2 and BMP-4 are commonly used in experiments for inducing ectopic ossification at various sites.
- BMP-7 has a relatively high affinity for ALK2, and BMP-9 is generally considered to have a high affinity for ALK1, but it also has a relatively high affinity for ALK2. I know. Since ectopic ossification via ALK2 occurs in FOP, the efficacy against ectopic bone induction by the activation of AMP2 mediated signal by BMP-7 and BMP-9 is verified. It is considered that the presence or absence of therapeutic and / or prophylactic effects can be confirmed.
- BMP signaling via ALK2 can be analyzed by a model for inducing differentiation into osteoblasts by BMP using C2C12 cells.
- the antibody against ALK2 of the present invention can be obtained, for example, by the method described in WO2009 / 091048, WO2011 / 027808, or WO2012 / 133572. That is, a non-human animal is immunized with a target antigen, lymphoid fluid, lymphoid tissue, blood cell sample or bone marrow-derived cells are collected from the immunized animal, and the non-human animal plasma cells that specifically bind to the target antigen and / or Alternatively, plasmablasts are selected.
- An antibody gene against the target antigen is collected from the obtained plasma cells and / or plasma blasts, the base sequence thereof is identified, and the antibody or antibody fragment can be obtained based on the base sequence of the identified gene.
- antibodies or antibody fragments can be obtained by obtaining plasma cells and / or plasmablasts from the blood of a human-infected patient.
- the obtained antibodies can be screened for antibodies applicable to human diseases by testing the binding to ALK2. Examples of the monoclonal antibody thus obtained include A2-11E, A2-15A, A2-25C, and A2-27D.
- amino acid positions assigned to the CDR / FR characterizing the antibody are KABAT numbering (KABAT et al., Sequences of Proteins of Immunological Institute, 5th Ed. Public Health Health. (1991)).
- Hybridomas can be established by fusing antibody-producing cells that produce antibodies against ALK2 and myeloma cells to obtain monoclonal antibodies. Specific examples of such a method are described in WO2009 / 48072 (published on April 16, 2009) and WO2010 / 117011 (published on October 14, 2010). However, the method for obtaining a monoclonal antibody corresponds to an established field, and is not limited to the above specific examples.
- the antibody of the present invention has a therapeutic / preventive effect, for example, a polyclonal antibody, or a genetically engineered gene modified for the purpose of reducing the heterologous antigenicity against humans, etc.
- a therapeutic / preventive effect for example, a polyclonal antibody, or a genetically engineered gene modified for the purpose of reducing the heterologous antigenicity against humans, etc.
- type antibodies for example, chimeric antibodies, humanized antibodies, human antibodies and the like. These antibodies can be produced using known methods.
- the chimeric antibody examples include antibodies in which the variable region and the constant region (Fc) of the antibody are different from each other, for example, a chimeric antibody in which a variable region of a mouse or rat-derived antibody is joined to a human-derived constant region (Proc. Natl. Acad. Sci. USA, 81, 6851-6855 (1984)).
- a chimeric antibody in which a variable region of a mouse or rat-derived antibody is joined to a human-derived constant region (Proc. Natl. Acad. Sci. USA, 81, 6851-6855 (1984)).
- the chimeric antibody derived from A2-15A it consists of a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 472 of SEQ ID NO: 20 in the sequence listing, and amino acid residues 21 to 237 of SEQ ID NO: 22.
- an antibody consisting of a light chain having an amino acid sequence a chimeric antibody derived from A2-27D, a heavy chain having an amino acid sequence consisting of the 20th to 470th amino acid residues of SEQ ID NO: 24 in the Sequence Listing, and SEQ ID NO: 26
- or 234th amino acid residue can be mentioned.
- Humanized antibodies include antibodies in which only CDRs are incorporated into human-derived antibodies (see Nature (1986) 321, p.522-525), and by CDR grafting, the amino acid residues of some frameworks in addition to the CDR sequences.
- Examples of the antibody include an antibody (International Publication No. WO90 / 07861 pamphlet) transplanted to a human antibody.
- the humanized antibody derived from the A2-15A antibody includes all six CDR sequences of A2-15A and is included in the antibody of the present invention as long as it has binding activity to ALK2.
- the heavy chain variable region of the A2-15A antibody includes CDRH1 (GFTFSHYYMA) consisting of the amino acid sequence shown in SEQ ID NO: 59, CDRH2 (SITNSGGSINYRDSVKG) consisting of the amino acid sequence shown in SEQ ID NO: 60, and SEQ ID NO: 61.
- CDRH3 EGGENYGGYPPFAY
- the light chain variable region of the A2-15A antibody is represented by CDRL1 (RANQGVSLSRYNLMH) consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRL2 (RSSNLAS) consisting of the amino acid sequence shown in SEQ ID NO: 63, and SEQ ID NO: 64.
- CDRL3 QQSRESPFT
- the humanized antibody derived from the A2-27D antibody is included in the antibody of the present invention as long as it contains all six A2-27D CDR sequences and has binding activity to ALK2.
- the heavy chain variable region of the A2-27D antibody is represented by CDRH1 (GSTFSNYGMK) consisting of the amino acid sequence shown in SEQ ID NO: 65, CDRH2 (SISRSSTYYYADTVKG) consisting of the amino acid sequence shown in SEQ ID NO: 66, and SEQ ID NO: 67.
- CDRH3 AISTPFYWYFDF
- the light chain variable region of the A2-27D antibody is represented by CDRL1 (LASSSVSYMT) consisting of the amino acid sequence shown in SEQ ID NO: 68, CDRL2 (GTSNLAS) consisting of the amino acid sequence shown in SEQ ID NO: 69, and SEQ ID NO: 70.
- CDRL3 LHLTSYPPPYT
- the humanized antibody derived from the A2-11E antibody includes all six CDR sequences of A2-11E and is included in the antibody of the present invention as long as it has binding activity to ALK2.
- the heavy chain variable region of the A2-11E antibody includes CDRH1 (GFTFSNYYMY) consisting of the amino acid sequence shown in SEQ ID NO: 72, CDRH2 (SINTDGSTYYPDSVKG) consisting of the amino acid sequence shown in SEQ ID NO: 73, and SEQ ID NO: 74.
- CDRH3 STPNIPLAY
- the light chain variable region of the A2-11E antibody is represented by CDRL1 (KASQNIYKYLN) consisting of the amino acid sequence shown in SEQ ID NO: 75, CDRL2 (YSNSLQT) consisting of the amino acid sequence shown in SEQ ID NO: 76, and SEQ ID NO: 77.
- CDRL3 FQYSSGPT
- the amino acid sequences of these CDRs are also shown in FIG.
- the humanized antibody derived from the A2-25C antibody includes all six CDR sequences of A2-25C and is included in the antibody of the present invention as long as it has binding activity to ALK2.
- the heavy chain variable region of the A2-25C antibody includes CDRH1 (GFTFSYYAMS) consisting of the amino acid sequence shown in SEQ ID NO: 78, CDRH2 (SISRGGDNTYYRDTVKG) consisting of the amino acid sequence shown in SEQ ID NO: 79, and SEQ ID NO: 80.
- CDRH3 LNYNNYFDY
- the light chain variable region of the A2-25C antibody is represented by CDRL1 (QASQDIGNWLS) consisting of the amino acid sequence shown in SEQ ID NO: 81, CDRL2 (GATSLAD) consisting of the amino acid sequence shown in SEQ ID NO: 82, and SEQ ID NO: 83.
- CDRL3 LQAYSAPFT
- CDRL2 examples include CDRL2 in which one amino acid is substituted in the amino acid sequence shown in SEQ ID NO: 34.
- CDRL2 RSSNLAQ
- RSSNLAQ consists of an amino acid sequence shown by sequence number 71. The amino acid sequence of this CDR is also described in FIG.
- humanized antibodies derived from the A2-15A antibody include an amino acid sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 28 of the sequence listing, and 20 to 20 of the amino acid sequence shown in SEQ ID NO: 30.
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of the 142nd amino acid residue, or an amino acid sequence consisting of the 20th to 142nd amino acid residues of the amino acid sequence shown in SEQ ID NO: 105 of the Sequence Listing, and SEQ ID NO:
- a preferred combination includes a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 28 and amino acids 21 to 133 of the amino acid sequence shown in SEQ ID NO: 32.
- a more preferable combination is a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 472 of the amino acid sequence shown in SEQ ID NO: 28 and amino acid residues 21 to 238 of the amino acid sequence shown in SEQ ID NO: 32.
- An antibody comprising a light chain comprising the amino acid sequence comprising the amino acid residue of the th, a heavy chain comprising an amino acid sequence comprising the 20th to 472th amino acid residues of the amino acid sequence represented by SEQ ID NO: 30, and the amino acid represented by SEQ ID NO: 32 Consisting of a light chain comprising an amino acid sequence consisting of amino acid residues 21 to 238 of the sequence A heavy chain containing an amino acid sequence consisting of amino acid residues 20 to 472 of the
- Further preferred combinations include a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 142 of the amino acid sequence shown in SEQ ID NO: 30 and amino acid sequences 21 to 133 of SEQ ID NO: 36.
- a heavy chain comprising the amino acid sequence consisting of amino acid residues 20 to 472 of the amino acid sequence shown in SEQ ID NO: 30 and the 21st to 238th amino acid residues of the amino acid sequence shown in SEQ ID NO: 36 are used.
- An antibody comprising a light chain comprising an amino acid sequence comprising a group, or a heavy chain comprising an amino acid sequence comprising amino acid residues 20 to 468 of the amino acid sequence represented by SEQ ID NO: 105 and 21 of the amino acid sequence represented by SEQ ID NO: 36
- or the 238th amino acid residue can be mentioned.
- the most preferred combination is a heavy chain comprising an amino acid sequence consisting of amino acid residues 20 to 468 of the amino acid sequence shown in SEQ ID NO: 105 and amino acid residues 21 to 238 of the amino acid sequence shown in SEQ ID NO: 36.
- humanized antibodies derived from the A2-27D antibody include an amino acid sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 40 of the sequence listing, and an amino acid sequence shown in SEQ ID NO: 42 of the sequence listing Amino acid sequence consisting of 20th to 140th amino acid residues, amino acid sequence consisting of 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 44 of the sequence listing, amino acid sequence shown in SEQ ID NO: 46 of the sequence listing Amino acid sequence consisting of 20th to 140th amino acid residues, amino acid sequence consisting of 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 48, and 20th to 140th amino acid sequences of amino acid sequence shown in SEQ ID NO: 107 An amino acid sequence consisting of amino acid residues, or the amino acid sequence shown in SEQ ID NO: 109 A heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of 0 to 140th amino acid residues
- a preferred combination includes a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 40 and amino acids 21 to 129 of the amino acid sequence shown in SEQ ID NO: 50.
- the antibody which consists of a light chain containing the light chain variable region sequence which consists of a 129th amino acid residue can be mentioned.
- a heavy chain comprising an amino acid sequence consisting of amino acid residues 20 to 470 of the amino acid sequence shown in SEQ ID NO: 40 and amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 50
- An antibody comprising a light chain comprising the amino acid sequence comprising: a heavy chain comprising the amino acid sequence of amino acids 20 to 470 of the amino acid sequence represented by SEQ ID NO: 40; and 21 to 234 of the amino acid sequence represented by SEQ ID NO: 52
- An antibody comprising a light chain comprising an amino acid sequence comprising the amino acid residue of the th, a heavy chain comprising an amino acid sequence comprising the 20th to 470th amino acid residues of the amino acid sequence represented by SEQ ID NO: 40, and the amino acid represented by SEQ ID NO: 54
- An anti-light chain comprising an amino acid sequence consisting of amino acid residues 21 to 234 of the sequence
- a heavy chain comprising an amino acid sequence comprising the 20th to 470th amino acid residues of the amino
- Further preferred combinations include a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 42 and amino acid sequences 21 to 129 of the amino acid sequence shown in SEQ ID NO: 52.
- a heavy chain containing the amino acid sequence consisting of the 20th to 470th amino acid residues of the amino acid sequence shown in SEQ ID NO: 42 and the 21st to 234th amino acid residues of the amino acid sequence shown in SEQ ID NO: 52 are used.
- An antibody comprising a light chain comprising an amino acid sequence comprising the 234th amino acid residue, a heavy chain comprising an amino acid sequence comprising the 20th to 470th amino acid residues of the amino acid sequence represented by SEQ ID NO: 107, and SEQ ID NO: 52 Is it a light chain comprising an amino acid sequence consisting of amino acid residues 21 to 234 of the amino acid sequence?
- a heavy chain comprising an amino acid sequence comprising amino acid residues 20 to 470 of the amino acid sequence represented by SEQ ID NO: 109 and an amino acid comprising amino acid residues 21 to 234 of the amino acid sequence represented by SEQ ID NO: 56
- Mention may be made of antibodies consisting of a light chain comprising a sequence.
- the most preferred combination is a heavy chain comprising an amino acid sequence consisting of amino acid residues 20 to 470 of the amino acid sequence shown in SEQ ID NO: 107 and amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 52.
- An antibody consisting of a light chain comprising an amino acid sequence consisting of the 234th amino acid residue can be mentioned.
- humanized antibodies derived from the A2-11E antibody include an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 111 of the sequence listing, or 20 of the amino acid sequence shown in SEQ ID NO: 113.
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 137 to 137, and an amino acid sequence consisting of amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 115, shown in SEQ ID NO: 117
- a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 128 of the amino acid sequence or an amino acid sequence consisting of amino acid sequences 21 to 128 of the amino acid sequence shown in SEQ ID NO: 119 Any combination can be mentioned.
- a preferred combination includes a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 111 and amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO: 115.
- a more preferred combination is a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 467 of the amino acid sequence shown in SEQ ID NO: 111 and amino acid residues 21 to 233 of the amino acid sequence shown in SEQ ID NO: 115.
- An antibody comprising a light chain comprising an amino acid sequence comprising the amino acid residue of the th, a heavy chain comprising an amino acid sequence comprising the 20th to 467th amino acid residues of the amino acid sequence represented by SEQ ID NO: 111, and the amino acid represented by SEQ ID NO: 119 Contains an amino acid sequence consisting of amino acid residues 21 to 233 of the sequence
- humanized antibodies derived from the A2-25C antibody include an amino acid sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 121 of the sequence listing, or 20 of the amino acid sequence shown in SEQ ID NO: 123.
- a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 137 to 137, and an amino acid sequence consisting of amino acid residues 21 to 129 of the amino acid sequence shown in SEQ ID NO: 125, shown in SEQ ID NO: 127
- a light chain comprising a light chain variable region comprising an amino acid sequence comprising the 21st to 129th amino acid residues of the amino acid sequence, or an amino acid sequence comprising the 21st to 129th amino acid residues of the amino acid sequence represented by SEQ ID NO: 129 Any combination can be mentioned.
- a preferred combination includes a heavy chain comprising a heavy chain variable region sequence consisting of amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 121 and amino acids 21 to 129 of the amino acid sequence shown in SEQ ID NO: 125.
- a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 467 of the amino acid sequence shown in SEQ ID NO: 121 and amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 125 An antibody consisting of a light chain comprising the amino acid sequence consisting of: a heavy chain comprising the amino acid sequence of amino acids 20 to 467 of the amino acid sequence shown in SEQ ID NO: 121; and 21 to 234 of the amino acid sequence shown in SEQ ID NO: 127
- An antibody comprising a light chain comprising the amino acid sequence comprising the amino acid residue of the th, a heavy chain comprising the amino acid sequence comprising the 20th to 467th amino acid residues of the amino acid sequence represented by SEQ ID NO: 121, and the amino acid represented by SEQ ID NO: 129 Includes an amino acid sequence consisting of amino acid residues 21 to 234 of the sequence
- an anti-ALK2 human antibody means a human antibody having only the gene sequence of an antibody derived from a human chromosome.
- the anti-ALK2 human antibody is a method using a human antibody-producing mouse having a human chromosome fragment containing the heavy and light chain genes of a human antibody (Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133. Kuroiwa, Y. et.al., Nucl.Acids Res. (1998) 26, p.3447-3448; Yoshida, H. et.al., Animal Cell Technology: Basic and Applied Aspects.10. p.
- the endogenous immunoglobulin heavy chain and light chain loci are disrupted, and instead human artificial chromosome (HAC) vectors and mouse artificial chromosomes (Mouse artificial chromosomes).
- HAC human artificial chromosome
- Mouse artificial chromosomes mouse artificial chromosomes
- MAC chromosome
- a recombinant human monoclonal antibody is produced by transforming a eukaryotic cell with a cDNA encoding each of the heavy chain and light chain of such a human antibody, preferably a vector containing the cDNA, by genetic recombination technology.
- This antibody can also be obtained from the culture supernatant by culturing the transformed cells.
- eukaryotic cells preferably CHO cells
- mammalian cells such as lymphocytes and myeloma can be used as the host.
- a method for obtaining a human antibody derived from phage display selected from a human antibody library (Wormstone, IM et al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Mé, S. et.al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p.189-203; Siriwardena, D. et., Ophthalmology (2002) 109 (3), p. 427-431 etc.) are also known.
- a phage display method (Nature Biotechnology (2005), 23, (9), p. 1105) in which a variable region of a human antibody is expressed on a phage surface as a single chain antibody (scFv) and a phage that binds to an antigen is selected. ⁇ 1116) can be used. By analyzing the gene of the phage selected by binding to the antigen, the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined.
- an expression vector having the sequence is prepared, and introduced into a suitable host for expression to obtain a human antibody (WO92 / 01047, WO92 / 20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388, Annu. Rev. Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23 (9), p. 1105-1116).
- Antibodies having the same epitope as the antibody provided by the present invention are also included in the antibody of the present invention. Examples thereof include antibodies having the same epitope as the A2-11E antibody, A2-15A antibody, A2-25C antibody and / or A2-27D antibody.
- the epitope of such antibody is determined by identifying amino acid residues on the antigen adjacent to the antibody using X-ray structural analysis Can do.
- an amino acid residue on an antigen having an interaction distance with an antibody can be specified by binding an antibody or a fragment thereof and an antigen or a fragment thereof for crystallization, and conducting structural analysis.
- the interaction distance is 8 angstroms ( ⁇ ) or less, preferably 6 ⁇ or less, and more preferably 4 ⁇ or less.
- One or more amino acid residues having an interaction distance with such an antibody may constitute an antibody epitope (antigen-binding site). When there are two or more such amino acid residues, each amino acid may not be adjacent to each other on the primary sequence.
- a peptide containing the Fab fragment of the chimeric A2-27D antibody and the human ALK2 ECD fragment (amino acid numbers 21 to 123 of SEQ ID NO: 84) was bound, and (2% (v / v) Tacsimate pH 7.0, 100 mM HEPES pH 7.
- the body group is monoclinic
- the space group is C121
- b 37.32 ⁇
- the phase can be determined by performing a molecular replacement method using the three-dimensional structure coordinates (see Example 16).
- the A2-27D antibody recognizes a partial higher order structure on human ALK2.
- the amino acid residues having an interaction distance with the A2-27D antibody, that is, the epitopes are the 18th glutamic acid (Glu), the 19th glycine (Gly), and the 39th isoleucine.
- An antibody that binds to such an epitope or has an interaction distance with such an amino acid residue, an antigen-binding fragment thereof, or a modified form thereof is also encompassed in the antibody, the antigen-binding fragment thereof, or a modified form thereof of the present invention.
- the phase can be determined by performing a molecular replacement method using the three-dimensional structural coordinates (see Example 21).
- the A2-25C antibody recognizes a partial higher order structure on human ALK2.
- the amino acid residues having an interaction distance with the A2-25C antibody, that is, the epitopes are the 18th glutamic acid (Glu), the 19th glycine (Gly), and the 20th leucine. (Leu), 39th isoleucine (Ile), 40th asparagine (Asn), 41st aspartic acid (Asp), 42nd glycine (Gly), 43rd phenylalanine (Phe), 44th histidine ( His), 45th valine (Val), 46th tyrosine (Tyr), 84th threonine (Thr).
- An antibody that binds to such an epitope or has an interaction distance with such an amino acid residue, an antigen-binding fragment thereof, or a modified form thereof is also encompassed in the antibody, the antigen-binding fragment thereof, or a modified form thereof of the present invention.
- the above antibody can be selected for a suitable antibody by evaluating the binding property to the antigen by the method shown in Example 2, Example 6, Example 9 or Example 10.
- the dissociation constant of the antibody is, for example, 1 ⁇ 10 ⁇ 6 ⁇ 1 ⁇ 10 ⁇ 12 M, but is not limited to this range as long as the desired therapeutic or prophylactic effect can be obtained with the antibody of the present invention.
- the dissociation constant between the antibody and the antigen can be measured using Biacore T200 (GE Healthcare Bioscience) based on the detection principle of surface plasmon resonance (SPR).
- the binding rate constant ka1, dissociation rate constant kd1, and dissociation constant (KD) KD kd1 / ka1) can be obtained.
- the evaluation of the binding to ALK2 is not limited to the use of Biacore T200, but a device based on surface plasmon resonance (SPR) as a detection principle, KinExA (Sapidyne Instruments, Inc.) based on a binding equilibrium exclusion method (Kinetic Exclusion Assay), A BLItz system (Pall) or an ELISA (Enzyme-Linked Immunosorbent Assay) method using a bio-layer interferometry (Bio-Layer Interferometry) as a detection principle is also possible.
- SPR surface plasmon resonance
- KinExA Stemetic Exclusion Assay
- a BLItz system Pall
- ELISA Enzyme-Linked Immunosorbent Assay
- An example of another index for comparing the properties of antibodies is antibody stability.
- DSC Differential scanning calorimetry
- Tm thermal denaturation midpoint
- the difference in thermal stability can be compared by measuring the Tm value using DSC and comparing the values.
- Tm thermal denaturation midpoint
- a suitable antibody can be selected using stability as an index.
- Other indicators for selecting antibodies include high yields in suitable host cells and low aggregation in aqueous solutions. For example, since the antibody with the highest yield does not necessarily exhibit the highest thermal stability, it is necessary to select the most suitable antibody for human administration based on a comprehensive judgment based on the above-mentioned indicators. .
- the antibody of the present invention may be an antibody having a single heavy chain variable region and no light chain sequence.
- Such an antibody is called a single domain antibody (sdAb) or nanobody, and is actually observed in a camel or llama and reported to retain antigen-binding ability.
- sdAb single domain antibody
- nanobody single domain antibody
- the above antibody can also be interpreted as a kind of antigen-binding fragment of the antibody in the present invention.
- WO99 / 54342, WO2000 / 61739, WO2002 / 31140 and the like are known as techniques for regulating antibody sugar chain modification, but are not limited thereto.
- an antibody gene When an antibody gene is once isolated and then introduced into an appropriate host to produce an antibody, a combination of an appropriate host and an expression vector can be used.
- the antibody gene include a gene (or polynucleotide) encoding the heavy chain sequence of the antibody described in the present specification, a gene (or polynucleotide) encoding the light chain sequence, or those genes (or polynucleotides). And a combination of nucleotides).
- polynucleotide encoding the antibody or antibody component (heavy chain or light chain) are as follows.
- polynucleotide (a) and / or (b).
- A a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 27; a2) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 29; a3) a nucleotide sequence consisting of nucleotides 58 to 426 of the nucleotide sequence shown in SEQ ID NO: 104; a4) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) to a3); a5) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) to a3); a6) a nucleotide sequence possessed by
- polynucleotide (a) and / or (b).
- A a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 39; a2) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 41; a3) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 43; a4) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 45; a5) a nucleotide sequence consisting of nucleotides 58 to 420 of the nucleotide sequence shown in SEQ ID NO: 47;
- polynucleotide (a) and / or (b).
- A a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 110; a2) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 112; a3) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) or a2); a4) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) or a2); a5) a nucleotide sequence possessed by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleo
- polynucleotide (a) and / or (b).
- A a polynucleotide selected from the group consisting of the following nucleotide sequences: a1) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 120; a2) a nucleotide sequence consisting of nucleotides 58 to 411 of the nucleotide sequence shown in SEQ ID NO: 122; a3) a nucleotide sequence having at least 95% identity with the nucleotide sequence of a1) or a2); a4) a nucleotide sequence having at least 99% identity with the nucleotide sequence of a1) or a2); a5) a nucleotide sequence possessed by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a nucleotide sequence complementary to the
- the heavy chain sequence gene (or polynucleotide) and the light chain sequence gene (or polynucleotide) can be inserted into the same expression vector, or can be expressed separately. It can also be inserted into a vector.
- animal cells include mammalian cells such as COS cells (Gluzman, Y. Cell (1981) 23, p.175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC No. CRL), which are monkey cells.
- -1658 Chinese hamster ovary cells (CHO cells, ATCC CCL-61) dihydrofolate reductase-deficient strain (Urlaub, G. and Chasin, LA Proc. Natl. Acad. Sci. USA) (1980) 77, p. 4126-4220).
- CHO cells ATCC CCL-61
- dihydrofolate reductase-deficient strain Urlaub, G. and Chasin, LA Proc. Natl. Acad. Sci. USA) (1980) 77, p. 4126-4220.
- Escherichia coli and Bacillus subtilis can be mentioned, for example.
- An antibody can be obtained by introducing a desired antibody gene into these cells by transformation, and culturing the transformed cells in vitro. In the above culture method, the yield may vary depending on the sequence of the antibody. From the antibodies having equivalent binding activity, those that can be easily produced as pharmaceuticals can be selected using the yield as an index.
- IgG IgG1, IgG2, IgG3, IgG4
- IgM IgA (IgA1, IgA2)
- IgD or IgE preferably IgG or IgM
- IgG1, IgG2 or IgG4 can be mentioned.
- IgG1 When IgG1 is used as the isotype of the antibody of the present invention, the effector function can be adjusted by substituting a part of the amino acid residues in the constant region (WO88 / 07089, WO94 / 28027, WO94 / 29351). reference).
- IgG1 mutants include IgG1 LALA (IgG1-L234A, L235A), IgG1 LAGA (IgG1-L235A, G237A), and preferably IgG1 LALA.
- IgG4 When IgG4 is used as the isotype of the antibody of the present invention, by substituting a part of the amino acid residues in the constant region, it is possible to suppress the division specific to IgG4 and to extend the half-life (Molecular Immunology, 30, 1-105-108 (1993)).
- IgG4 variants include IgG4 pro (IgG4-S241P).
- the antibody of the present invention may be an antigen-binding fragment of an antibody having an antigen-binding portion of the antibody or a modified product thereof.
- a fragment of the antibody can be obtained by treating the antibody with a proteolytic enzyme such as papain or pepsin, or modifying the antibody gene by a genetic engineering technique and expressing it in an appropriate cultured cell.
- a fragment that retains all or part of the functions of the full-length antibody molecule can be referred to as an antigen-binding fragment of an antibody.
- Antibody functions generally include antigen-binding activity, activity that inhibits antigen activity, activity that enhances antigen activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and complement-dependence Mention may be made of cellular cytotoxic activity.
- the function of the antigen-binding fragment of the antibody in the present invention is ALK2 binding activity, preferably activity that inhibits ALK2 activity, more preferably activity that suppresses BMP signaling through ALK2. Most preferably, the activity is to suppress ectopic ossification and / or bone dysplasia.
- antibody fragments include Fab, F (ab ′) 2 , Fv, or single chain Fv (scFv) in which Fv of heavy chain and light chain are linked by an appropriate linker, diabody (diabody or diabodies), Examples include linear antibodies and multispecific antibodies formed from antibody fragments.
- Fab ′ which is a monovalent fragment of the variable region of an antibody obtained by treating F (ab ′) 2 under reducing conditions, is also included in the antibody fragment.
- the antibody of the present invention may be a multispecific antibody having specificity for at least two different antigens.
- a molecule binds to two types of antigens (ie, bispecific antibodies), but the “multispecific antibody” in the present invention is more than that (for example, three types). It includes an antibody having specificity for the antigens.
- the multispecific antibody of the present invention may be a full-length antibody or a fragment of such an antibody (for example, a bispecific antibody).
- Bispecific antibodies can be prepared by combining the heavy and light chains (HL pairs) of two types of antibodies, or by hybridizing hybridomas that produce different monoclonal antibodies to produce a bispecific antibody. It can also be produced by producing cells (Millstein et al., Nature (1983) 305, p. 537-539).
- the antibody of the present invention may be a single chain antibody (also referred to as scFv).
- a single-chain antibody is obtained by linking an antibody heavy chain variable region and light chain variable region with a polypeptide linker (Pluckthun, The Pharmacology of Monoclonal Antibodies, 113 (Rosenberg and Moore, edited by Springer Verlag, New). York, p. 269-315 (1994), Nature Biotechnology (2005), 23, p. 1126-1136)
- a BiscFv fragment produced by linking two scFvs with a polypeptide linker is used as a bispecific antibody. It can also be used.
- the heavy chain variable region and the light chain variable region are linked via a linker that does not form a conjugate, preferably a polypeptide linker (Huston, JS et al., Proc. Natl. Acad. Sci.U.S.A. (1988), 85, p.5879-5883).
- the heavy chain variable region and the light chain variable region in scFv may be derived from the same antibody or different antibodies.
- the polypeptide linker that links the variable regions for example, any single chain peptide consisting of 12 to 19 residues is used.
- the scFv-encoding DNA is a DNA encoding the heavy chain or heavy chain variable region of the antibody, and a DNA encoding the light chain or light chain variable region.
- an expression vector containing them and a host transformed with the expression vector can be obtained in accordance with conventional methods.
- ScFv can be obtained according to the method.
- These antibody fragments can be produced by a host after obtaining and expressing the gene in the same manner as described above.
- the antibody of the present invention may be one that has been increased in quantity and has increased affinity for the antigen.
- the antibody that multiplies may be one type of antibody or a plurality of antibodies that recognize multiple epitopes of the same antigen. Examples of the method for increasing the number of antibodies include binding of IgG CH3 domain and two scFvs, binding to streptavidin, introduction of helix-turn-helix motif, and the like.
- the antibody of the present invention may be a polyclonal antibody that is a mixture of a plurality of types of anti-ALK2 antibodies having different amino acid sequences.
- a polyclonal antibody a mixture of plural kinds of antibodies having different CDRs can be mentioned.
- a polyclonal antibody a mixture of cells producing different antibodies can be cultured, and an antibody purified from the culture can be used (see WO2004 / 061104).
- the antibody of the present invention may be an antibody having 80% to 99% identity compared to the heavy chain and / or light chain of the above antibody.
- identity shall have the general definition used in the art.
- The% identity refers to the percentage of the number of identical amino acids per total number of amino acids (including gaps) when the two amino acid sequences are aligned (aligned) for maximum amino acid identity.
- amino acid sequence in which 1 to several amino acid residues are substituted, deleted, and / or added to the heavy chain and / or light chain amino acid sequences, various actions equivalent to those of the above antibodies can be achieved. It is possible to select an antibody having.
- the number of amino acid residues to be substituted, deleted and / or added is generally 10 amino acid residues or less, preferably 5 to 6 amino acid residues, more preferably 2 to 3 amino acid residues or less. And most preferably 1 amino acid residue.
- deletion of these heavy chain sequences or modification of heavy or light chain sequences has an effect on the antigen-binding ability and effector functions (such as complement activation and antibody-dependent cytotoxicity) of antibodies. Does not reach.
- the present invention includes antibodies that have undergone such deletions or modifications, and deletions in which one or two amino acids have been deleted at the heavy chain carboxyl terminus, and such deletions that have been amidated (for example, carboxyls)
- a heavy chain in which the proline residue at the terminal site is amidated an antibody in which the amino terminal amino acid residue of the heavy chain or light chain is pyroglutamylated, and the like.
- the carboxyl-terminal deletion of the heavy chain of the antibody according to the present invention is not limited to the above type.
- the two heavy chains constituting the antibody according to the present invention may be either one of the full length and the heavy chain selected from the group consisting of the above-mentioned deletion forms, or a combination of any two of them. It may be a thing.
- the amount ratio of each deletion can be influenced by the type and culture conditions of cultured mammalian cells producing the antibody according to the present invention, but the main component of the antibody according to the present invention is the carboxyl in both of the two heavy chains. A case where one terminal amino acid residue is deleted can be mentioned.
- Blast algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, ZhangDangMl, Web. (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25: 3389-3402).
- Blast algorithm can be found on the Internet at www. ncbi. nlm. nih. It can also be used by accessing gov / blast. Note that two types of percentage values of Identity (or Identities) and Positivity (or Positivity) are calculated by the above Blast algorithm.
- the former is a value when amino acid residues are identical between two types of amino acid sequences whose identity is to be obtained, and the latter is a numerical value considering amino acid residues having similar chemical structures.
- the identity value is defined by having the identity value when the amino acid residues match.
- an antibody conjugated with various molecules such as polyethylene glycol (PEG) can also be used.
- PEG polyethylene glycol
- the antibody of the present invention may be one in which these antibody and another drug form a conjugate (Immunoconjugate).
- conjugate examples include those in which the antibody is bound to a radioactive substance or a compound having a pharmacological action (Nature Biotechnology (2005) 23, p. 1137-1146).
- the obtained antibody can be purified to homogeneity. Separation and purification of antibodies may be carried out using separation and purification methods used for ordinary proteins. For example, antibodies can be separated and purified by appropriately selecting and combining column chromatography, filter filtration, ultrafiltration, salting out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing, etc. (Stratesies) for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R.Marshak et al.eds, Cold Spring Harbor Laboratory Press (1996); Antibodies:. A Laboratory Manual.Ed Harlow and David Lane, Cold Spring Harbor Laboratory ( 988)) it is not intended to be limited thereto.
- chromatography examples include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, and adsorption chromatography.
- chromatography can be performed using liquid chromatography such as HPLC or FPLC.
- Examples of columns used for affinity chromatography include protein A columns and protein G columns.
- Hyper D Hyper D
- POROS Sepharose F. F. (GE health care) and the like.
- Drug containing anti-ALK2 antibody From the anti-ALK2 antibody obtained by the method described in the above-mentioned section "4. Production of anti-ALK2 antibody", an antibody that inhibits the biological activity of ALK2 can be obtained. Since these antibodies that inhibit the biological activity of ALK2 inhibit the biological activity of ALK2 in vivo, that is, BMP signaling through ALK2, as a medicine, treatment for ectopic ossification and / or bone dysplasia and It can be used as a preventive agent or / and a treatment and / or preventive agent for anemia.
- FOP progressive ossification fibrosis
- POH progressive bone dysplasia
- traumatic ectopic ossification artificial joint Ectopic ossification after replacement
- SpA spondyloarthritis
- AS ankylosing spondylitis
- DIPG diffuse pontine glioma
- FOP progressive ossification Dysplasia
- POH progressive bone dysplasia
- traumatic ectopic ossification or ectopic ossification after artificial joint replacement
- progressive ossification fiber if it is a dysplasia (FOP), if it is a disease resulting from BMP signaling via ALK2, it is not limited to these.
- FOP progressive ossification Dysplasia
- POH progressive bone dysplasia
- traumatic ectopic ossification or ectopic ossification after artificial joint replacement
- progressive ossification fiber if it is a disease resulting from BMP signaling via ALK2, it is not limited to these.
- fusion or deformation of fingers and toes, fusion or deformation of the cervical spine, etc. are also observed, and hearing loss is also observed, but these are also included in diseases caused by BMP signaling via ALK2.
- mutations have been observed in ALK2 in all FOP patients, and more than 10 mutation types have been reported so far. All of these mutations are known to be amino acid mutations (missense mutations) present in the intracellular region of the ALK2 protein, and there is no change in the amino acid sequence of the extracellular region. Since the antibody of the present invention binds to the extracellular region of ALK2, it can be used as a therapeutic and / or prophylactic agent for all FOP patients regardless of the type of mutation.
- the treatment of FOP means healing of symptoms of FOP, improvement of symptoms, reduction of symptoms, or suppression of progression of symptoms.
- ⁇ Prevention of FOP means avoiding or suppressing the occurrence of flare-up or ectopic ossification.
- Non-inherited ectopic ossification includes ectopic ossification after brain contusion, ectopic ossification after spinal cord injury, ectopic ossification after burn injury, ectopic bone after artificial joint replacement For example.
- immune cells such as neuropeptides, mast cells and macrophages has been reported as the cause of these non-inherent ectopic ossifications (J. Cell.
- the antibody of the present invention can be used not only for ectopic ossification in FOP but also as a therapeutic and / or prophylactic agent for non-inherited ectopic ossification.
- Hepcidin is known as a target gene whose transcription is positively controlled by the anemia BMP-ALK signaling pathway (see Blood, 118, 15 (2011)). Hepcidin is a peptide hormone produced mainly in the liver, and controls the degradation of a transporter (Ferroportin) involved in iron absorption expressed in the digestive tract (see Science, 306, 5704 (2004)). Since inhibition of Hepcidin function or suppression of expression level leads to promotion of iron uptake from the gastrointestinal tract through increase in expression level of Ferroportin, it has been reported that it may be a therapeutic drug for anemia (Pharmacol Ther, 146 (2015).). Therefore, the antibody of the present invention can also be used as a therapeutic and / or prophylactic agent for iron deficiency anemia by increasing iron absorption through suppression of hepcidin expression in the liver.
- the antibody of the present invention can also be used as a therapeutic and / or prophylactic agent for diffuse bridge glioma (DIPG).
- DIPG is a diffuse (invasive) astrocytic tumor found in the brainstem bridge, and is said to account for about 75-80% of childhood brainstem tumors. There is a report that the survival rate is reduced to about 10% in 2 years because the function is controlled (Khuong-Quung DA et al., Acta Neuropathol 124: 439-447, 2012).
- the antibody of the present invention can also be used as a therapeutic and / or prophylactic agent for DIPG.
- Examples of the above-mentioned anti-ALK2 antibody as a medicament were prepared from the A2-15A antibody, A2-27D antibody, A2-11E antibody, or A2-25C antibody by the method described in “4. Production of anti-ALK2 antibody”. Mention may be made of chimeric antibodies or humanized antibodies. In addition, chimeric antibodies, humanized antibodies and human antibodies having the same epitope as the A2-15A antibody, A2-27D antibody A2-11E antibody, and / or A2-25C antibody can also be used as medicaments.
- ALK2 biological activity includes, for example, luciferase assay using a BMP response element-inserted reporter plasmid, phosphorylation of SMAD1 / 5/8, BMP target gene This can be confirmed by measuring alkaline phosphatase activity in mouse myoblast C2C12 in which differentiation into osteoblasts was induced by expression analysis or stimulation with BMP ligand.
- the treatment or prevention effect of ectopic ossification or bone dysplasia of anti-ALK2 antibody using an in vivo experimental animal is, for example, an ectopic ossification induction model in which a BMP ligand-containing pellet is transplanted into a mouse muscle,
- anti-ALK2 antibody can be administered subcutaneously or intravenously to FOP model mice into which mutant ALK2 has been introduced, and the formation of ectopic bone can be confirmed.
- the anti-AKL2 antibody thus obtained is useful as a pharmaceutical, particularly as a pharmaceutical composition for the treatment or prevention of ectopic ossification such as progressive ossification fibrosis (FOP). .
- FOP progressive ossification fibrosis
- the anti-ALK2 antibody may be administered alone or in combination with at least one other ectopic ossification therapeutic agent for the treatment or prevention of ectopic ossification. it can.
- an anti-ALK2 antibody can be administered in combination with a therapeutically effective amount of a therapeutic agent.
- Other ectopic ossification treatments that can be administered in combination with anti-ALK2 antibodies include anti-inflammatory agents, steroids, bisphosphonates, muscle relaxants, retinoic acid receptor (RAR) ⁇ agonists, etc. However, it is not limited to these.
- anti-inflammatory agent examples include aspirin, diclofenac, indomethacin, ibuprofen, ketoprofen, naproxen, piroxicam, rofecoxib, celecoxib, azathioprine, penicillamine, methotrexate, sulfasalazine, leflunomide, infliximab, etanercept, etc. Piroxicam or celecoxib.
- steroid agent examples include prednisolone, beclomethasone, betamethasone, fluticasone, dexamethasone, hydrocortisone, and prednisolone is preferable.
- bisphosphonates include alendronate, simadronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, pamidronate, pyridronate, risedronate, tiludronate, zoledronate, and preferably pamidronate. Or zoledronate.
- muscle relaxant examples include cyclobenzaprine, metaxalone, baclofen and the like, preferably baclofen.
- retinoic acid receptor ⁇ agonists examples include Palovarotene and the like.
- two, three or more other therapeutic agents may be administered, and these other therapeutic agents may be of the same formulation. It can be administered simultaneously by encapsulating in. Other therapeutic agents and the anti-ALK2 antibody can be administered simultaneously by encapsulating them in the same preparation. Alternatively, the anti-ALK2 antibody and other therapeutic agent can be encapsulated in separate preparations and administered simultaneously. Furthermore, another drug and anti-ALK2 antibody can be administered separately in succession.
- a therapeutic agent containing an anti-ALK2 antibody or an antigen-binding fragment of the antibody as an active ingredient is administered after administration of another therapeutic agent, or an anti-ALK2 antibody or an antigen-binding fragment of the antibody is contained as an active ingredient
- Other therapeutic agents may be administered after the therapeutic agent is administered.
- the protein ectopic ossification therapeutic agent gene and the anti-ALK2 antibody gene can be inserted separately or downstream of the same promoter region, separately or in the same vector Can be introduced.
- any antibody fragment can be applied as long as the recognition of ALK2 is not completely lost.
- fragments such as Fab, F (ab ′) 2 , and Fv are examples.
- antibodies and fragments thereof can be used in the same manner.
- the binding mode of the anti-ALK2 antibody or a fragment of the antibody and the FOP therapeutic agent is described in M.M. C.
- Garnet “Targeted drug conjugates: principals and progress”, Advanced Drug Delivery Reviews, (2001) 53, 171-216, G.A. T. T. et al. Hermanson “Bioconjugate Technologies” Academic Press, California (1996), Putnam and J. et al.
- Kopecek Polymer Conjugates with Anticancer Activity” Advances in Polymer Science (1995) 122, 55-123. That is, mention may be made of a mode in which an anti-ALK2 antibody and an ectopic ossification therapeutic agent are bound chemically directly or via a spacer such as an oligopeptide, or a mode in which a suitable drug carrier is bound. it can.
- Examples of drug carriers include liposomes and water-soluble polymers. More specifically, these drug carriers are intervened in such a manner that the ectopic ossification therapeutic agent is included in the liposome, the liposome and the antibody are bound, and the ectopic ossification therapeutic agent includes For example, a mode in which an antibody is bound to a water-soluble polymer (a compound having a molecular weight of about 1,000 to 100,000) chemically or directly through a spacer such as an oligopeptide and the antibody is bound to the water-soluble polymer. it can.
- a water-soluble polymer a compound having a molecular weight of about 1,000 to 100,000
- Binding of the antibody (or the fragment) to a drug carrier such as an ectopic ossification therapeutic agent, a liposome and a water-soluble polymer is described in G. T. T. et al. Hermanson “Bioconjugate Technologies” Academic Press, California (1996), Putnam and J. et al. It can be carried out by methods well known to those skilled in the art, such as the method described in Kopecek "Polymer Conjugates with Anticancer Activity” Advances in Polymer Science (1995) 122, 55-123. Inclusion of ectopic ossification therapeutic agents in liposomes is described in D.C. D. Lasic "Liposomes: From Physics to Applications", Elsevier Science Publishers B.
- Binding of the ectopic ossification therapeutic agent to the water-soluble polymer is described in D.C. It can be carried out by methods well known to those skilled in the art, such as the method described in Putnam and J Kopecek, “Polymer Conjugates with Anticancer Activity” Advances in Polymer Science (1995) 122, 55-123.
- a complex of an antibody (or the fragment) and a proteinous ectopic ossification therapeutic agent (or the fragment) can be prepared by a method well known to those skilled in the art in genetic engineering in addition to the above method. .
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically and / or prophylactically effective amount of an anti-ALK2 antibody and a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and / or adjuvant.
- the present invention includes a therapeutically and / or prophylactically effective amount of an anti-ALK2 antibody, a therapeutically and / or prophylactically effective amount of at least one ectopic ossification therapeutic agent, a pharmaceutically acceptable diluent, carrier, Also provided are pharmaceutical compositions comprising solubilizers, emulsifiers, preservatives and / or adjuvants.
- the substance used in the preparation acceptable in the pharmaceutical composition of the present invention is preferably a substance that is non-toxic to a person who is administered the pharmaceutical composition at a dosage or concentration.
- the pharmaceutical composition of the present invention changes or maintains pH, osmotic pressure, viscosity, transparency, color, isotonicity, sterility, stability, dissolution rate, sustained release rate, absorption rate, and penetration rate. Can be included for the formulation.
- Substances for formulation may include, but are not limited to: amino acids such as glycine, alanine, glutamine, asparagine, arginine or lysine, antibacterial agents, ascorbic acid, sodium sulfate or sodium bisulfite Antioxidants, phosphoric acid, citric acid, boric acid buffer, sodium bicarbonate, buffer such as Tris-HCl (Tris-HCl) solution, filler such as mannitol and glycine, chelating agent such as ethylenediaminetetraacetic acid (EDTA) , Caffeine, polyvinylpyrrolidine, complexing agents such as ⁇ -cyclodextrin and hydroxypropyl- ⁇ -cyclodextrin, bulking agents such as glucose, mannose or dextrin, other carbohydrates such as monosaccharides and disaccharides, coloring agents, flavors Agent, diluent, emulsifier, polyvinylpyrrolidine, etc.
- amino acids such as gly
- Hydrophilic polymers low molecular weight polypeptides, salt-forming counterions, benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorexidine, sorbic acid or hydrogen peroxide preservatives, glycerin, propylene ⁇ Solvents such as glycol or polyethylene glycol, sugar alcohols such as mannitol or sorbitol, suspension agents, sorbitan esters, polysorbates such as polysorbate 20 and polysorbate 80, surface activity such as triton, tromethamine, lecithin or cholesterol Agents, stabilization enhancers such as sucrose and sorbitol, elasticity enhancers such as sodium chloride, potassium chloride and mannitol / sorbitol, transport agents, excipients, and / Or pharmaceutically adjuvants.
- solvents such as glycol or polyethylene glycol, sugar alcohols such as
- the added amount of these substances for preparation is preferably 0.01 to 100 times, particularly 0.1 to 10 times the weight of the anti-ALK2 antibody.
- the composition of a suitable pharmaceutical composition in the preparation can be appropriately determined by those skilled in the art depending on the disease to be applied, the route of administration and the like.
- the excipient or carrier in the pharmaceutical composition may be liquid or solid.
- Appropriate excipients and carriers may be water for injection, physiological saline, artificial cerebrospinal fluid and other substances commonly used for parenteral administration.
- Neutral physiological saline or physiological saline containing serum albumin can also be used as a carrier.
- the pharmaceutical composition may include Tris buffer at pH 7.0-8.5, acetate buffer at pH 4.0-5.5, citrate buffer at pH 3.0-6.2. These buffers may also contain sorbitol and other compounds.
- Examples of the pharmaceutical composition of the present invention include a pharmaceutical composition containing an anti-ALK2 antibody and a pharmaceutical composition containing an anti-ALK2 antibody and at least one ectopic ossification therapeutic agent.
- the pharmaceutical composition containing the anti-ALK2 antibody and the pharmaceutical composition containing the anti-ALK2 antibody and at least one ectopic ossification therapeutic agent are molded as a lyophilized product using an appropriate excipient such as sucrose. You can also.
- the pharmaceutical composition of the present invention can be prepared for parenteral administration or for oral digestive tract absorption.
- the composition and concentration of the preparation can be determined by the administration method, and the affinity of the anti-ALK2 antibody for ALK2, that is, the dissociation constant (KD value) for ALK2, contained in the pharmaceutical composition of the present invention
- KD value dissociation constant
- the human anti-ALK2 antibody is administered to a human, for example, about 0.1 to 100 mg / kg may be administered once or several times for 1 to 180 days.
- the dose and frequency of administration should generally be determined in consideration of the patient's gender, weight, age, symptoms, severity, side effects, etc., they are not limited to the above doses and usages.
- the dose and frequency of administration should generally be determined in consideration of the patient's gender, weight, age, symptoms, severity, side effects, etc., they are not
- Examples of the form of the pharmaceutical composition of the present invention include, but are not limited to, an injection containing a drip, a suppository, a nasal agent, a sublingual agent, and a transdermal absorption agent.
- the administration route is an oral route or a parenteral route, and examples of the parenteral route include, but are not limited to, intravenous, intraarterial, intramuscular, rectal, transmucosal, intradermal and the like.
- Example 1 Preparation of rat anti-ALK2 antibody (11E2, 15A6, 25C11, and 27D11: hereinafter abbreviated as A2-11E, A2-15A, A2-25C, and A2-27D) 1) -1 Preparation of antigen mALK2-Fc as antigen Is Sino Biological Inc. Mouse ALK2-His & Fc (Cat. # 50297-M03H) manufactured by KK was used.
- an antigen diluted with PBS to 1 ⁇ g / ml was immobilized on a 96-well ELISA plate (NUNC, Cat. # 442404) for 2 hours at room temperature or overnight at 4 ° C. .
- the solid phase was removed, and blocking was performed for 30 minutes at room temperature with a 0.5% skim milk solution dissolved in PBS.
- the culture supernatant of the hybridoma was added and allowed to stand at room temperature for 1 hour.
- an ALP-labeled anti-rat IgG antibody manufactured by SBA
- diluted 1: 2500 with 0.5% skim milk was added, and the plate was further allowed to stand at room temperature for 1 hour.
- the phenylphosphate substrate was reacted at room temperature for 20 minutes, and then the absorbance at a wavelength of 492 nm was measured.
- hybridoma was cloned twice or more by the limiting dilution method.
- hybridoma strains producing monoclonal antibodies A2-11E, A2-15A, A2-25C, and A2-27D were isolated.
- Example 2 In vitro evaluation of rat anti-ALK2 antibodies (A2-11E, A2-15A, A2-25C, and A2-27D) 2) -1 Antibody screening by flow cytometry 2) -1-1 Mouse and human ALK2 expressing cells Preparation HEK293A cells were seeded in a 100 mm dish at 3 ⁇ 10 4 cells / cm 2 and cultured overnight in DMEM medium containing 15% FBS under conditions of 37 ° C. and 5% CO 2 .
- pcDEF3 / mouse ALK2 (WT) -EGFP, pcDEF3 / human ALK2 (WT) -EGFP, pcDEF3 / human ALK2 (R206H) -pcGFP, and pcDEF3 were introduced into HEK293A cells using Lipofectamine 2000 (Invitrogen). And further cultured overnight.
- 100 ⁇ L of the cell suspension adjusted to 1 ⁇ 10 6 cells / mL was dispensed into 1.5 mL microcentrifuge tubes, centrifuged at 500 g for 5 minutes, and then the supernatant was removed.
- FIGS. 2A to 2D Monoclonal antibodies produced by the hybridomas A2-11E, A2-15A, A2-25C, and A2-27D do not recognize fluorescent protein EGFP-expressing cells (FIG. 2A), but do not recognize mouse ALK2-expressing cells (FIG. 2B) and wild type. It was confirmed to specifically recognize type A and FOP human ALK2 expressing cells (FIGS. 2C and 2D, respectively). This result indicates that the monoclonal antibodies produced by the hybridomas A2-11E, A2-15A, A2-25C, and A2-27D are antibodies that bind to the extracellular region of ALK2.
- the OPTI-MEM I containing serially diluted monoclonal antibody and 10 ng / mL BMP7 (manufactured by Miltenney) or 0.5 ng / mL BMP9 (manufactured by Peprotech) was replaced and further cultured overnight.
- Firefly and Renilla's luciferase activities were measured with a plate reader GENios (manufactured by TECAN) using Dual-Glo Luciferase Assay System (manufactured by Promega).
- Monoclonal antibodies produced by hybridomas A2-11E, A2-15A, A2-25C, and A2-27D are BMP7-induced luciferase activity induced by BMP7 in HEK293A cells overexpressing wild-type and R206H mutants of ALK2. Was confirmed to be suppressed in a dose-dependent manner.
- OPTI-MEM I containing serially diluted monoclonal antibody and 200 ng / mL BMP2 (manufactured by Corefront), 200 ng / mL BMP7 (manufactured by Miltenney), or 20 ng / mL GDF2 / BMP9 (manufactured by Peprotech). And further cultured for 3 days. After removing the medium of C2C12 cells and washing with PBS, the cells were treated with 50 ⁇ L / well of ice-cold acetone: ethanol (1: 1) solution for 1 minute and further washed 3 times with PBS. ALP activity was measured as an index of differentiation into osteoblast cells.
- Measurement of ALP activity was performed using 100 ⁇ L / well of substrate solution (1 mg / mL 4-Nitrophenyl phosphate (Sigma-Aldrich) and 0.1 M Diethanolamine (Sigma-Aldrich) -HCl, pH 10. containing 1 mM MgCl 2 . 0) was added and allowed to react at room temperature for 15-30 minutes on a stirring shaker. The reaction was stopped by adding 50 ⁇ L of 3M NaOH, and the absorbance at a wavelength of 405 nm was measured using a microplate reader infinite F50 (manufactured by TECAN).
- Example 3 Determination of nucleotide sequence of cDNA encoding variable region of rat anti-ALK2 antibody (A2-11E, A2-15A, A2-25C, A2-27D) 3) -1 Nucleotide sequence of cDNA encoding variable region of A2-11E 3) -1-1 Preparation of total RNA from A2-11E-producing hybridoma To amplify cDNA containing the variable region of A2-11E, total RNA was used from A2-11E-producing hybridoma using TRIzol Reagent (Ambion). Was prepared.
- a cDNA containing the variable region of the heavy chain of A2-11E was obtained by 5′-RACE PCR using the combination of this primer and the cDNA synthesized in Example 3) -1-2 (5′-RACE-Ready cDNA) as a template. Amplified. PCR was performed using a touchdown PCR program according to the manual of SMARTER RACE cDNA Amplification Kit (Clontech) using KOD-Plus- (TOYOBO, Japan) as Polymerase.
- the cDNA containing the variable region of the heavy chain amplified by 5'-RACE PCR was purified using MinElute PCR Purification Kit (QIAGEN), cloned using Zero Blunt TOPO PCR Cloning Kit (Invitrogen), and cloned. Sequence analysis of the nucleotide sequence of the cDNA containing the variable region of the strand was performed.
- an oligonucleotide having the sequence of 5′-CTCCAGAGTTCCAGGTCACGGTGAACTGGGC-3 ′ (RG2AR3; SEQ ID NO: 88) designed from the sequence of the rat heavy chain in the database, and NUP (Nested Universal Primer A: SMARTer RACE cDNA cDNA A Kit included).
- nucleotide sequence of the cDNA encoding the determined variable region of the heavy chain of A2-11E is shown in SEQ ID NO: 1 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 2.
- a cDNA containing the variable region of the light chain of A2-11E was obtained by 5′-RACE PCR using the combination of this primer and the cDNA synthesized in Example 3) -1-2 (5′-RACE-Ready cDNA) as a template. Amplified. PCR was performed using a touchdown PCR program according to the manual of SMARTER RACE cDNA Amplification Kit (Clontech) using KOD-Plus- (TOYOBO, Japan) as Polymerase.
- a cDNA containing a light chain variable region amplified by 5'-RACE PCR was purified using MinElute PCR Purification Kit (QIAGEN), then cloned using Zero Blunt TOPO PCR Cloning Kit (Invitrogen), and cloned. Sequence analysis of the nucleotide sequence of the cDNA containing the variable region of the strand was performed.
- the sequence primer was designed from the sequence of the constant region of the rat light chain in the database.
- oligonucleotide having the sequence of 5'-TCAGTAACACTGTCCAGGACACCCATTC-3 '(RKR5; SEQ ID NO: 89) and NUP (Nested Universal Primer A: attached to SMARTER RACE cDNA Amplification Kit) were used.
- nucleotide sequence of the cDNA encoding the determined variable region of the light chain of A2-11E is shown in SEQ ID NO: 3 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 4.
- RNA was prepared from the A2-15A producing hybridoma in the same manner as in Example 3) -1-1.
- nucleotide sequence of the cDNA encoding the determined variable region of the heavy chain of A2-15A is shown in SEQ ID NO: 5 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 6.
- Example 3 3) -2-4 Amplification of cDNA containing A2-15A light chain variable region by 5′-RACE PCR and determination of sequence
- Example 3 cDNA synthesized in 2-2 (5′-RACE-Ready cDNA) was used as a template to amplify a cDNA containing the light chain variable region of A2-15A in the same manner as in Example 3) -1-4, and the sequence was determined.
- nucleotide sequence of the cDNA encoding the determined variable region of the light chain of A2-15A is shown in SEQ ID NO: 7 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 8.
- nucleotide sequence of the cDNA encoding the determined variable region of the heavy chain of A2-25C is shown in SEQ ID NO: 9 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 10.
- nucleotide sequence of the cDNA encoding the determined variable region of the light chain of A2-25C is shown in SEQ ID NO: 11 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 12.
- RNA was prepared from the A2-27D producing hybridoma in the same manner as in Example 3) -1-1.
- nucleotide sequence of the cDNA encoding the determined variable region of the heavy chain of A2-27D is shown in SEQ ID NO: 13 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 14.
- nucleotide sequence of the cDNA encoding the determined variable region of the light chain of A2-27D is shown in SEQ ID NO: 15 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 16.
- Example 4 In vivo evaluation of rat anti-ALK2 antibodies (A2-15A and A2-27D) 4) -1 Preparation of hybridoma culture supernatant 1.0 ⁇ 10 6 hybridomas obtained in Example 1) -4 were 10% The cells were cultured in FBS-containing TIL high glucose medium (T75 flask), and then high-density culture was performed in INTEGRA CL1000 (10% FBS medium). Next, the medium was replaced with serum-free medium, and after further culturing with INTEGRA CL1000, a required amount of hybridoma culture supernatant was obtained. The obtained hybridoma culture supernatant was stored at 2 to 8 ° C. until purification.
- Example 4 Purification of antibody from hybridoma culture supernatant
- the antibody was purified from the culture supernatant obtained in Example 4) -1 by Protein G affinity chromatography (under 4-6 ° C) in one step.
- the buffer replacement step after purification by Protein G affinity chromatography was performed at 4 to 6 ° C.
- the culture supernatant of the hybridoma was applied to a column packed with Protein G (GE Healthcare Bioscience) equilibrated with PBS. After all of the culture supernatant liquid entered the column, the column was washed with PBS having a column volume of 2 times or more.
- the IgG concentration was adjusted to 8 mg / ml or more by concentration with Centrifugal UF Filter Device VIVASPIN 20 (fractionated molecular weight UF10K, Sartorius, 4 ° C.). Finally, it was filtered through a Minisart-Plus filter (Sartorius) to obtain a purified sample.
- VIVASPIN 20 fractionated molecular weight UF10K, Sartorius, 4 ° C.
- C57BL / 6 mice aged 8-10 weeks are anesthetized using a simple inhalation anesthesia device for small animal experiments (Natsume Seisakusho Co., Ltd., Japan) and 2% isoflurane (Wako Pure Chemical Industries, Ltd., Japan).
- One BMP-containing pellet was transplanted into each thigh muscle tissue.
- Monoclonal antibodies produced by the hybridomas A2-15A and A2-27D are administered subcutaneously at 10 mg / kg once / week from 1 week before transplantation, and maintained in the same manner until 2 weeks after transplantation. did.
- the control group was administered with an equal volume of solvent (25 mM Histidine / 5% Sorbitol, pH 6.0).
- Two weeks after transplantation of the BMP-containing pellet the BMP-containing pellet transplanted together with the femur was removed, and the formation of ectopic bone was analyzed by micro CT ( ⁇ CT35, manufactured by SCANCO).
- mice transplanted with BMP7 and GDF2 / BMP9 and treated with vehicle ectopic bone was induced on the right side of the femur by micro CT analysis.
- the mice administered with the monoclonal antibodies produced by the hybridomas A2-15A and A2-27D no ectopic bone was detected even after transplantation with BMP7 and GDF2 / BMP9. Therefore, it was confirmed that the monoclonal antibodies produced by the hybridomas A2-15A and A2-27D suppress ectopic bone induction in skeletal muscle tissue induced by BMP7 and GDF2 / BMP9.
- Example 5 Preparation of human chimerized anti-ALK2 antibody (cA2-15A, cA2-27D) 5) -1 Construction of chimera and humanized antibody light chain expression vector pCMA-LK And an about 5.4 kb fragment obtained by digestion with PmeI, and a DNA fragment comprising the DNA sequence encoding the human ⁇ chain secretion signal and human ⁇ chain constant region shown in SEQ ID NO: 17 as an In-Fusion Advantage PCR cloning kit (Clontech) was used to produce pcDNA3.3 / LK.
- PCR was carried out with the following primer set, and the obtained 3.8 kb fragment was phosphorylated and self-ligated to downstream of the CMV promoter to establish a signal sequence, cloning site, and human kappa chain.
- Chimeric and humanized antibody light chain expression vectors pCMA-LK with normal regions were constructed.
- Primer set 5'-TATACCGTCGACTCTCTAGCTAGAGCTTGGC-3 '(3.3-F1; SEQ ID NO: 90) 5′-GCTATGGCAGGGCCTGCCGCCCCCGACGTTG-3 ′ (3.3-R1; SEQ ID NO: 91)
- the obtained expression vector was designated as “pCMA-G1 / cA2-15A”.
- the nucleotide sequence of the cA2-15A heavy chain is shown in SEQ ID NO: 19, and the amino acid sequence is shown in SEQ ID NO: 20.
- cA2-15A heavy chain primer set 5′-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGGAGTCTGGCGGGAG-3 ′ (A2-15AH-F; SEQ ID NO: 92) 5'-CTTGGTGGAGGCTGAGCTGACAGTGACCAGAGTGCCCTGGCCCCAG-3 '(A2-15AH-R; SEQ ID NO: 93)
- cA2-15A The light chain nucleotide sequence of cA2-15A is shown in SEQ ID NO: 21 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 22.
- cA2-15A light chain primer set 5′-ATCTCCGGCGCGTACCGGCGACATGTCTTGACCCAGCTCTCCTGC-3 ′ (A2-15AL-F; SEQ ID NO: 94) 5′-GGAGGGGGCGGGCCACAGCCCGTTTCAGTTCCAGCTTGTCCCAG-3 ′ (A2-15AL-R; SEQ ID NO: 95)
- the obtained expression vector was designated as “pCMA-G1 / cA2-27D”.
- the nucleotide sequence of the cA2-27D heavy chain is shown in SEQ ID NO: 23, and the amino acid sequence is shown in SEQ ID NO: 24.
- cA2-27D heavy chain primer set 5′-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGGAGTCTGGAGGAG-3 ′ (A2-27DH-F; SEQ ID NO: 96) 5'-CTTGGTGGAGGCTGAGCTCACGGTGGACCACGGTTCCTGGGCCCCAG-3 '(A2-27DH-R; SEQ ID NO: 97)
- the nucleotide sequence of the light chain of the cA2-27D antibody is shown in SEQ ID NO: 25 in the sequence listing, and the amino acid sequence is shown in SEQ ID NO: 26.
- cA2-27D light chain primer set 5′-ATCTCCGGCGCGTACGGGCGAAATTGTTCTCACTCAGCTCTCCAAC-3 ′ (A2-27DL-F; SEQ ID NO: 98) 5′-GGAGGGGGCGGGCCACAGCCCGTTTCAGTTCCAGCTTGTCCCAG-3 ′ (A2-15AL-R; SEQ ID NO: 95)
- Polyethyleneimine (Polyscience # 24765) 1.8 mg was dissolved in 20 ml of Opti-Pro SFM medium (Invitrogen), and then the H chain expression vector (0.24 mg) and L prepared using NucleoBond Xtra (TaKaRa, Japan) Chain expression vector (0.36 mg) was added to 20 ml of Opti-Pro SFM medium (Invitrogen). 20 ml of an expression vector / Opti-Pro SFM mixture was added to 20 ml of a polyethyleneimine / Opti-Pro SFM mixture, gently stirred, allowed to stand for another 5 minutes, and then added to FreeStyle 293F cells.
- the chimeric antibody of rat antibody A2-15A obtained by the combination of pCMA-G1 / cA2-15A and pCMA-LK / cA2-15A was named “cA2-15A”, and pCMA-G1 / cA2-27D and pCMA-
- the chimeric antibody of rat antibody A2-27D obtained by combination with LK / cA2-27D was named “cA2-27D”.
- the fraction was replaced with PBS by dialysis (Thermo Scientific, Slide-A-Lyzer Dialysis cassette), and then an antibody solution diluted 5-fold with a buffer of 5 mM sodium phosphate / 50 mM MES / pH 7.0 was diluted with 5 mM NaPi / This was applied to a ceramic hydroxyapatite column (Nippon Bio-Rad, Bio-Scale CHT Type-1 Hydroxyapatite Column) equilibrated with a buffer of 50 mM MES / 30 mM NaCl / pH 7.0. Linear gradient elution with sodium chloride was performed and the fractions containing antibody were collected.
- the fraction was subjected to liquid replacement with HBSor (25 mM histidine / 5% sorbitol, pH 6.0) by dialysis (Thermo Scientificsha, Slide-A-Lyzer Dialysis cassette).
- HBSor 25 mM histidine / 5% sorbitol, pH 6.0
- the IgG concentration was adjusted to 2 mg / ml or more by concentration with Centrifugal UF Filter Device VIVASPIN 20 (fractionated molecular weight UF10K, Sartorius, 4 ° C.). Finally, it was filtered through a Minisart-Plus filter (Sartorius) to obtain a purified sample.
- Example 6 In vitro activity evaluation of human chimerized anti-ALK2 antibodies (cA2-15A, cA2-27D) 6) -1 Antibody evaluation by luciferase reporter assay The inhibitory activity of intracellular signal via ALK2 of the produced human chimerized antibody is BMP Analysis was performed using a specific luciferase reporter. HEPG2 cells were seeded on a 96-well white plate for luciferase assay (CORNING) at 1 ⁇ 10 4 cells / well, and 37 ° C., 5% CO 2 in DMEM medium containing 10% FBS.
- CORNING luciferase assay
- pGL4.26 / Id1WT4F-luc (Genes Cells, 7,949 (2002)) was introduced using Lipofectamine 2000 (Invitrogen). After 2.5 hours, the medium was replaced with fresh OPTI-MEM I (manufactured by Life Technologies), and further cultured for 3 hours. Thereafter, the antibody was replaced with OPTI-MEM I containing serially diluted monoclonal antibody and 10 ng / mL BMP7 (Milteny), and further cultured overnight. On the next day, luciferase activity was measured with a plate reader SpectraMaxM4 (Molecular Devices) using Dual-Glo Luciferase Assay System (Promega).
- C2C12 cells were seeded in a 96-well plate (manufactured by IWAKI) at 5 ⁇ 10 3 cells / well, and were cultured in a DMEM medium containing 15% FBS under conditions of 37 ° C. and 5% CO 2. Cultured overnight.
- Measurement of ALP activity was carried out using 100 ⁇ L / well of substrate solution (1 mg / mL 4-Nitrophenyl phosphate (Sigma-Aldrich) and 0.1 M Diethanolamine (Sigma-Aldrich) -HCl, pH 10 containing 1 mM MgCl 2. 0.0) and allowed to react on a shaker at room temperature for 15-30 minutes. The reaction was stopped by adding 50 ⁇ L of 3 M NaOH, and the absorbance at a wavelength of 405 nm was measured using a plate reader SpectraMaxM4 (manufactured by Molecular Devices).
- the results are shown in FIG.
- the chimerized antibodies cA2-15A and cA2-27D were confirmed to suppress the differentiation of C2C12 cells induced by BMP into osteoblast-like cells in a dose-dependent manner.
- This result indicates that the chimerized antibodies cA2-15A and cA2-27D are antibodies that suppress endogenous ALK2 that is physiologically expressed by C2C12 cells.
- the inhibitory activity is equivalent to each of the rat monoclonal antibodies A2-15A and A2-27D.
- Example 7 Anti-ALK2 antibodies A2-15A and A2-27D humanized design 7) -1 Humanized hA2-15A design 7) -1-1 Molecular modeling of the variable region of A2-15A A2-15A variable region molecule Modeling was performed by a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). Primary sequence of variable region of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) (three-dimensional structure derived from X-ray crystal structure is available) was compared to the variable region of A2-15A determined above.
- 3KYM and 3S35 were selected as having the highest sequence identity to the heavy and light chain variable regions of A2-15A, respectively.
- the three-dimensional structure of the framework region was created by combining the 3KYM and 3S35 coordinates corresponding to the heavy and light chains of A2-15A to obtain a “framework model”. A representative conformation for each CDR was then incorporated into the framework model.
- the sequence of the framework region of A2-15A was compared with the framework region of the human subgroup consensus sequence.
- KABAT et al. Sequence of four groups of subgroups in the sequence of subgroups of subgroups of sequences in the sequence of human groups in the Sequence of Sequences of Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service of Health, Bethesda, MD. (1991)). was selected as an acceptor due to its high sequence identity in its framework region.
- the amino acid residues in the framework regions for the human ⁇ chain subgroup 3 consensus sequence and the human ⁇ chain subgroup 4 consensus sequence are aligned with the amino acid residues for A2-15A, and the positions where different amino acids are used are Identified.
- the positions of these residues are analyzed using the 3D model of A2-15A constructed above, and the donor residues to be grafted on the acceptor are described in Queen et al. (Proc. Natl. Acad. Sci. USA 86, 1000029-10033 (1989)).
- the sequence of humanized hA2-15A was constructed as described in the examples below by transferring several selected donor residues into the acceptor antibody.
- the humanized hA2-15A heavy chain which was designed with asparagine and amino acid number 107 (serine) replaced with alanine, amino acid number 112 (threonine) with valine, and amino acid number 116 (threonine) with alanine was “humanized” hA2-15A-H1 type heavy chain "(sometimes called" hA2-15A-H1 " ) It was named.
- the amino acid sequence of the humanized hA2-15A-H1 type heavy chain is described in SEQ ID NO: 28 in the sequence listing.
- the sequence consisting of amino acid residues 1 to 19 of the amino acid sequence of SEQ ID NO: 28, the sequence consisting of amino acid residues 20 to 142, the sequence consisting of amino acid residues 143 to 472 are a signal sequence and a heavy chain, respectively. It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 28 is described in SEQ ID NO: 27 of the sequence listing.
- the sequence consisting of the 1st to 57th nucleotides, the sequence consisting of the 58th to 426th nucleotides, and the sequence consisting of the 427th to 1416th nucleotides of the nucleotide sequence of SEQ ID NO: 27 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 27 and the amino acid sequence of SEQ ID NO: 28 are also shown in FIG.
- the amino acid sequence of the humanized hA2-15A-H4 type heavy chain is described in SEQ ID NO: 30 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 142nd amino acid residues, and the sequence consisting of the 143th to 472nd amino acid residues of the amino acid sequence of SEQ ID NO: 30 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 30 is set forth in SEQ ID NO: 29 of the Sequence Listing.
- sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 426, and the sequence consisting of nucleotides 427 to 1416 of the nucleotide sequence of SEQ ID NO: 29 are a signal sequence, a heavy chain variable region sequence and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 29 and the amino acid sequence of SEQ ID NO: 30 are also shown in FIG.
- amino acid number 29 is aspartic acid
- amino acid number 29-30 is serine
- amino acid number 36 is glutamic acid
- amino acid number 41 is asparagine
- amino acid Number 66 is proline
- amino acid number 81 is valine
- amino acid number 83 is aspartic acid
- amino acid number 99 is aspartic acid
- amino acid number 100 proline
- Amino acid number 101 is leucine
- amino acid number 104 is Amino acid number 106 (isoleucine) to valine
- amino acid number 108 isthreonine
- amino acid number 123 (alanine) to glutamine
- amino acid number 127 leucine
- amino acid number 129 leucine
- the humanized hA2-15A light chain designed with the replacement of is replaced with iso
- the amino acid sequence of the humanized hA2-15A-L1 type light chain is described in SEQ ID NO: 32 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 133rd amino acid residues, and the sequence consisting of the 134th to 238th amino acid residues of the amino acid sequence of SEQ ID NO: 32 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 32 is described in SEQ ID NO: 31 of the Sequence Listing.
- the sequence consisting of the 26th to 85th nucleotides, the sequence consisting of the 86th to 424th nucleotides, and the sequence consisting of the 425th to 739th nucleotides of the nucleotide sequence of SEQ ID NO: 31, respectively, are a signal sequence, a light chain variable region sequence, and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 31 and the amino acid sequence of SEQ ID NO: 32 are also shown in FIG.
- hA2-15A-L4 type light chain The amino acid number 29 (alanine) of the light chain of the chimeric cA2-15A shown in SEQ ID NO: 22 is replaced by aspartic acid, and between amino acid numbers 29-30 (deleted) Residue) to serine, amino acid number 36 (glutamine) to glutamic acid, amino acid number 41 (serine) to asparagine, amino acid number 99 (asparagine) to serine, amino acid number 100 (proline) to serine, amino acid number 108
- the humanized hA2-15A light chain designed with the replacement of (threonine) with valine and amino acid number 123 (alanine) with glutamine is referred to as “humanized hA2-15A-L4 type light chain” (“hA2-15A-L4 "Sometimes called").
- the amino acid sequence of the humanized hA2-15A-L4 type light chain is set forth in SEQ ID NO: 34 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 133rd amino acid residues, and the sequence consisting of the 134th to 238th amino acid residues of the amino acid sequence of SEQ ID NO: 34 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 34 is described in SEQ ID NO: 33 of the Sequence Listing.
- the sequence consisting of the 26th to 85th nucleotides, the sequence consisting of the 86th to 424th nucleotides, and the sequence consisting of the 425th to 739th nucleotides of the nucleotide sequence of SEQ ID NO: 33 are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 33 and the amino acid sequence of SEQ ID NO: 34 are also shown in FIG.
- the amino acid sequence of the humanized hA2-15A-L6 type light chain is set forth in SEQ ID NO: 36 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 133rd amino acid residues, and the sequence consisting of the 134th to 238th amino acid residues of the amino acid sequence of SEQ ID NO: 36 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 36 is described in SEQ ID NO: 35 of the sequence listing.
- a sequence consisting of nucleotides 26 to 85, a sequence consisting of nucleotides 86 to 424, and a sequence consisting of nucleotides 425 to 739 of the nucleotide sequence of SEQ ID NO: 35 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 35 and the amino acid sequence of SEQ ID NO: 36 are also shown in FIG.
- the amino acid sequence of the humanized hA2-15A-L7 type light chain is set forth in SEQ ID NO: 38 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 133rd amino acid residues, and the sequence consisting of the 134th to 238th amino acid residues of the amino acid sequence of SEQ ID NO: 38 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 38 is set forth in SEQ ID NO: 37 of the Sequence Listing.
- a sequence consisting of nucleotides 26 to 85, a sequence consisting of nucleotides 86 to 424, and a sequence consisting of nucleotides 425 to 739 of the nucleotide sequence of SEQ ID NO: 37 are a signal sequence, a light chain variable region sequence, and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 37 and the amino acid sequence of SEQ ID NO: 38 are also shown in FIG.
- An antibody consisting of a humanized hA2-15A-H4 type heavy chain and a humanized hA2-15A-L1 type light chain was designed and called “humanized hA2-15A-H4 / L1” (“hA2-15A-H4 / L1”) Sometimes named).
- An antibody consisting of a humanized hA2-15A-H4 type heavy chain and a humanized hA2-15A-L4 type light chain was designed and called “humanized hA2-15A-H4 / L4” (“hA2-15A-H4 / L4”) Sometimes named).
- An antibody consisting of a humanized hA2-15A-H4 type heavy chain and a humanized hA2-15A-L6 type light chain was designed and called “humanized hA2-15A-H4 / L6” (“hA2-15A-H4 / L6”) Sometimes named).
- An antibody consisting of a humanized hA2-15A-H4 type heavy chain and a humanized hA2-15A-L7 type light chain was designed and called “humanized hA2-15A-H4 / L7” (“hA2-15A-H4 / L7”).
- the antibody designed as described above can be prepared according to Example 8 and evaluated according to Examples 2 and 4.
- variable region of A2-27D is performed by a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). Primary sequence of variable region of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) (three-dimensional structure derived from X-ray crystal structure is available) was compared to the variable region of A2-27D determined above. As a result, 3EYQ and 4I9W were selected as having the highest sequence identity to the A2-27D heavy and light chain variable regions, respectively.
- the three-dimensional structure of the framework region was created by combining the 3EYQ and 4I9W coordinates corresponding to the A2-27D heavy and light chains to obtain a “framework model”. A representative conformation for each CDR was then incorporated into the framework model.
- sequence of the framework region of A2-27D was compared with the framework region of the human subgroup consensus sequence.
- KABAT et al. Sequences of the sequence group and sub-groups of subgroups of the sequence group (subgroup ⁇ ) of subsequences of the sequence group of sequences in the sequence of sequences in the Sequence of Sequence of Proteins of Immunological Interest, 5th Ed. Public Health Service of Health, Bethesda, MD. was selected as an acceptor due to its high sequence identity in its framework region.
- the amino acid residues in the framework regions for the human ⁇ chain subgroup 3 consensus sequence and the human ⁇ chain subgroup 3 consensus sequence are aligned with the amino acid residues for A2-27D, and the positions where different amino acids are used are Identified.
- the positions of these residues are analyzed using the 3-dimensional model of A2-27D constructed above, and the donor residues to be grafted on the acceptor are described in Queen et al. (Proc. Natl. Acad. Sci. USA 86, 1000029-10033 (1989)).
- the sequence of humanized hA2-27D was constructed as described in the examples below by transferring several selected donor residues into the acceptor antibody.
- amino acid number 35 (arginine) of the heavy chain of chimeric cA2-27D shown in SEQ ID NO: 24 was converted to glycine
- amino acid number 38 (lysine) is arginine
- amino acid number 42 (leucine) is alanine
- amino acid number 56 (isoleucine) is valine
- amino acid number 68 (alanine) is serine
- amino acid number 94 (alanine) is serine.
- amino acid number 95 is lysine
- amino acid number 103 is asparagine
- amino acid number 107 is alanine
- amino acid number 112 is valine
- amino acid number 117 is arginine.
- Amino acid number 132 proline to glutamine
- amino acid number 1 The humanized hA2-15A heavy chain designed to replace 5 (valine) with leucine is referred to as a “humanized hA2-27D-H1 type heavy chain” (sometimes referred to as “hA2-27D-H1”). Named.
- the amino acid sequence of the humanized hA2-27D-H1 type heavy chain is described in SEQ ID NO: 40 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 40 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 40 is set forth in SEQ ID NO: 39 of the Sequence Listing.
- the sequence consisting of the 1st to 57th nucleotides, the sequence consisting of the 58th to 420th nucleotides, and the sequence consisting of the 421th to 1410th nucleotides of the nucleotide sequence of SEQ ID NO: 39 are the signal sequence, heavy chain variable region sequence and heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 39 and the amino acid sequence of SEQ ID NO: 40 are also shown in FIG.
- the amino acid sequence of the humanized hA2-27D-H2 type heavy chain is described in SEQ ID NO: 42 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 42 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 42 is set forth in SEQ ID NO: 41 of the sequence listing.
- the sequence consisting of the 1st to 57th nucleotides, the sequence consisting of the 58th to 420th nucleotides, and the sequence consisting of the 421th to 1410th nucleotides of the nucleotide sequence of SEQ ID NO: 41 are the signal sequence, heavy chain variable region sequence and heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 41 and the amino acid sequence of SEQ ID NO: 42 are also shown in FIG.
- the amino acid number 35 (arginine) of the heavy chain of the chimeric cA2-27D shown in SEQ ID NO: 24 is glycine, the amino acid number 38 (lysine) is arginine, Amino acid number 42 (leucine) to alanine, amino acid number 94 (alanine) to serine, amino acid number 95 (arginine) to lysine, amino acid number 103 (threonine) to asparagine, amino acid number 107 (serine) to alanine,
- the humanized hA2-27D heavy chain designed with the replacement of amino acid number 112 (leucine) with valine, amino acid number 132 (proline) with glutamine, and amino acid number 135 (valine) with leucine is replaced with “humanized hA2- 27D-H3 type heavy chain "(also referred to as" hA2-27D-H3 " That) and was named.
- the amino acid sequence of the humanized hA2-27D-H3 type heavy chain is described in SEQ ID NO: 44 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 44 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 44 is set forth in SEQ ID NO: 43 of the Sequence Listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 420, and the sequence consisting of nucleotides 421 to 1410 of the nucleotide sequence of SEQ ID NO: 43 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 43 and the amino acid sequence of SEQ ID NO: 44 are also shown in FIG.
- hA2-27D-H4 Humanized hA2-27D-H4 type heavy chain
- the amino acid number 35 (arginine) of the heavy chain of the chimeric cA2-27D shown in SEQ ID NO: 24 is glycine
- the amino acid number 38 (lysine) is arginine
- Amino acid number 42 (leucine) to alanine amino acid number 94 (alanine) to serine
- amino acid number 95 arginine) to lysine
- amino acid number 103 threonine
- a humanized hA2-27D heavy chain designed to replace amino acid number 135 (valine) with leucine may be referred to as a “humanized hA2-27D-H4 type heavy chain” (“hA2-27D-H4”). ).
- the amino acid sequence of the humanized hA2-27D-H4 type heavy chain is described in SEQ ID NO: 46 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 46 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 46 is described in SEQ ID NO: 45 of the sequence listing.
- the sequence consisting of the 1st to 57th nucleotides, the sequence consisting of the 58th to 420th nucleotides, and the sequence consisting of the 421th to 1410th nucleotides of the nucleotide sequence of SEQ ID NO: 45 are the signal sequence, heavy chain variable region sequence and heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 45 and the amino acid sequence of SEQ ID NO: 46 are also shown in FIG.
- hA2-27D-H5 type heavy chain Amino acid number 35 (arginine) of the heavy chain of the chimeric cA2-27D shown in SEQ ID NO: 24 as glycine, amino acid number 38 (lysine) as arginine, Humanized hA2 designed to replace amino acid number 42 (leucine) with alanine, amino acid number 95 (arginine) with lysine, amino acid number 103 (threonine) with asparagine, and amino acid number 135 (valine) with leucine.
- the ⁇ 27D heavy chain was named “humanized hA2-27D-H5 type heavy chain” (sometimes referred to as “hA2-27D-H5”).
- the amino acid sequence of the humanized hA2-27D-H5 type heavy chain is set forth in SEQ ID NO: 48 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 48 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 48 is set forth in SEQ ID NO: 47 of the Sequence Listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 420, and the sequence consisting of nucleotides 421 to 1410 of the nucleotide sequence of SEQ ID NO: 47 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 47 and the amino acid sequence of SEQ ID NO: 48 are also shown in FIG.
- Amino acid number 66 (tryptophan) to leucine, amino acid number 77 (valine) To isoleucine, amino acid number 79 (asparagine) to aspartic acid, amino acid number 89 (serine) to aspartic acid, amino acid number 90 (tyrosine) to phenylalanine, amino acid number 91 (serine) to threonine, amino acid number 93 (alanine) ) To threonine, amino acid number 96 (serine) to arginine, amino acid number 97 (methionine) to leucine, amino acid number 99 (alanine) to proline, amino acid number 102 (valine) to phenylalanine, amino acid number 104 (threonine) ) For valine, amino acid number 120 (alanine) for glutamine, amino acid number 124 (leucine) for valine, and amino acid number 126 (leucine) for isoleucine. It was designated humanized h
- the amino acid sequence of the humanized hA2-27D-L1 type light chain is set forth in SEQ ID NO: 50 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 50 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 50 is set forth in SEQ ID NO: 49 of the Sequence Listing.
- a sequence consisting of nucleotides 26 to 85, a sequence consisting of nucleotides 86 to 412 and a sequence consisting of nucleotides 413 to 727 of the nucleotide sequence of SEQ ID NO: 49 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively. The normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 49 and the amino acid sequence of SEQ ID NO: 50 are also shown in FIG.
- Amino acid number 29 (threonine for glycine, amino acid number 31 (methionine) for leucine, amino acid for the light chain of the chimeric cA2-27D shown in SEQ ID NO: 26
- Amino acid number 90 (tyrosine) to phenylalanine
- Amino acid number 91 (serine) to threonine
- amino acid number 93 (alanine) to threonine
- amino acid number 96 (serine) to arginine
- amino acid number 97 (methionine) to leucine
- amino acid number 99 (alanine) to proline
- Amino acid number 102 valine
- amino acid number 104 (threonine) to valine
- amino acid number 120 (alanine) to glutamine
- amino acid number 124 (leucine) to valine
- amino acid number 126 (leucine) to isoleucine
- the humanized hA2-27D light chain designed with replacement was named “humanized hA2-27D-L2 type light chain” (sometimes referred to as “hA2-27D-L2”).
- the amino acid sequence of the humanized hA2-27D-L2 type light chain is set forth in SEQ ID NO: 52 of the Sequence Listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 52 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 52 is described in SEQ ID NO: 51 of the Sequence Listing.
- a sequence consisting of nucleotides 26 to 85, a sequence consisting of nucleotides 86 to 412 and a sequence consisting of nucleotides 413 to 727 of the nucleotide sequence of SEQ ID NO: 51 are respectively a signal sequence, a light chain variable region sequence and a light chain constant. The normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 51 and the amino acid sequence of SEQ ID NO: 52 are also shown in FIG.
- Amino acid number 29 (threonine for glycine, amino acid number 31 (methionine) for leucine, amino acid for the light chain of the chimeric cA2-27D shown in SEQ ID NO: 26
- Amino acid number 93 (alanine) to threonine amino Number 96 (serine) is arginine, amino acid number 97 (methionine) is leucine, amino acid number 99 (alanine) is proline, amino acid number 102 (valine) is phenylalanine, amino acid number 124 (leucine) is valine, amino acid A humanized hA2-27D light chain designed to replace number 126 (leucine) with isoleucine is referred to as a “humanized hA2-27D-L3 type light chain” (sometimes referred to as “hA2-27D-L3”) Named.
- the amino acid sequence of the humanized hA2-27D-L3 type light chain is set forth in SEQ ID NO: 54 of the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 54 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 54 is described in SEQ ID NO: 53 of the Sequence Listing.
- the sequence consisting of the 26th to 85th nucleotides, the sequence consisting of the 86th to 412th nucleotides, and the sequence consisting of the 413th to 727th nucleotides of the nucleotide sequence of SEQ ID NO: 53 are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 53 and the amino acid sequence of SEQ ID NO: 54 are also shown in FIG.
- the amino acid sequence of the humanized hA2-27D-L4 type light chain is set forth in SEQ ID NO: 56 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 56 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 56 is set forth in SEQ ID NO: 55 of the Sequence Listing.
- a sequence consisting of nucleotides 26 to 85, a sequence consisting of nucleotides 86 to 412 and a sequence consisting of nucleotides 413 to 727 of the nucleotide sequence of SEQ ID NO: 55 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 55 and the amino acid sequence of SEQ ID NO: 56 are also shown in FIG.
- the amino acid sequence of the humanized hA2-27D-L5 type light chain is set forth in SEQ ID NO: 58 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 58 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 58 is set forth in SEQ ID NO: 57 of the Sequence Listing.
- sequence consisting of nucleotides 26 to 85, the sequence consisting of nucleotides 86 to 412 and the sequence consisting of nucleotides 413 to 727 of the nucleotide sequence of SEQ ID NO: 57 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 57 and the amino acid sequence of SEQ ID NO: 58 are also shown in FIG.
- An antibody consisting of a humanized hA2-27D-H1 type heavy chain and a humanized hA2-27D-L3 type light chain was designed and called “humanized hA2-27D-H1 / L3” (“hA2-27D-H1 / L3”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H2-type heavy chain and a humanized hA2-27D-L1-type light chain was designed and called “humanized hA2-27D-H2 / L1” (“hA2-27D-H2 / L1”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H2-type heavy chain and a humanized hA2-27D-L2-type light chain was designed and called “humanized hA2-27D-H2 / L2” (“hA2-27D-H2 / L2”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H2 type heavy chain and a humanized hA2-27D-L3 type light chain was designed and referred to as "humanized hA2-27D-H2 / L3"("hA2-27D-H2 / L3") Sometimes named).
- An antibody consisting of a humanized hA2-27D-H3 type heavy chain and a humanized hA2-27D-L1 type light chain was designed and referred to as "humanized hA2-27D-H3 / L1"("hA2-27D-H3 / L1")
- An antibody consisting of a humanized hA2-27D-H3 type heavy chain and a humanized hA2-27D-L2 type light chain was designed and referred to as “humanized hA2-27D-H3 / L2” (“hA2-27D-H3 / L2”).
- hA2-27D-H3 / L2 humanized hA2-27D-H3 / L2
- An antibody consisting of a humanized hA2-27D-H3 type heavy chain and a humanized hA2-27D-L3 type light chain was designed and called “humanized hA2-27D-H3 / L3” (“hA2-27D-H3 / L3”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H3 type heavy chain and a humanized hA2-27D-L4 type light chain was designed and called “humanized hA2-27D-H3 / L4” (“hA2-27D-H3 / L4”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H4 type heavy chain and a humanized hA2-27D-L3 type light chain was designed and referred to as "humanized hA2-27D-H4 / L3"("hA2-27D-H4 / L3") Sometimes named).
- An antibody consisting of a humanized hA2-27D-H4 type heavy chain and a humanized hA2-27D-L4 type light chain was designed and referred to as “humanized hA2-27D-H4 / L4” (“hA2-27D-H4 / L4”).
- hA2-27D-H4 / L4 humanized hA2-27D-H4 / L4
- An antibody consisting of a humanized hA2-27D-H4 type heavy chain and a humanized hA2-27D-L5 type light chain was designed and called “humanized hA2-27D-H4 / L5” (“hA2-27D-H4 / L5”) Sometimes named).
- An antibody consisting of a humanized hA2-27D-H5 type heavy chain and a humanized hA2-27D-L4 type light chain was designed and called “humanized hA2-27D-H5 / L4” (“hA2-27D-H5 / L4”) Sometimes named).
- the antibody designed as described above can be prepared according to Example 8 and evaluated according to Examples 2 and 4.
- Example 8 Construction of humanized A2-15A antibody and humanized A2-27D antibody expression vector and preparation of antibody 8) -1 Construction of humanized A2-15A heavy chain expression vector 8) -1-1 Humanized hA2-15A -Construction of H1-type heavy chain expression vector Including the DNA sequence encoding the variable region of humanized hA2-15A-H1 shown in nucleotide numbers 36 to 443 of the nucleotide sequence of humanized hA2-15A-H1 shown in SEQ ID NO: 27 A DNA fragment was synthesized (Geneart Artificial Gene Synthesis Service).
- a DNA fragment containing the DNA sequence encoding the variable region of humanized hA2-15A-H1 was amplified with KOD-Plus- (TOYOBO, Japan) and the following primer set, and chimeric and human
- the humanized hA2-15A-H1 expression vector was constructed by inserting the cloned antibody IgG1-type heavy chain expression vector pCMA-G1 into the site cut with the restriction enzyme BlpI using the In-Fusion HD PCR cloning kit (Clontech). .
- the obtained expression vector was designated as “pCMA-G1 / hA2-15A-H1”.
- Humanized hA2-15A-H4 type heavy chain expression vector Humanized hA2-15A- represented by nucleotide numbers 36 to 443 of the nucleotide sequence of humanized hA2-15A-H4 represented by SEQ ID NO: 29 A DNA fragment containing a DNA sequence encoding the variable region of H4 was synthesized (GENEART artificial gene synthesis service).
- a humanized hA2-15A-L1 expression vector was constructed by insertion with the In-Fusion HD PCR cloning kit (Clontech) after digestion with PmeI and removal of the kappa chain secretion signal and the human kappa chain constant region. did.
- the obtained expression vector was designated as “pCMA / hA2-15A-L1”.
- Primer set 5′-CCAGCCCTCCGGACTCTAGAGCCACC-3 ′ (CM-inf-F; SEQ ID NO: 101)
- 5′-AGTTAGCCTCCCCCCCTTTAAACTC-3 ′ CM-inf-R; SEQ ID NO: 102
- Example 9 In vitro activity evaluation of humanized A2-15A antibody (IgG1) and humanized A2-27D antibody (IgG1) 9) -1 Antibody evaluation by luciferase reporter assay Humanized hA2-prepared in Example 8) -5 15A-H4 / L6, humanized hA2-27D-H2 / L2, and humanized hA2-27D-H3 / L4 were analyzed for the inhibitory activity of intracellular signals via ALK2, using a BMP-specific luciferase reporter did.
- PGL4.26 / Id1WT4F-luc (Genes Cells, 7,949 (2002)) was introduced into HEPG2 cells in the same manner as in Example 6) -1, and the medium was replaced with fresh FreeStyle293 expression medium (Invitrogen) after 3 hours. Exchanged). Thereafter, humanized antibody and 10 ng / mL BMP7 (Milteny) were added, and luciferase activity was measured the next day.
- Example 10 Evaluation of binding of humanized A2-15A antibody (IgG1) and humanized A2-27D antibody (IgG1) to human ALK2 Humanized hA2-15A-H4 / L6 prepared in Example 8) -5, humanized hA2- Dissociation constant measurement between 27D-H2 / L2 and humanized hA2-27D-H3 / L4 and antigen (Recombinant Human ALK2 Fc Chimera, Sino Biological Inc.) uses Biacore T200 (GE Healthcare Biosciences) Then, the antigen was immobilized as a ligand, and the antibody was measured as an analyte.
- the antigen was added at 1.25 ⁇ g / mL for 60 seconds and immobilized on the sensor chip CM5 (GE Healthcare Biosciences).
- HBS-EP + (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% Surfactant P20) was used as a running buffer.
- An antibody dilution series solution (0.2-50 nM) was added to the antigen-immobilized chip for 300 seconds at a flow rate of 30 ⁇ l / min, and then the dissociation phase for 1800 seconds was monitored.
- 10 mM glycine hydrochloride solution pH 1.5 was added twice for 30 seconds at a flow rate of 10 ⁇ l / min.
- Example 11 Preparation of humanized A2-15A antibody (IgG2) 11) -1 Construction of humanized IgG2-type heavy chain expression vector pCMA-G2 The pCMA-LK constructed in Example 5) -1 was digested with XbaI and PmeI and kappa chain In-Fusion Advantage PCR cloning of a DNA fragment (SEQ ID NO: 103) containing the nucleotide sequence encoding the amino acid sequence of the human heavy chain secretion signal sequence and human IgG2 constant region, and the DNA fragment from which the secretion signal and human ⁇ chain constant region have been removed Using a kit (Clontech), a chimeric and humanized IgG2 type heavy chain expression vector pCMA-G2 having a signal sequence, a cloning site, and a human IgG2 heavy chain constant region downstream of the CMV promoter was constructed.
- the nucleotide sequence of the humanized hA2-15A-H4 IgG2 type heavy chain is shown in SEQ ID NO: 104, and the amino acid sequence is shown in SEQ ID NO: 105.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 426, and the sequence consisting of nucleotides 427 to 1404 of the nucleotide sequence of SEQ ID NO: 104 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 142nd amino acid residues, and the sequence consisting of the 143th to 468th amino acid residues of the amino acid sequence of SEQ ID NO: 105 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence of SEQ ID NO: 104 and the amino acid sequence of SEQ ID NO: 105 are also shown in FIG.
- Humanized hA2-15A-H4 IgG2 type heavy chain primer set 5′-CAGATGGGTGCTGAGCGAAGTGCAGCTGGTGGAATCTGGC-3 ′
- A-H4-F 5′-CTTGGGTCTGGCTGAGCTGACGGTCACGAGGGTGCC-3 ′
- A-H4-R 5′-CTTGGGTCTGGCTGAGCTGACGGTCACGAGGGTGCC-3 ′
- Example 12 Preparation of humanized A2-27D antibody (IgG1 LALA) 12) -1 Construction of humanized hA2-27D-H2-LALA type heavy chain expression vector pCMA-G1 / hA2-27D constructed in Example 8) -3-2 A hA2-27D-H2-LALA type heavy chain expression vector was constructed by introducing mutations using -H2 as a template and the following primer set and KOD-Plus- Mutagenesis Kit (TOYOBO). The constructed expression vector was named “pCMA-G1 / hA2-27D-H2-LALA”.
- the nucleotide sequence of the humanized hA2-27D-H2-LALA type heavy chain is shown in SEQ ID NO: 106, and the amino acid sequence is shown in SEQ ID NO: 107.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 420, and the sequence consisting of nucleotides 421 to 1410 of the nucleotide sequence of SEQ ID NO: 106 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 107 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence of SEQ ID NO: 106 and the amino acid sequence of SEQ ID NO: 107 are also shown in FIG.
- Primer set 5′-GCGGGGGGACCCCCAGCTCTCTCCTTCCCCC-3 ′ (LALA-F; SEQ ID NO: 132) 5′-GGCTTCAGGGTCTGGGCAGGGTGGGGCATGTG-3 ′ (LALA-R; SEQ ID NO: 133)
- Example 12) Construction of humanized hA2-27D-H3-LALA type heavy chain expression vector Example 12) -1 using pCMA-G1 / hA2-27D-H3 constructed in Example 8) -3-3 as a template
- the hA2-27D-H3-LALA type heavy chain expression vector was constructed in the same manner as described above.
- the constructed expression vector was named “pCMA-G1 / hA2-27D-H3-LALA”.
- the nucleotide sequence of the humanized hA2-27D-H3-LALA type heavy chain is shown in SEQ ID NO: 108, and the amino acid sequence is shown in SEQ ID NO: 109.
- the sequence consisting of the 1st to 57th nucleotides, the sequence consisting of the 58th to 420th nucleotides, and the sequence consisting of the 421th to 1410th nucleotides of the nucleotide sequence of SEQ ID NO: 108 are the signal sequence, heavy chain variable region sequence and heavy chain constant, respectively.
- the normal region sequence is encoded.
- sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 140th amino acid residues, and the sequence consisting of the 141st to 470th amino acid residues of the amino acid sequence of SEQ ID NO: 109 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence of SEQ ID NO: 108 and the amino acid sequence of SEQ ID NO: 109 are also shown in FIG.
- Humanized A2-27D antibody (IgG1 LALA) Production was carried out in the same manner as in Example 5) -7.
- the antibody was named “humanized hA2-27D-H2 / L2 (IgG1 LALA)” and was constructed in Example 12) -2, and pCMA-G1 / hA2-27D-H3-LALA and Example 8) -4-4
- the humanized A2-27D antibody obtained by the pCMA / hA2-27D-L4 combination constructed in 1 was named “humanized hA2-27D-H3 / L4 (IgG1 LALA)”.
- Example 12) Two-step purification of humanized A2-27D antibody (IgG1 LALA) The culture supernatant obtained in Example 12) -3 was purified in the same manner as in Example 5) -8.
- Example 13 In vitro activity evaluation of humanized A2-15A antibody (IgG2) and humanized A2-27D antibody (IgG1 LALA) 13) -1 Antibody evaluation by luciferase reporter assay Humanized A2- prepared in Example 11) -4 15A-H4 / L6 (IgG2), inhibitory activity of intracellular signal via ALK2 of humanized A2-27D-H2 / L2 (IgG1 LALA) obtained in Example 12) -4 is a BMP-specific luciferase -Analyzed using a reporter.
- PGL4.26 / Id1WT4F-luc (Genes Cells, 7,949 (2002)) was introduced into HEPG2 cells in the same manner as in Example 6) -1, and the medium was replaced with fresh FreeStyle293 expression medium (Invitrogen) after 3 hours. Exchanged). Thereafter, humanized antibody and 2.5 ng / mL BMP9 were added, and luciferase activity was measured on the next day in the same manner as in Example 6) -1.
- Example 14 Evaluation of binding of humanized A2-15A antibody (IgG2) and humanized A2-27D antibody (IgG1 LALA) to human ALK2 14) -1 Purification of human ALK2 extracellular domain Human ALK2 extracellular domain (NCBI protein database DNA encoding ACCESSION number NP_001096, a polypeptide consisting of amino acid residues 21 to 123 of the amino acid sequence, is incorporated into vector pET-28b (+) (Novagen, catalog number: 69865), and His tag is located on the C-terminal side. A plasmid was constructed to express the protein with linked sequences.
- Escherichia coli SHuffle T7 (New England Biolabs, catalog number: C3029H) was transformed and cultured in TB medium (Sigma Aldrich, catalog number: T0918). After culture, the ultrasonically disrupted cells were centrifuged, and the supernatant was purified with a HisTrap FF crude column (GE Healthcare, catalog number: 17-5286-01). Thereafter, the human ALK2 extracellular domain was purified by electrophoresis using a HiLoad 26/600 Superdex 200 column (GE Healthcare, catalog number: 28-9893-36) to a single band with a molecular weight of 12 kDa.
- Capture and the capture method was performed by measuring the antigen as an analyte.
- An anti-human IgG (Fc) antibody Human Antibody Capture kit, GE Healthcare Biosciences
- CM5 Sensor Chip
- the reference cell was similarly fixed.
- Example 15 In vivo activity evaluation of humanized A2-15A antibody (IgG2) and humanized A2-27D antibody (IgG1 LALA) Humanized hA2-15A-H4 / L6 (IgG2) prepared in Example 11) -4 and Examples 12) -4 The inhibitory activity against ectopic ossification of humanized hA2-27D-H2 / L2 (IgG1 LALA) produced in 4) -4 was analyzed using an ectopic ossification model by transplantation of BMP7 using mice.
- a Collapape (manufactured by Zimmer Dental) cut into a 4 mm diameter circle and BMP7 (manufactured by Miltenney) soaked with 2.5 micro G ( ⁇ g) was frozen overnight at ⁇ 80 ° C. and then vacuum-dried.
- the hair of the skin near the femur of a mouse (C57BL / 6: 8-9 weeks old) was removed, incised under isoflurane suction anesthesia, and freeze-dried filter paper was transplanted into skeletal muscle. Two weeks after transplantation, ectopic ossification was analyzed by micro CT (Comscan), and then ectopic bone in skeletal muscle was taken out and weighed. did.
- the antibody was administered subcutaneously once a week (Day-1, Day 6 with Day 0 as the transplant date). Dilution was performed with a solvent (HBSor) so that the concentration of the administered antibody was 1, 3, 10 mg / kg.
- HBSor a solvent
- IgG manufactured by JACKSON IMMUNORESEARCH
- JACKSON IMMUNORESEARCH was prepared in a solvent so as to be 10 mg / kg and administered.
- Example 16 Epitope analysis of A2-27D antibody 16) -1 Preparation of human chimeric cA2-27D Fab fragment A Fab fragment was prepared from the human chimeric cA2-27D antibody obtained in Example 5) -8 using Pierce Fab Preparation Kit.
- X-ray diffraction data was collected under a 95K nitrogen stream at BL1A of the Synchrotron Radiation Research Laboratory, High Energy Accelerator Research Organization. From the obtained diffraction image, the diffraction intensity was quantified using software XDS (Acta Cryst. (2010). D66, 125-132) to obtain the crystal structure factor.
- a molecular replacement method was performed to determine the phase.
- a software phaser (CCP4: Collaborative Computation Project No. 4) was used for the calculation.
- the crystal contained one complex per asymmetric unit.
- the structure was refined using software refmac5 (CCP4), and the model was corrected using software coot. This operation was repeated to obtain a final R value of 22.3% and a freeR value of 26.7% with a resolution of 2.6 mm.
- the model consists of one complex, A2-27D Fab L chain amino acid residues 1-211, H chain amino acid residues 1-134 and 141-223, ALK2-ECD amino acid residues 11-89, and 61 Contains water molecules.
- amino acid residues of ALK2-ECD within 4 km from the determined A2-27D Fab are as follows: Glu18, Gly19, Ile39, Asn40, Asp41, Gly42, Phe43, His44, Val45, Tyr46, Asn82, Thr84, Gln86, Leu87.
- FIG. 37 shows a ribbon model of the entire composite.
- Example 17 Design of humanized A2-11E antibody and humanized A2-25C antibody 17) -1 Design of humanized hA2-11E 17) -1-1 Molecular modeling of variable region of A2-11E A2-11E variable region molecule Modeling was performed by a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). Primary sequence of variable region of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) (three-dimensional structure derived from X-ray crystal structure is available) was compared to the variable region of A2-11E determined above.
- 3BN9 was selected as having the highest sequence identity to the heavy and light chain variable regions of A2-11E.
- the three-dimensional structure of the framework region was created by combining the coordinates of 3BN9 to obtain a “framework model”. A representative conformation for each CDR was then incorporated into the framework model.
- the amino acid residues in the framework regions for the human ⁇ chain subgroup 3 consensus sequence and the human ⁇ chain subgroup 1 consensus sequence are aligned with the amino acid residues for A2-11E, and the positions where different amino acids are used are Identified.
- the positions of these residues are analyzed using the 3D model of A2-11E constructed above, and the donor residues to be grafted on the acceptor are described in Queen et al. (Proc. Natl. Acad. Sci. USA 86, 1000029-10033 (1989)).
- the sequence of humanized hA2-11E was constructed as described in the examples below by transferring several selected donor residues into the acceptor antibody.
- the amino acid sequence of the humanized hA2-11E-H3 type heavy chain is described in SEQ ID NO: 111 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 137th amino acid residues, the sequence consisting of the 138th to 467th amino acid residues of the amino acid sequence of SEQ ID NO: 111 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 111 is described in SEQ ID NO: 110 of the sequence listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 411, the sequence consisting of nucleotides 412 to 1401 of the nucleotide sequence of SEQ ID NO: 110 are a signal sequence, a heavy chain variable region sequence and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 110 and the amino acid sequence of SEQ ID NO: 111 are also shown in FIG.
- the humanized hA2-11E heavy chain designed to replace amino acid number 88 (serine) with alanine and amino acid number 93 (threonine) with valine was named “hA2-11E-H4 type heavy chain”.
- the amino acid sequence of the humanized hA2-11E-H4 type heavy chain is described in SEQ ID NO: 113 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 137th amino acid residues, and the sequence consisting of the 138th to 467th amino acid residues of the amino acid sequence of SEQ ID NO: 113 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 113 is set forth in SEQ ID NO: 112 of the Sequence Listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 411, and the sequence consisting of nucleotides 412 to 1401 of the nucleotide sequence of SEQ ID NO: 112 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 112 and the amino acid sequence of SEQ ID NO: 113 are also shown in FIG.
- the amino acid sequence of the humanized hA2-11E-L2 type light chain is set forth in SEQ ID NO: 115 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 128th amino acid residues, and the sequence consisting of the 129th to 233rd amino acid residues of the amino acid sequence of SEQ ID NO: 115 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 115 is set forth in SEQ ID NO: 114 in the sequence listing.
- the sequence consisting of nucleotides 1 to 60, the sequence consisting of nucleotides 61 to 384, the sequence consisting of nucleotides 385 to 699 of the nucleotide sequence of SEQ ID NO: 114 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 114 and the amino acid sequence of SEQ ID NO: 115 are also shown in FIG.
- amino acid number 10 (leucine) of the A2-11E light chain shown in SEQ ID NO: 4 of the sequence listing is serine, and amino acid number 21 (leucine) is isoleucine.
- Amino acid number 22 (serine) to threonine amino acid number 40 (leucine) to proline
- amino acid number 42 amino acid number 42 (glutamic acid) to lysine
- amino acid number 83 valine
- amino acid number 85 isoleucine
- the amino acid sequence of the humanized hA2-11E-L3 type light chain is set forth in SEQ ID NO: 117 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 128th amino acid residues, and the sequence consisting of the 129th to 233rd amino acid residues of the amino acid sequence of SEQ ID NO: 117 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 117 is described in SEQ ID NO: 116 in the sequence listing.
- the sequence consisting of the 1st to 60th nucleotides, the sequence consisting of the 61st to 384th nucleotides, and the sequence consisting of the 385th to 699th nucleotides of the nucleotide sequence of SEQ ID NO: 116 are a signal sequence, a light chain variable region sequence and a light chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 116 and the amino acid sequence of SEQ ID NO: 117 are also shown in FIG.
- the amino acid number 10 (leucine) of the A2-11E light chain shown in SEQ ID NO: 4 in the sequence listing is serine, and amino acid number 21 (leucine) is isoleucine.
- the amino acid number 40 (leucine) is proline, the amino acid number 83 (valine) is phenylalanine, the amino acid number 103 (leucine) is valine, the amino acid number 105 (leucine) is isoleucine, and the amino acid number 108 (alanine) is threonine.
- the humanized hA2-11E light chain designed with replacement was named “hA2-11E-L4 type light chain”.
- the amino acid sequence of the humanized hA2-11E-L4 type light chain is set forth in SEQ ID NO: 119 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 128th amino acid residues, and the sequence consisting of the 129th to 233rd amino acid residues of the amino acid sequence of SEQ ID NO: 119 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 119 is set forth as SEQ ID NO: 118 in the Sequence Listing.
- the sequence consisting of the 1st to 60th nucleotides of the nucleotide sequence of SEQ ID NO: 118, the sequence consisting of the 61st to 384th nucleotides, the sequence consisting of the 385th to 699th nucleotides are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 118 and the amino acid sequence of SEQ ID NO: 119 are also shown in FIG.
- An antibody consisting of a humanized hA2-11E-H3 type heavy chain and a humanized hA2-11E-L4 type light chain was designed and called “humanized hA2-11E-H3 / L4” (“hA2-11E-H3 / L4”) Sometimes named).
- An antibody consisting of a humanized hA2-11E-H4 type heavy chain and a humanized hA2-11E-L2 type light chain was designed and called “humanized hA2-11E-H4 / L2” (“hA2-11E-H4 / L2”) Sometimes named).
- An antibody consisting of a humanized hA2-11E-H4 type heavy chain and a humanized hA2-11E-L3 type light chain was designed and called “humanized hA2-11E-H4 / L3” (“hA2-11E-H4 / L3”) Sometimes named).
- An antibody consisting of a humanized hA2-11E-H4 type heavy chain and a humanized hA2-11E-L4 type light chain was designed and called “humanized hA2-11E-H4 / L4” (“hA2-11E-H4 / L4”) Sometimes named).
- the antibody designed as described above can be prepared according to Example 18 and evaluated according to Examples 2 and 4.
- variable region of A2-25C is a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). Primary sequence of variable region of human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) (three-dimensional structure derived from X-ray crystal structure is available) was compared to the variable region of AA2-25C determined above. As a result, 3BN9 was selected as having the highest sequence identity to the A2-25C heavy and light chain variable regions. The three-dimensional structure of the framework region was created by combining the coordinates of 3BN9 to obtain a “framework model”. A representative conformation for each CDR was then incorporated into the framework model.
- the sequence of the framework region of A2-25C was compared with the framework region of the human subgroup consensus sequence.
- KABAT et al. Sequences of subgroups of subgroups of sequence group 1 in the sequence of subgroups of sequences in sequence of sequence of humans, sequence of humans, sequence of humans, health services, health, bethesda, MD. (1991)).
- the amino acid residues of the framework regions for the human ⁇ chain subgroup 3 consensus sequence and the human ⁇ chain subgroup 1 consensus sequence are aligned with the amino acid residues for A2-25C, and the positions where different amino acids are used are Identified.
- the amino acid sequence of the humanized hA2-25C-H3 type heavy chain is described in SEQ ID NO: 121 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 137th amino acid residues, and the sequence consisting of the 138th to 467th amino acid residues of the amino acid sequence of SEQ ID NO: 121 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 121 is described in SEQ ID NO: 120 of the sequence listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 411, the sequence consisting of nucleotides 412 to 1401 of the nucleotide sequence of SEQ ID NO: 120 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 120 and the amino acid sequence of SEQ ID NO: 121 are also shown in FIG.
- the amino acid number 19 (lysine) of the A2-25C heavy chain shown in SEQ ID NO: 10 of the sequence listing is arginine, and amino acid number 38 (cysteine) is arginine.
- the amino acid number 42 (threonine) is glycine, the amino acid number 63 (threonine) is serine, the amino acid number 75 (alanine) is serine, the amino acid number 84 (aspartic acid) is asparagine, and the amino acid number 88 (serine) is alanine.
- the humanized hA2-25C heavy chain designed by substituting amino acid number 113 (methionine) for leucine was named “hA2-25C-H4 type heavy chain”.
- the amino acid sequence of the humanized hA2-25C-H4 type heavy chain is described in SEQ ID NO: 123 in the sequence listing.
- the sequence consisting of the 1st to 19th amino acid residues, the sequence consisting of the 20th to 137th amino acid residues, and the sequence consisting of the 138th to 467th amino acid residues of the amino acid sequence of SEQ ID NO: 123 are respectively a signal sequence and a heavy chain It corresponds to the variable region and heavy chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 123 is described in SEQ ID NO: 122 in the sequence listing.
- the sequence consisting of nucleotides 1 to 57, the sequence consisting of nucleotides 58 to 411, the sequence consisting of nucleotides 412 to 1401 of the nucleotide sequence of SEQ ID NO: 122 are a signal sequence, a heavy chain variable region sequence, and a heavy chain constant, respectively.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 122 and the amino acid sequence of SEQ ID NO: 123 are also shown in FIG.
- the amino acid sequence of the humanized hA2-25C-L1 type light chain is set forth in SEQ ID NO: 125 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 125 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 125 is described in SEQ ID NO: 124 in the sequence listing.
- the sequence consisting of the 1st to 60th nucleotides of the nucleotide sequence of SEQ ID NO: 124, the sequence consisting of the 61st to 387th nucleotides, and the sequence consisting of the 388th to 702th nucleotides are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 124 and the amino acid sequence of SEQ ID NO: 125 are also shown in FIG.
- Amino acid number 9 (alanine) of the A2-25C light chain shown in SEQ ID NO: 12 of the sequence listing is serine, and amino acid number 15 (leucine) is valine.
- the amino acid number 16 (glutamic acid) is glycine
- the amino acid number 17 (glutamic acid) is aspartic acid
- the amino acid number 18 (isoleucine) is arginine
- the amino acid number 43 (serine) is alanine
- the amino acid number 45 (glutamine) is lysine.
- Amino acid number 70 (glutamine) aspartic acid, amino acid number 72 (serine) as threonine, amino acid number 74 (lysine) as threonine, amino acid number 77 (arginine) as serine, amino acid number 79 (arginine) as Glutamine, amino acid number 80 (valine) to proline Amino acid number 83 (isoleucine) to phenylalanine, amino acid number 84 (glycine) to alanine, amino acid number 85 (isoleucine) to threonine, amino acid number 100 (serine) to glutamine, amino acid number 104 (leucine) to valine, A humanized hA2-25C light chain designed to replace amino acid number 109 (alanine) with threonine was named “hA2-25C-L2 type light chain”.
- the amino acid sequence of the humanized hA2-25C-L2 type light chain is set forth in SEQ ID NO: 127 in the sequence listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 127 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 127 is described in SEQ ID NO: 126 in the sequence listing.
- the sequence consisting of the 1st to 60th nucleotides of the nucleotide sequence of SEQ ID NO: 126, the sequence consisting of the 61st to 387th nucleotides, and the sequence consisting of the 388th to 702th nucleotides are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 126 and the amino acid sequence of SEQ ID NO: 127 are also shown in FIG.
- the amino acid number 9 (alanine) of the A2-25C light chain shown in SEQ ID NO: 12 of the sequence listing is serine, and amino acid number 15 (leucine) is valine.
- the amino acid number 16 (glutamic acid) is glycine
- the amino acid number 17 (glutamic acid) is aspartic acid
- the amino acid number 18 (isoleucine) is arginine
- the amino acid number 45 (glutamine) is lysine
- the amino acid number 72 (serine) is threonine.
- amino acid number 74 (lysine) is threonine
- amino acid number 77 (arginine) is serine
- amino acid number 79 (arginine) is glutamine
- amino acid number 80 (valine) is proline
- amino acid number 83 (isoleucine) is phenylalanine.
- Amino acid number 84 (glycine) The humanized hA2-25C light chain designed to replace amino acid number 85 (isoleucine) with threonine, amino acid number 104 (leucine) with valine, and amino acid number 109 (alanine) with threonine, -25C-L3 type light chain ".
- the amino acid sequence of the humanized hA2-25C-L3 type light chain is set forth in SEQ ID NO: 129 in the Sequence Listing.
- the sequence consisting of the 1st to 20th amino acid residues, the sequence consisting of the 21st to 129th amino acid residues, and the sequence consisting of the 130th to 234th amino acid residues of the amino acid sequence of SEQ ID NO: 129 are respectively a signal sequence and a light chain It corresponds to the variable region and the light chain constant region.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 129 is set forth in SEQ ID NO: 128 of the Sequence Listing.
- sequence consisting of the 1st to 60th nucleotides of the nucleotide sequence of SEQ ID NO: 128, the sequence consisting of the 61st to 387th nucleotides, and the sequence consisting of the 388th to 702th nucleotides are respectively a signal sequence, a light chain variable region sequence and a light chain constant.
- the normal region sequence is encoded.
- the nucleotide sequence of SEQ ID NO: 128 and the amino acid sequence of SEQ ID NO: 129 are also shown in FIG.
- An antibody consisting of a humanized hA2-125C-H3 type heavy chain and a humanized hA2-25C-L3 type light chain was designed and called “humanized hA2-25C-H3 / L3” (“hA2-25C-H3 / L3”) Sometimes named).
- An antibody consisting of a humanized hA2-25C-H4 type heavy chain and a humanized hA2-25C-L1 type light chain was designed and referred to as “humanized hA2-25C-H4 / L1” (“hA2-25C-H4 / L1”).
- humanized hA2-25C-H4 / L1 (“hA2-25C-H4 / L1”).
- An antibody consisting of a humanized hA2-25C-H4 type heavy chain and a humanized hA2-25C-L2 type light chain was designed and called “humanized hA2-25C-H4 / L2” (“hA2-25C-H4 / L2”) Sometimes named).
- An antibody consisting of a humanized hA2-25C-H4 type heavy chain and a humanized hA2-25C-L3 type light chain was designed and called “humanized hA2-25C-H4 / L3” (“hA2-25C-H4 / L3”) Sometimes named).
- the antibody designed as described above can be prepared according to Example 18 and evaluated according to Examples 2 and 4.
- Example 18 Construction and preparation of humanized A2-11E antibody (IgG1) and humanized A2-25C antibody (IgG1) vector 18) -1 Construction of humanized A2-11E heavy chain expression vector 18) -1-1 Humanization Construction of hA2-11E-H3 type heavy chain expression vector DNA encoding the variable region of humanized hA2-11E-H3 shown in nucleotide numbers 36 to 428 of the nucleotide sequence of humanized hA2-11E-H3 shown in SEQ ID NO: 110 A DNA fragment containing the sequence was synthesized (Geneart Artificial Gene Synthesis Service).
- humanized hA2-11E-H4 type heavy chain expression vector Humanized hA2-11E- represented by nucleotide numbers 36 to 428 of the nucleotide sequence of humanized hA2-11E-H4 represented by SEQ ID NO: 112
- a DNA fragment containing a DNA sequence encoding the variable region of H4 was synthesized (GENEART artificial gene synthesis service).
- Example 8 A humanized hA2-11E-H4 expression vector was constructed in the same manner as in 1-1. The obtained expression vector was designated as “pCMA-G1 / hA2-11E-H4”.
- a DNA fragment containing a DNA sequence encoding the variable region of humanized hA2-11E-L2 was amplified with KOD-Plus- (TOYOBO) and the following primer set, and Example 5)-
- the humanized hA2-11E-L2 by inserting the chimeric and humanized antibody light chain expression vector pCMA-LK constructed in 1 into the site cleaved with the restriction enzyme BsiWI using the In-Fusion HD PCR cloning kit (Clontech). An expression vector was constructed. The obtained expression vector was designated as “pCMA / hA2-11E-L2”.
- Primer set 5′-CTGTGGATCTCCGGCCGCGTACGCC-3 ′ (CM-LKF; SEQ ID NO: 134) 5′-GGAGGGGGCGCCACCCGTACG-3 ′ (KCL-Inf-R; SEQ ID NO: 135)
- Opti-Pro SFM Invitrogen
- 200 ⁇ L of the expression vector / Opti-Pro SFM mixed solution was added to 200 ⁇ L of the Polyethyleneimine / Opti-Pro SFM mixed solution, gently stirred, allowed to stand for another 5 minutes, and then added to FreeStyle 293F cells.
- a culture supernatant obtained by shaking culture at 90 rpm for 7 days in a 37 ° C., 8% CO 2 incubator was subjected to a Minisart-Plus filter (Sartorius) and filtered to obtain a sample for evaluation.
- Example 19 In vitro activity evaluation of humanized A2-11E antibody (IgG1) and humanized A2-25C antibody (IgG1) 19) -1 Antibody evaluation by BMP osteoblast differentiation induction assay Human prepared in Example 18) -5 Inhibitory activity of intracellular signal via endogenous ALK2 of humanized A2-11E antibody (IgG1) and humanized A2-25C antibody (IgG1) was similar to that in Example 6) -2. It analyzed by the effect with respect to the differentiation-inducing activity to a cell. For differentiation induction, 2.5 ng / mL GDF2 / BMP9 (manufactured by RD-SYSTEMS) was used.
- Example 20 Evaluation of binding of humanized A2-11E antibody (IgG1) and humanized A2-25C antibody (IgG1) to human ALK2 Humanized A2-11E antibody (IgG1) prepared in Example 18) -5, and humanized A2 Measurement of dissociation constant between -25C antibody (IgG1) and antigen (human ALK2 extracellular domain prepared in Example 14) -1 was performed using Biacore T200 (GE Healthcare Biosciences).
- the anti-human IgG (Fc) antibody was captured (captured) using an antibody as a ligand and the antigen was measured as an analyte, and the capture method was used.
- An anti-human IgG (Fc) antibody (Human Antibody Capture kit, GE Healthcare Biosciences) was covalently bound to sensor chip CM5 (GE Healthcare Biosciences) by about 1000 RU by the amine coupling method. .
- the reference cell was similarly fixed.
- the dissociation phase for 600 seconds was monitored.
- 3M MgCl 2 was added at a flow rate of 10 ⁇ l / min for 30 seconds.
- Example 21 Epitope analysis of A2-25C antibody 21) -1
- Human chimeric cA2-25C Fab fragment Human chimeric cA2-25C prepared in the same manner as in Example 5) -8 was prepared by using Papain (Sigma-Aldrich) with Fab fragment and Fc fragment. And added to a HiTrap Protein A HP column (GE Healthcare). The Fab fragment collected in the flow-through fraction was concentrated.
- Example 21) -2 Crystallization and Structural Analysis of Human Chimeric cA2-25C Fab Fragment and ALK2-ECD Complex
- Example 21) -1 Chimeric A2-25C Fab fragment obtained in Example 21 and ALK2-ECD prepared according to Example 14 The complex was concentrated to 3.8 mg / mL and used for crystallization. A vapor diffusion method was used for crystallization.
- the diffraction intensity was quantified from the obtained diffraction image using software mosflm (CCP4: Collaborative Computation Project No. 4) to obtain the crystal structure factor.
- a molecular replacement method was performed to determine the phase.
- a software phaser (CCP4: Collaborative Computation Project No. 4) was used for the calculation.
- the crystal contained two complexes in the asymmetric unit.
- the structure was refined using software refmac5 (CCP4), and the model was corrected using software coot. This operation was repeated to obtain a final R value of 22.4% and a freeR value of 25.3% with a resolution of 2.1 mm.
- the model consists of two complexes: A2-25C Fab L chain amino acid residue 1-212, H chain amino acid residue 1-219, ALK2-ECD amino acid residues 12-52 and 66-88, and 411 Contains water molecules.
- amino acid residues of ALK2-ECD that are commonly within 4 cm from the two determined A2-25C Fabs are as follows: Glu18, Gly19, Leu20, Ile39, Asp41, Gly42, Phe43, His44, Val45, Tyr46 , Thr84.
- FIG. 49 shows a ribbon model of the entire composite.
- Example 22 Evaluation of inhibitory activity of A2-27D against various mutant ALK2 Thirteen mutants identified from FOP cases (L196P, delP197_F198insL, R202I, R206H, Q207E, R258S, R258G, G325A, G328E, G328R, G328W, G356D) In addition, the inhibitory activity of A2-27 against R375P) and wild type ALK2 was analyzed with a BMP-specific Id1WT4F-luciferase reporter using HEK293A cells in the same manner as in Example 2) -3.
- the culture medium was fresh OPTI-MEM I (Life Technologies) containing 10 ng / mL BMP7 (Milteney), 3 ⁇ g / mL rat IgG1 (R & D Systems), or A2-27D. And the cells were cultured overnight. The next day, luciferase activity was measured using Dual-Glo Luciferase Assay System (manufactured by Promega).
- the chimeric or humanized anti-ALK2 antibody of the present invention has an inhibitory action on BMP signaling through ALK2, and the pharmaceutical composition containing the anti-ALK2 antibody has ectopic ossification and / or dysplasia, anemia, Alternatively, it can be a therapeutic or preventive agent for diffuse bridge glioma (DIPG).
- DIPG diffuse bridge glioma
- SEQ ID NO: 1 Nucleotide sequence of cDNA encoding heavy chain variable region of A2-11E SEQ ID NO: 2: Amino acid sequence of heavy chain variable region of A2-11E SEQ ID NO: 3: Light chain variable region of A2-11E Nucleotide sequence of cDNA encoding SEQ ID NO: 4: amino acid sequence of light chain variable region of A2-11E SEQ ID NO: 5: nucleotide sequence of cDNA encoding heavy chain variable region of A2-15A SEQ ID NO: 6: of A2-15A Amino acid sequence of heavy chain variable region SEQ ID NO: 7: nucleotide sequence of cDNA encoding light chain variable region of A2-15A SEQ ID NO: 8: amino acid sequence of variable region of light chain of A2-15A SEQ ID NO: 9: A2- Nucleotide sequence of cDNA encoding the variable region of the heavy chain of 25C SEQ ID NO: 10: Amino acid sequence of the variable region of the heavy chain of A
Abstract
Description
(a)配列番号84に示されるアミノ酸配列
(b)配列番号84に示されるアミノ酸配列の21乃至123番目のアミノ酸残基からなるアミノ酸配列
(c)配列番号86に示されるアミノ酸配列
(d)配列番号86に示されるアミノ酸配列の21乃至123番目のアミノ酸残基からなるアミノ酸配列
(e)(a)乃至(d)のいずれか一つに記載のアミノ酸配列に1乃至数アミノ酸残基の置換、欠失又は付加を伴うアミノ酸配列
(f)配列番号85に示されるヌクレオチド配列
(g)配列番号85に示されるヌクレオチド配列の728乃至1036番目のヌクレオチド残基からなるヌクレオチド配列
(h)配列番号87に示されるヌクレオチド配列
(i)配列番号87に示されるヌクレオチド配列の728乃至1036番目のヌクレオチド残基からなるヌクレオチド配列
(j)(f)乃至(i)のいずれか一つに記載のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドのヌクレオチド配列
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号75に示されるアミノ酸配列からなり、前記CDRL2は配列番号76に示されるアミノ酸配列からなり、前記CDRL3は、配列番号77に示されるアミノ酸配列からなること;
を特徴とする、(1)乃至(8)のいずれかに記載の抗体又は該抗体の抗原結合断片。
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号62に示されるアミノ酸配列からなり、前記CDRL2は配列番号63又は配列番号71に示されるアミノ酸配列からなり、前記CDRL3は、配列番号64に示されるアミノ酸配列からなること;
を特徴とする、(1)乃至(8)のいずれかに記載の抗体又は該抗体の抗原結合断片。
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号81に示されるアミノ酸配列からなり、前記CDRL2は配列番号82に示されるアミノ酸配列からなり、前記CDRL3は、配列番号83に示されるアミノ酸配列からなること;
を特徴とする、(1)乃至(10)、(13)乃至(14)のいずれかに記載の抗体又は該抗体の抗原結合断片。
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号68に示されるアミノ酸配列からなり、前記CDRL2は配列番号69に示されるアミノ酸配列からなり、前記CDRL3は、配列番号70に示されるアミノ酸配列からなること;
を特徴とする、(1)乃至(8)、(11)乃至(14)のいずれかに記載の抗体又は該抗体の抗原結合断片。
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号28に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号30に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a3) 配列番号105に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a4) a1)乃至a3)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a5) a1)乃至a3)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a6) a1)乃至a3)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号32に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号34に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号36に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b4) 配列番号38に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b5) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b6) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b7) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号40に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号42に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a3) 配列番号44に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a4) 配列番号46に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a5) 配列番号48に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a6) 配列番号107に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a7) 配列番号109に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a8) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a9) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a10) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号50に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号52に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号54に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b4) 配列番号56に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b5) 配列番号58に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b6) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b7) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b8) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号111に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号113に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a3) a1)又はa2)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a4) a1)又はa2)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a5) a1)又はa2)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号115に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号117に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号119に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b4) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b5) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b6) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号121に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号123に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a3) a1)又はa2)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a4) a1)又はa2)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a5) a1)又はa2)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号125に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号127に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号129に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b4) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b5) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b6) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。
a1) 配列番号27に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号29に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号104に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a4) a1)乃至a3)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a5) a1)乃至a3)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a6) a1)乃至a3)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a7) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号31に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号33に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号35に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号37に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b5) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b6) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b7) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b8) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
a1) 配列番号39に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号41に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号43に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a4) 配列番号45に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a5) 配列番号47に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a6) 配列番号106に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a7) 配列番号108に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a8) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a9) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a10) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a11) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号49に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号51に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号53に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号55に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b5) 配列番号57に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b6) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b7) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b8) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b9) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
a1) 配列番号110に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号112に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号114に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号116に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号118に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
a1) 配列番号120に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号122に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号124に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号126に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号128に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
本明細書中において、「遺伝子」という語には、DNAのみならずmRNA、cDNA及びcRNAも含まれるものとする。
ALK2遺伝子は、骨格筋組織を含む軟組織において異所性骨形成を誘導するBMPの受容体の一種をコードするFOPの責任遺伝子である。家族性、および孤発性FOP症例からは、アミノ酸置換を伴った変異型ALK2が見出されている。ヒトALK2の変異型としては、L196P(196番目のロイシンがプロリンに置換された変異)、delP197_F198insL(197番目のプロリン及び198番目のフェニルアラニンが欠失し、ロイシンが挿入された変異)、R202I(202番目のアルギニンがイソロイシンに置換された変異)、R206H(206番目のアルギニンがヒスチジンに置換された変異)、Q207E(207番目のグルタミンがグルタミン酸に置換された変異)、R258S(258番目のアルギニンがセリンに置換された変異)、R258G(258番目のアルギニンがグリシンに置換された変異)、G325A(325番目のグリシンがアラニンに置換された変異)、G328E(328番目のグリシンがグルタミン酸に置換された変異)、G328R(328番目のグリシンがアルギニンに置換された変異)、G328W(328番目のグリシンがトリプトファンに置換された変異)、G356D(356番目のグリシンがアスパラギン酸に置換された変異)、R375P(375番目のアルギニンがプロリンに置換された変異)等が知られている。
ALK2を介したBMPシグナル伝達により、異所性骨化及び/又は骨形成異常が惹起される。
本発明のALK2に対する抗体は、例えば、WO2009/091048、WO2011/027808、又はWO2012/133572に記載の方法で得ることができる。すなわち、非ヒト動物を目的抗原で免疫し、免疫成立後の動物からリンパ液、リンパ組織、血球試料又は骨髄由来の細胞を採取し、目的抗原に特異的に結合する非ヒト動物の形質細胞及び/又は形質芽細胞を選択する。得られた形質細胞及び/又は形質芽細胞から目的抗原に対する抗体遺伝子を採取し、その塩基配列を同定し、同定した遺伝子の塩基配列に基づいて上記抗体又は抗体の断片を得ることができる。また、ヒト感染患者の血液から同様に形質細胞及び/又は形質芽細胞を得ることにより、抗体又は抗体断片を得ることができる。取得された抗体はALK2に対する結合性を試験することによって、ヒトの疾患に適用可能な抗体を選別できる。このようにして得られたモノクローナル抗体の例としては、A2-11E、A2-15A、A2-25C、A2-27Dを挙げることができる。
(a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号27に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号29に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号104に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a4) a1)乃至a3)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a5) a1)乃至a3)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a6) a1)乃至a3)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a7) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号31に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号33に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号35に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号37に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b5) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b6) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b7) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b8) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
(a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号39に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号41に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号43に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a4) 配列番号45に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a5) 配列番号47に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a6) 配列番号106に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a7) 配列番号108に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a8) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a9) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a10) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a11) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号49に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号51に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号53に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号55に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b5) 配列番号57に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b6) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b7) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b8) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b9) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
(a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号110に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号112に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号114に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号116に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号118に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
(a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号120に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号122に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号124に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号126に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号128に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。
上述の「4.抗ALK2抗体の製造」の項に記載された方法で得られる抗ALK2抗体の中から、ALK2の生物活性を阻害する抗体を得ることができる。これらALK2の生物活性を阻害する抗体は、生体内でのALK2の生物活性、すなわちALK2を介するBMPシグナル伝達を阻害することから、医薬として、異所性骨化及び/又は骨形成異常に対する治療及び/又は予防剤、又は貧血に対する治療及び/又は予防剤として用いることができる。
ラット抗ALK2抗体(11E2、15A6、25C11、および27D11:以下、A2-11E、A2-15A、A2-25C、およびA2-27Dと略す)の作製
1)-1 抗原の調製
抗原となるmALK2-Fcは、Sino Biological Inc.社製のマウスALK2-His&Fc(Cat.#50297-M03H)を用いた。
1mg/mLのマウスALK2-His&FcとTiterMaxGold (TiterMax、USA)を等量混合しエマルジョンを作製した。6週齢のWister雌ラット、2匹に、1匹あたり100μgの抗原をアジュバントと共に、2回に分けて皮下投与した。1~2週間後に抗原溶液のみを40μg皮下投与し、3日後に抗体産生細胞として脾臓細胞と各種リンパ節を無菌的に摘出し、以下の細胞融合に供した。
上記の抗体産生細胞を、BALB/cマウスから得られた株化骨髄腫細胞(P3U1細胞)と5:1~10:1の割合に調整し、50%ポリエチレングリコール1500を用いて3分間融合させ、その後、6分間かけて希釈した。融合した細胞は、ラット1匹あたり10枚の96穴プレートを用いて、フィーダー細胞(胸腺細胞)と共に播種した。培地として、HATサプリメントを含む15%FBS含有RPMI1640培地(グルタミン、ピルビン酸、ペニシリン、ストレプトマイシン含有)で培養した。
細胞融合から1週間後、それぞれの培養上清を用いて、酵素結合免疫吸着法(ELISA)で、抗原として用いたマウスALK2-His&Fcを認識するクローンを選択し、さらに、ヒトFc(Sino Biological Inc.社製)のみを認識するクローンを除外した。ELISAは以下のように行った。
ラット抗ALK2抗体(A2-11E、A2-15A、A2-25C、およびA2-27D)のin vitro評価
2)-1 フローサイトメトリー法による抗体スクリーニング
2)-1-1 マウスおよびヒトALK2発現細胞の調製
HEK293A細胞を、3×104細胞/cm2となるように100mmディッシュに播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、pcDEF3/マウスALK2(WT)-EGFP、pcDEF3/ヒトALK2(WT)-EGFP、pcDEF3/ヒトALK2(R206H)-EGFP、pcDEF3を、それぞれHEK293A細胞にLipofectamine 2000(Invitrogen社製)を用いて導入し、さらに一晩培養した。翌日、1×106細胞/mLとなるように調整した細胞懸濁液を、100μLずつ1.5mL微量遠心管に分注し、500gで5分間遠心した後に上清を除去した。細胞に、1μg/mLに希釈した精製IgG100μLを加え、4℃で30分間静置した。細胞をPBSで3回洗浄後、1:200に希釈したAlexa flour 647 Goat anti-Rat IgG(H+L)(Life Technologies社製)100μLを加え、さらに4℃で30分間静置した。細胞をPBSで3回洗浄後、フローサイトメーター(FACS Aria II:BD Biosciences社製)で蛍光を検出した。データはBD Diva Software(BD Biosciences社製)で解析し、細胞の発現するEGFPの強度と、染色されたAlexa flour 647の蛍光強度をプロットした。
2)-2-1 ヒトALK1、ALK2、ALK3、ALK6発現細胞の調製
マウスC2C12細胞を5×103細胞/穴となるように、96穴プレート(グライナー社製)に播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、pcDEF3/ヒトALK1-EGFP、pcDEF3/ヒトALK2-EGFP、pcDEF3/ヒトALK3-EGFP、pcDEF3/ヒトALK6-EGFP、およびコントロールのpcDEF3を、それぞれC2C12細胞にLipofectamine 2000(Invitrogen社製)を用いて導入し、さらに一晩培養した。
C2C12細胞を、10%中性ホルマリン(ナカライテスク社製、日本)で、室温、20分間固定後、10%ヤギ正常血清で30分間ブロッキングを行った。ブロッキング液を除去した後、ブロッキング液で10μg/mLに希釈した精製IgGを加え、室温で1時間静置した。PBSで3回洗浄後、ブロッキング液で1:1000に希釈したGoat Alexa594-conjugated anti-rat IgG(Invitrogen社製)を加えて、室温で1時間静置した。PBSで3回洗浄後、10%中性ホルマリンで室温、15分固定し、DAPI(LifeTechnologies社製)を用いて核染色を施した。蛍光シグナルは、蛍光顕微鏡BZ-9000(Keyence社製)を用いて観察した。
マウスC2C12細胞を0.5×103細胞/穴となるように、96穴プレート(グライナー社製)に播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、pcDEF3に組み込んだヒトALK2 cDNAの野生型、およびpcDEF3/ヒトALK2―L196P、pcDEF3/ヒトALK2―P197_F198delinsL,pcDEF3/ヒトALK2―R202I,pcDEF3/ヒトALK2―R206H,pcDEF3/ヒトALK2―Q207E,pcDEF3/ヒトALK2―R258S,pcDEF3/ヒトALK2―G325A,pcDEF3/ヒトALK2―G328E,pcDEF3/ヒトALK2―G328R,pcDEF3/ヒトALK2―G328W,pcDEF3/ヒトALK2―G356D,およびpcDEF3/ヒトALK2―R375Pの各FOPで同定された変異体、およびコントロールのpcDEF3を、それぞれC2C12細胞にLipofectamine 2000(Invitrogen社製)を用いて導入し、さらに一晩培養した。
C2C12細胞を、10%中性ホルマリン(ナカライテスク社製、日本)で、室温、20分間固定後、10%ヤギ正常血清で30分間ブロッキングを行った。ブロッキング液を除去した後、ブロッキング液で10μg/mLに希釈した精製IgGを加え、室温で1時間静置した。PBSで3回洗浄後、ブロッキング液で1:1000に希釈したGoat Alexa594-conjugated anti-rat IgG(Invitrogen社製)を加えて、室温で1時間静置した。PBSで3回洗浄後、10%中性ホルマリンで室温、15分固定し、DAPI(LifeTechnologies社製)を用いて核染色を施した。蛍光シグナルは、蛍光顕微鏡BZ-9000(Keyence社製)を用いて観察した。
モノクローナル抗体のALK2を介した細胞内シグナルの阻害活性は、BMP特異的なルシフェラーゼ・レポーターを用いて解析した。HEK293A細胞を、1×104細胞/穴となるように、ルシフェラーゼ・アッセイ用96穴白色プレート(グライナー社製)に播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、pcDEF3/ヒトALK2(WT)-V5-His、またはpcDEF3/ヒトALK2(R206H)-V5-His、pGL4.26/Id1WT4F-luc(Genes Cells,7,949(2002))、phRL SV40(Promega社製)を、Lipofectamine 2000(Invitrogen社製)を用いて導入した。2.5時間後、培地を新鮮なOPTI-MEM I(LifeTechnologies社製)に交換し、さらに1時間培養した。その後、段階希釈したモノクローナル抗体と10ng/mLのBMP7(Milteney社製)、または0.5ng/mLのBMP9(Peprotech社製)を含むOPTI-MEM Iに交換し、さらに一晩培養した。翌日、Dual-Glo Luciferase Assay System(Promega社製)を用いて、Firefly、およびRenillaのルシフェラーゼ活性をプレートリーダーGENios(TECAN社製)で測定した。
モノクローナル抗体の内在性ALK2を介した細胞内シグナルの阻害活性は、BMPによるC2C12細胞の骨芽細胞への分化誘導活性に対する効果で解析した。C2C12細胞を、0.5×103細胞/穴となるように、96穴プレート(グライナー社製)に播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、段階希釈したモノクローナル抗体と200ng/mLのBMP2(コアフロント社製)、200ng/mLのBMP7(Milteney社製)、または20ng/mLのGDF2/BMP9(Peprotech社製)を含むOPTI-MEM Iに交換し、さらに3日間培養した。C2C12細胞の培地を除き、PBSで洗浄した後、細胞を50μL/穴の氷冷したアセトン:エタノール(1:1)溶液で1分間処理し、さらに3回、PBSで洗浄した。骨芽細胞用細胞への分化の指標として、ALP活性を測定した。ALP活性の測定は、100μL/穴の基質溶液(1 mg/mL 4-Nitrophenyl phosphate(Sigma-Aldrich社製)と1mM MgCl2を含む0.1M Diethanolamine(Sigma-Aldrich社製)-HCl,pH10.0)を加え、室温で15-30分間、撹拌振盪機上で反応させた。反応は、50μLの3M NaOHを添加して停止させ、波長405nmの吸光度をマイクロプレートリーダーinfinite F50(TECAN社製)を用いて測定した。
ラット抗ALK2抗体(A2-11E,A2-15A,A2-25C,A2-27D)の可変領域をコードするcDNAのヌクレオチド配列の決定
3)-1 A2-11Eの可変領域をコードするcDNAのヌクレオチド配列の決定
3)-1-1 A2-11E産生ハイブリドーマからのtotal RNAの調製
A2-11Eの可変領域を含むcDNAを増幅するため、A2-11E産生ハイブリドーマよりTRIzol Reagent(Ambion社)を用いてtotal RNAを調製した。
cDNA(5’-RACE-Ready cDNA)の合成は実施例3)-1-1で調製したtotal RNAの1μgを用い、SMARTer RACE cDNA Amplification Kit(Clontech社)を用いて実施した。
A2-11Eの重鎖遺伝子の可変領域のcDNAをPCRで増幅するためのプライマーとして、UPM (Universal Primer A Mix:SMARTer RACE cDNA Amplification Kitに付属)、及び
5’-CTCCAGAGTTCCAGGTCACGGTGACTGGC-3’(RG2AR3;配列番号88)の配列を有するオリゴヌクレオチドを用いた。UPMはSMARTer RACE cDNA Amplification Kit(Clontech社)に付属のものを使用し、RG2AR3はデータベースのラット重鎖の定常領域の配列から設計した。
5’-CTCCAGAGTTCCAGGTCACGGTGACTGGC-3’(RG2AR3;配列番号88)の配列を有するオリゴヌクレオチド、及びNUP (Nested Universal Primer A:SMARTer RACE cDNA Amplification Kitに付属)を用いた。
A2-11Eの軽鎖遺伝子の可変領域のcDNAをPCRで増幅するためのプライマーとして、UPM (Universal Primer A Mix:SMARTer RACE cDNA Amplification Kitに付属)、及び
5’-TCAGTAACACTGTCCAGGACACCATCTC-3’(RKR5;配列番号89)の配列を有するオリゴヌクレオチドを用いた。UPMはSMARTer RACE cDNA Amplification Kit(Clontech社)に付属のものを使用し、RKR5はデータベースのラット軽鎖の定常領域の配列から設計した。
3)-2-1 A2-15A産生ハイブリドーマからのtotal RNAの調製
A2-15Aの可変領域を含むcDNAを増幅するため、A2-15A生産ハイブリドーマより実施例3)-1-1と同様の方法でtotal RNAを調製した。
cDNA(5’-RACE-Ready cDNA)の合成は実施例3)-2-1で調製したtotal RNAの1μgを用い、実施例3)-1-2と同様の方法で実施した。
実施例3)-2-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-3と同様の方法でA2-15Aの重鎖可変領域を含むcDNAを増幅して配列を決定した。
実施例3)-2-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-4と同様の方法でA2-15Aの軽鎖可変領域を含むcDNAを増幅して配列を決定した。
3)-3-1 A2-25C産生ハイブリドーマからのtotal RNAの調製
A2-25Cの可変領域を含むcDNAを増幅するため、A2-25C生産ハイブリドーマより実施例3)-1-1と同様の方法でtotal RNAを調製した。
cDNA(5’-RACE-Ready cDNA)の合成は実施例3)-3-1で調製したtotal RNAの1μgを用い、実施例3)-1-2と同様の方法で実施した。
実施例3)-3-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-3と同様の方法でA2-25Cの重鎖可変領域を含むcDNAを増幅して配列を決定した。
実施例3)-3-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-4と同様の方法でA2-25Cの軽鎖可変領域を含むcDNAを増幅して配列を決定した。
3)-4-1 A2-27D産生ハイブリドーマからのtotal RNAの調製
A2-27Dの可変領域を含むcDNAを増幅するため、A2-27D生産ハイブリドーマより実施例3)-1-1と同様の方法でtotal RNAを調製した。
cDNA(5’-RACE-Ready cDNA)の合成は実施例3)-4-1で調製したtotal RNAの1μgを用い、実施例3)-1-2と同様の方法で実施した。
実施例3)-4-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-3と同様の方法でA2-27Dの重鎖可変領域を含むcDNAを増幅して配列を決定した。
実施例3)-4-2で合成したcDNA(5’-RACE-Ready cDNA)を鋳型として用いて、実施例3)-1-4と同様の方法でA2-27Dの軽鎖可変領域を含むcDNAを増幅して配列を決定した。
ラット抗ALK2抗体(A2-15A、およびA2-27D)のin vivo評価
4)-1 ハイブリドーマ培養上清の調製
実施例1)-4で得られた1.0×106個のハイブリドーマを10%FBS含有TILハイグルコース培地で培養し(T75フラスコ)、その後INTEGRA CL1000にて高密度培養を行った(10%FBS培地)。次に培地を無血清に置換し、さらにINTEGRA CL1000での培養を行った後に必要量のハイブリドーマ培養上清を取得した。取得したハイブリドーマ培養上清は精製に供するまで2~8℃で保存した。
実施例4)-1で得られた培養上清から抗体をProtein Gアフィニティークロマトグラフィー(4~6℃下)一段階工程で精製した。Protein Gアフィニティークロマトグラフィー精製後のバッファー置換工程は4~6℃下で実施した。最初に、PBSで平衡化したProtein G(GE Healthcare Bioscience社)が充填されたカラムにハイブリドーマの培養上清をアプライした。培養上清液がカラムに全て入ったのち、カラム容量2倍以上のPBSでカラムを洗浄した。次に0.1 Mグリシン/塩酸水溶液(pH2.7)で溶出し、抗体の含まれる画分を集めた。集めた画分に1M Tris-HCl(pH9.0)を加えてpH7.0~7.5に調製した後に、透析(Thermo Scientificsha,Slide-A-Lyzer Dialysis Cassette)によりHBSor(25mM ヒスチジン/5% ソルビトール、pH6.0)への液置換を行った。Centrifugal UF Filter Device VIVASPIN20(分画分子量UF10K,Sartorius社、4℃下)にて濃縮し、IgG濃度を8mg/ml以上に調製した。最後にMinisart-Plus filter(Sartorius社)でろ過し、精製サンプルとした。
モノクローナル抗体の骨格筋組織における異所性骨化の抑制活性は、マウスにおけるBMPによる異所性骨誘導実験で解析した。BMP含有ペレットは、1μgのBMP7(Milteney社製)、または1μgのGDF2/BMP9(Peprotech社製)を、直径4mmに調整したI型コラーゲンスポンジ(Collatape、Zimmer Dental社製)に染み込ませ、一晩、凍結乾燥機(FDU-810、東京理科器械社製、日本)にて凍結乾燥して作製した。8-10週令のC57BL/6マウスを、小動物実験用簡易吸入麻酔装置(夏目製作所社製、日本)および2%イソフルラン(和光純薬工業社製、日本)を用いて全身麻酔し、左右下肢の大腿筋組織内にBMP含有ペレットを1個ずつ移植した。ハイブリドーマA2-15A、およびA2-27Dの産生するモノクローナル抗体を、移植1週間前から、10mg/kg、1回/週、皮下投与し、移植後2週目まで、同様に抗体を投与しながら飼育した。対照群には、等量の溶媒(25mM Histidine/5%Sorbitol,pH6.0)を投与した。BMP含有ペレット移植2週間後、大腿骨とともに移植したBMP含有ペレットを摘出し、マイクロCT(μCT35,SCANCO社製)で異所性骨の形成を解析した。
ヒトキメラ化抗ALK2抗体(cA2-15A、cA2-27D)の作製
5)-1キメラ及びヒト化抗体軽鎖発現ベクターpCMA-LKの構築
プラスミドpcDNA3.3-TOPO/LacZ(Invitrogen社)を制限酵素XbaI及びPmeIで消化して得られる約5.4kbのフラグメントと、配列番号17に示すヒトκ鎖分泌シグナル及びヒトκ鎖定常領域をコードするDNA配列を含むDNA断片を、In-Fusion Advantage PCRクローニングキット(Clontech社)を用いて結合して、pcDNA3.3/LKを作製した。
プライマーセット
5’-TATACCGTCGACCTCTAGCTAGAGCTTGGC-3’(3.3-F1;配列番号90)
5’-GCTATGGCAGGGCCTGCCGCCCCGACGTTG-3’(3.3-R1;配列番号91)
pCMA-LKをXbaI及びPmeIで消化してκ鎖分泌シグナル及びヒトκ鎖定常領域を取り除いたDNA断片と、配列番号18に示すヒト重鎖シグナル配列及びヒトIgG1定常領域のアミノ酸をコードするDNA配列を含むDNA断片を、In-Fusion Advantage PCRクローニングキット(Clontech社)を用いて結合して、CMVプロモーターの下流にシグナル配列、クローニングサイト、ヒトIgG1重鎖定常領域をもつキメラ及びヒト化抗体IgG1タイプ重鎖発現ベクターpCMA-G1を構築した。
実施例3)-2-3で得られたA2-15Aの重鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社、日本)と下記のプライマーセットで重鎖の可変領域をコードするcDNAを含むDNA断片を増幅し、キメラ及びヒト化IgG1タイプ重鎖発現ベクターpCMA-G1を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cA2-15A重鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/cA2-15A」と命名した。cA2-15A重鎖のヌクレオチド配列を配列番号19に示し、アミノ酸配列を配列番号20に示した。
cA2-15A重鎖用プライマーセット
5’-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGGAGTCTGGCGGAG-3’(A2-15AH-F;配列番号92)
5’-CTTGGTGGAGGCTGAGCTGACAGTGACCAGAGTGCCTTGGCCCCAG-3’(A2-15AH-R;配列番号93)
実施例3)-2-4で得られたA2-15Aの軽鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社、日本)と下記のプライマーセットで軽鎖の可変領域をコードするcDNAを含むDAN断片を増幅し、キメラ及びヒト化軽鎖発現汎用ベクターpCMA-LKを制限酵素BsiWIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cA2-15Aの軽鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-LK/cA2-15A」と命名した。cA2-15Aの軽鎖のヌクレオチド配列を配列表の配列番号21に示し、アミノ酸配列を配列番号22に示した。
cA2-15A軽鎖用プライマーセット
5’-ATCTCCGGCGCGTACGGCGACATTGTCTTGACCCAGTCTCCTGC-3’(A2-15AL-F;配列番号94)
5’-GGAGGGGGCGGCCACAGCCCGTTTCAGTTCCAGCTTGGTCCCAG-3’(A2-15AL-R;配列番号95)
実施例3)-4-3で得られたA2-27Dの重鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社、日本)と下記のプライマーセットで重鎖の可変領域をコードするcDNAを含むDNA断片を増幅し、キメラ及びヒト化IgG1タイプ重鎖発現ベクターpCMA-G1を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cA2-27D重鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/cA2-27D」と命名した。cA2-27D重鎖のヌクレオチド配列を配列番号23に示し、アミノ酸配列を配列番号24に示した。
cA2-27D重鎖用プライマーセット
5’-CCAGATGGGTGCTGAGCGAGGTGCAGCTGGTGGAGTCTGGAGGAG-3’(A2-27DH-F;配列番号96)
5’-CTTGGTGGAGGCTGAGCTCACGGTGACCACGGTTCCTGGGCCCCAG-3’(A2-27DH-R;配列番号97)
実施例3)-4-4で得られたA2-27Dの軽鎖の可変領域を含むcDNAをテンプレートとして、KOD-Plus-(TOYOBO社、日本)と下記のプライマーセットで軽鎖の可変領域をコードするcDNAを含むDAN断片を増幅し、キメラ及びヒト化抗体軽鎖発現汎用ベクターpCMA-LKを制限酵素BsiWIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、cA2-27D抗体の軽鎖発現ベクターを構築した。得られた発現ベクターを「pCMA-LK/cA2-27D」と命名した。cA2-27D抗体の軽鎖のヌクレオチド配列を配列表の配列番号25に示し、アミノ酸配列を配列番号26に示した。
cA2-27D軽鎖用プライマーセット
5’-ATCTCCGGCGCGTACGGCGAAATTGTTCTCACTCAGTCTCCAAC-3’(A2-27DL-F;配列番号98)
5’-GGAGGGGGCGGCCACAGCCCGTTTCAGTTCCAGCTTGGTCCCAG-3’(A2-15AL-R;配列番号95)
FreeStyle 293F細胞(Invitrogen社)はマニュアルに従い、継代、培養をおこなった。対数増殖期の1.2×109個のFreeStyle 293F細胞(Invitrogen社)を3L Fernbach Erlenmeyer Flask(CORNING社)に播種し、FreeStyle293 expression medium (Invitrogen社)で希釈して2.0×106細胞/mlに調製したのちに、37℃、8%CO2インキュベーター内で90rpmで1時間振とう培養した。Polyethyleneimine(Polyscience #24765)1.8mgをOpti-Pro SFM培地(Invitrogen社)20mlに溶解し、次にNucleoBond Xtra(TaKaRa社、日本)を用いて調製したH鎖発現ベクター(0.24mg)及びL鎖発現ベクター(0.36mg)を20mlのOpti-Pro SFM培地(Invitrogen社)に添加した。Polyethyleneimine/Opti-Pro SFM混合液20mlに、発現ベクター/Opti-Pro SFM混合液20mlを加え穏やかに攪拌し、さらに5分間放置した後にFreeStyle 293F細胞に添加した。37℃、8%CO2インキュベーターで4時間、90rpmで振とう培養後に600mlのEX-CELL VPRO培地(SAFC Biosciences社)、18mlのGlutaMAX I(GIBCO社)、及び30mlのYeastolate Ultrafiltrate(GIBCO社)を添加し、37℃、8%CO2インキュベーターで7日間、90rpmで振とう培養して得られた培養上清をDisposable Capsule Filter (Advantec #CCS-045-E1H)でろ過した。
実施例5)-7で得られた培養上清から抗体をrProtein Aアフィニティークロマトグラフィー(4-6℃下)とセラミックハイドロキシアパタイト(室温下)の二段階工程で精製した。rProtein Aアフィニティークロマトグラフィー精製後とセラミックハイドロキシアパタイト精製後のバッファー置換工程は4-6℃下で実施した。PBSで平衡化したMabSelectSuRe(GE Healthcare Bioscience社製、HiTrapカラム)に培養上清をアプライした。培養上清がカラムに全て入ったのち、カラム容量2倍以上のPBSでカラムを洗浄した。次に2Mアルギニン塩酸塩溶液(pH4.0)で溶出し、抗体の含まれる画分を集めた。その画分を透析(Thermo Scientific社、Slide-A-Lyzer Dialysis Cassette)によりPBSに置換した後、5mMリン酸ナトリウム/50mM MES/pH7.0のバッファーで5倍希釈した抗体溶液を、5mM NaPi/50mM MES/30mM NaCl/pH7.0のバッファーで平衡化されたセラミックハイドロキシアパタイトカラム(日本バイオラッド、Bio-Scale CHT Type―1 Hydroxyapatite Column)にアプライした。塩化ナトリウムによる直線的濃度勾配溶出を実施し、抗体の含まれる画分を集めた。その画分を透析(Thermo Scientificsha,Slide-A-Lyzer Dialysis Cassette)によりHBSor(25mM ヒスチジン/5%ソルビトール、pH6.0)への液置換を行った。Centrifugal UF Filter Device VIVASPIN20(分画分子量UF10K,Sartorius社、4℃下)にて濃縮し、IgG濃度を2mg/ml以上に調整した。最後にMinisart-Plus filter(Sartorius社)でろ過し、精製サンプルとした。
ヒトキメラ化抗ALK2抗体(cA2-15A、cA2-27D)のin vitro活性評価
6)-1 ルシフェラーゼ・レポーター・アッセイによる抗体評価
作製したヒトキメラ化抗体のALK2を介した細胞内シグナルの阻害活性は、BMP特異的なルシフェラーゼ・レポーターを用いて解析した。HEPG2細胞を、1×104細胞/穴となるように、ルシフェラーゼ・アッセイ用96穴白色プレート(CORNING社製)に播種し、10%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、pGL4.26/Id1WT4F-luc(Genes Cells,7,949(2002))を、Lipofectamine 2000(Invitrogen社製)を用いて導入した。2.5時間後、培地を新鮮なOPTI-MEM I(LifeTechnologies社製)に交換し、さらに3時間培養した。その後、段階希釈したモノクローナル抗体と10ng/mLのBMP7(Milteney社製)を含むOPTI-MEM Iに交換し、さらに一晩培養した。翌日、Dual-Glo Luciferase Assay System(Promega社製)を用いてルシフェラーゼ活性をプレートリーダーSpectraMaxM4(Molecular Devices社製)で測定した。
作製したヒトキメラ化抗体の内在性ALK2を介した細胞内シグナルの阻害活性は、BMPによるC2C12細胞の骨芽細胞への分化誘導活性に対する効果で解析した。C2C12細胞を、5×103細胞/穴となるように、96穴プレート(IWAKI社製)に播種し、15%FBSを含むDMEM培地中で、37℃、5%CO2の条件下で一晩培養した。翌日、培地を新鮮なOPTI-MEM I(LifeTechnologies社製)に交換し、段階希釈したモノクローナル抗体と2 ng/mLのGDF2/BMP9(Peprotech社製)を含むOPTI-MEM Iに交換し、さらに3日間培養した。C2C12細胞の培地を除き、PBSで洗浄した後、細胞を50μL/穴の氷冷したアセトン:エタノール(1:1)溶液で1分間処理し、さらに3回、PBSで洗浄した。骨芽細胞用細胞への分化の指標として、ALP活性を測定した。ALP活性の測定は、100 μL/穴の基質溶液(1 mg/mL 4-Nitrophenyl phosphate(Sigma-Aldrich社製)と1mM MgCl2を含む0.1M Diethanolamine(Sigma-Aldrich社製)-HCl,pH10.0)を加え、室温で15-30分間、撹拌振盪機上で反応させた。反応は、50 μLの3 M NaOHを添加して停止させ、波長405nmの吸光度をプレートリーダーSpectraMaxM4(Molecular Devices社製)を用いて測定した。
抗ALK2抗体A2-15A、および A2-27Dのヒト化体デザイン
7)-1 ヒト化hA2-15Aの設計
7)-1-1 A2-15Aの可変領域の分子モデリング
A2-15Aの可変領域の分子モデリングは、ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153,(1991))によって実行された。Protein Data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されるヒト免疫グロブリンの可変領域の1次配列(X線結晶構造から誘導される三次元構造が入手可能である)を、上で決定されたA2-15Aの可変領域と比較した。結果として、3KYMと3S35がそれぞれA2-15Aの重鎖と軽鎖の可変領域に対して最も高い配列同一性を有するとして選択された。フレームワーク領域の三次元構造は、A2-15Aの重鎖及び軽鎖に対応する3KYM及び3S35の座標を組み合わせて、「フレームワークモデル」を得ることによって作製された。次いで、それぞれのCDRについての代表的なコンホメーションがフレームワークモデルに組み込まれた。
ヒト化hA2-15Aの構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知の方法によって行った。アクセプター抗体は、フレームワーク領域内のアミノ酸同一性に基づいて選択された。
7)-2-1 ヒト化hA2-15A-H1タイプ重鎖
配列番号20に示されるキメラcA2-15Aの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号61(スレオニン)をグリシンに、アミノ酸番号94(アラニン)をセリンに、アミノ酸番号96(セリン)をアスパラギンに、アミノ酸番号103(アスパラギン酸)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに、アミノ酸番号112(スレオニン)をバリンに、アミノ酸番号116(スレオニン)をアラニンに置き換えることを伴い設計されたヒト化hA2-15A重鎖を「ヒト化hA2-15A-H1タイプ重鎖」(「hA2-15A-H1」と呼ぶこともある)と命名した。
配列番号20に示されるキメラcA2-15Aの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号61(スレオニン)をグリシンに、アミノ酸番号103(アスパラギン酸)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに置き換えることを伴い設計されたヒト化hA2-15A重鎖を「ヒト化hA2-15A-H4タイプ重鎖」(「hA2-15A-H4」と呼ぶこともある)と命名した。
7)-3-1 ヒト化hA2-15A-L1タイプ軽鎖
配列番号22に示されるキメラcA2-15Aの軽鎖のアミノ酸番号24(ロイシン)をメチオニンに、アミノ酸番号29(アラニン)をアスパラギン酸に、アミノ酸番号29-30の間(欠損残基)をセリンに、アミノ酸番号36(グルタミン)をグルタミン酸に、アミノ酸番号41(セリン)をアスパラギンに、アミノ酸番号66(リジン)をプロリンに、アミノ酸番号81(イソロイシン)をバリンに、アミノ酸番号83(アラニン)をアスパラギン酸に、アミノ酸番号99(アスパラギン)をセリンに、アミノ酸番号100(プロリン)をセリンに、アミノ酸番号101(バリン)をロイシンに、アミノ酸番号104(アスパラギン酸)をグルタミン酸に、アミノ酸番号106(イソロイシン)をバリンに、アミノ酸番号108(スレオニン)をバリンに、アミノ酸番号123(アラニン)をグルタミンに、アミノ酸番号127(ロイシン)をバリンに、アミノ酸番号129(ロイシン)をイソロイシンに置き換えることを伴い設計されたヒト化hA2-15A軽鎖を「ヒト化hA2-15A-L1タイプ軽鎖」(「hA2-15A-L1」と呼ぶこともある)と命名した。
配列番号22に示されるキメラcA2-15Aの軽鎖のアミノ酸番号29(アラニン)をアスパラギン酸に、アミノ酸番号29-30の間(欠損残基)をセリンに、アミノ酸番号36(グルタミン)をグルタミン酸に、アミノ酸番号41(セリン)をアスパラギンに、アミノ酸番号99(アスパラギン)をセリンに、アミノ酸番号100(プロリン)をセリンに、アミノ酸番号108(スレオニン)をバリンに、アミノ酸番号123(アラニン)をグルタミンに置き換えることを伴い設計されたヒト化hA2-15A軽鎖を「ヒト化hA2-15A-L4タイプ軽鎖」(「hA2-15A-L4」と呼ぶこともある)と命名した。
配列番号22に示されるキメラcA2-15Aの軽鎖のアミノ酸番号29(アラニン)をアスパラギン酸に、アミノ酸番号29-30の間(欠損残基)をセリンに、アミノ酸番号36(グルタミン)をグルタミン酸に、アミノ酸番号41(セリン)をアスパラギンに、アミノ酸番号79(セリン)をグルタミンに、アミノ酸番号99(アスパラギン)をセリンに、アミノ酸番号100(プロリン)をセリンに、アミノ酸番号108(スレオニン)をバリンに、アミノ酸番号123(アラニン)をグルタミンに置き換えることを伴い設計されたヒト化hA2-15A軽鎖を「ヒト化hA2-15A-L6タイプ軽鎖」(「hA2-15A-L6」と呼ぶこともある)と命名した。
配列番号22に示されるキメラcA2-15Aの軽鎖のアミノ酸番号29(アラニン)をアスパラギン酸に、アミノ酸番号29-30の間(欠損残基)をセリンに、アミノ酸番号36(グルタミン)をグルタミン酸に、アミノ酸番号41(セリン)をアスパラギンに、アミノ酸番号70(ロイシン)をアラニンに、アミノ酸番号99(アスパラギン)をセリンに、アミノ酸番号100(プロリン)をセリンに、アミノ酸番号108(スレオニン)をバリンに、アミノ酸番号123(アラニン)をグルタミンに置き換えることを伴い設計されたヒト化hA2-15A軽鎖を「ヒト化hA2-15A-L7タイプ軽鎖」(「hA2-15A-L7」と呼ぶこともある)と命名した。
ヒト化hA2-15A-H1タイプ重鎖及びヒト化hA2-15A-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H1/L1」(「hA2-15A-H1/L1」と呼ぶこともある)と命名した。ヒト化hA2-15A-H1タイプ重鎖及びヒト化hA2-15A-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H1/L4」(「hA2-15A-H1/L4」と呼ぶこともある)と命名した。ヒト化hA2-15A-H4タイプ重鎖及びヒト化hA2-15A-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H4/L1」(「hA2-15A-H4/L1」と呼ぶこともある)と命名した。ヒト化hA2-15A-H4タイプ重鎖及びヒト化hA2-15A-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H4/L4」(「hA2-15A-H4/L4」と呼ぶこともある)と命名した。ヒト化hA2-15A-H4タイプ重鎖及びヒト化hA2-15A-L6タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H4/L6」(「hA2-15A-H4/L6」と呼ぶこともある)と命名した。ヒト化hA2-15A-H4タイプ重鎖及びヒト化hA2-15A-L7タイプ軽鎖からなる抗体を設計し「ヒト化hA2-15A-H4/L7」(「hA2-15A-H4/L7」と呼ぶこともある)と命名した。以上により設計した抗体は、実施例8に準じて作製し、実施例2及び4に準じて評価することができる。
7)-5-1 A2-27Dの可変領域の分子モデリング
A2-27Dの可変領域の分子モデリングは、ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153,(1991))によって実行された。Protein Data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されるヒト免疫グロブリンの可変領域の1次配列(X線結晶構造から誘導される三次元構造が入手可能である)を、上で決定されたA2-27Dの可変領域と比較した。結果として、3EYQと4I9WがそれぞれA2-27Dの重鎖と軽鎖の可変領域に対して最も高い配列同一性を有するとして選択された。フレームワーク領域の三次元構造は、A2-27Dの重鎖及び軽鎖に対応する3EYQ及び4I9Wの座標を組み合わせて、「フレームワークモデル」を得ることによって作製された。次いで、それぞれのCDRについての代表的なコンホメーションがフレームワークモデルに組み込まれた。
ヒト化hA2-27Dの構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知の方法によって行った。アクセプター抗体は、フレームワーク領域内のアミノ酸同一性に基づいて選択された。
7)-6-1 ヒト化hA2-27D-H1タイプ重鎖
配列番号24に示されるキメラcA2-27Dの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(ロイシン)をアラニンに、アミノ酸番号56(イソロイシン)をバリンに、アミノ酸番号68(アラニン)をセリンに、アミノ酸番号94(アラニン)をセリンに、アミノ酸番号95(アルギニン)をリジンに、アミノ酸番号103(スレオニン)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに、アミノ酸番号112(ロイシン)をバリンに、アミノ酸番号117(アラニン)をアルギニンに、アミノ酸番号132(プロリン)をグルタミンに、アミノ酸番号135(バリン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-15A重鎖を「ヒト化hA2-27D-H1タイプ重鎖」(「hA2-27D-H1」と呼ぶこともある)と命名した。
配列番号24に示されるキメラcA2-27Dの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(ロイシン)をアラニンに、アミノ酸番号68(アラニン)をセリンに、アミノ酸番号94(アラニン)をセリンに、アミノ酸番号95(アルギニン)をリジンに、アミノ酸番号103(スレオニン)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに、アミノ酸番号112(ロイシン)をバリンに、アミノ酸番号132(プロリン)をグルタミンに、アミノ酸番号135(バリン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-27D重鎖を「ヒト化hA2-27D-H2タイプ重鎖」(「hA2-27D-H2」と呼ぶこともある)と命名した。
配列番号24に示されるキメラcA2-27Dの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(ロイシン)をアラニンに、アミノ酸番号94(アラニン)をセリンに、アミノ酸番号95(アルギニン)をリジンに、アミノ酸番号103(スレオニン)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに、アミノ酸番号112(ロイシン)をバリンに、アミノ酸番号132(プロリン)をグルタミンに、アミノ酸番号135(バリン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-27D重鎖を「ヒト化hA2-27D-H3タイプ重鎖」(「hA2-27D-H3」と呼ぶこともある)と命名した。
配列番号24に示されるキメラcA2-27Dの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(ロイシン)をアラニンに、アミノ酸番号94(アラニン)をセリンに、アミノ酸番号95(アルギニン)をリジンに、アミノ酸番号103(スレオニン)をアスパラギンに、アミノ酸番号107(セリン)をアラニンに、アミノ酸番号135(バリン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-27D重鎖を「ヒト化hA2-27D-H4タイプ重鎖」(「hA2-27D-H4」と呼ぶこともある)と命名した。
配列番号24に示されるキメラcA2-27Dの重鎖のアミノ酸番号35(アルギニン)をグリシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(ロイシン)をアラニンに、アミノ酸番号95(アルギニン)をリジンに、アミノ酸番号103(スレオニン)をアスパラギンに、アミノ酸番号135(バリン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-27D重鎖を「ヒト化hA2-27D-H5タイプ重鎖」(「hA2-27D-H5」と呼ぶこともある)と命名した。
7)-7-1 ヒト化hA2-27D-L1タイプ軽鎖
配列番号26に示されるキメラcA2-27Dの軽鎖のアミノ酸番号29(スレオニンをグリシンに、アミノ酸番号31(メチオニン)をロイシンに、アミノ酸番号32(アラニン)をセリンに、アミノ酸番号33(アラニン)をロイシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号39(バリン)をアラニンに、アミノ酸番号42(アスパラギン)をセリンに、アミノ酸番号59(セリン)をプロリンに、アミノ酸番号61(アラニン)をグルタミンに、アミノ酸番号62(セリン)をアラニンに、アミノ酸番号64(リジン)をアルギニンに、アミノ酸番号66(トリプトファン)をロイシンに、アミノ酸番号77(バリン)をイソロイシンに、アミノ酸番号79(アスパラギン)をアスパラギン酸に、アミノ酸番号89(セリン)をアスパラギン酸に、アミノ酸番号90(チロシン)をフェニルアラニンに、アミノ酸番号91(セリン)をスレオニンに、アミノ酸番号93(アラニン)をスレオニンに、アミノ酸番号96(セリン)をアルギニンに、アミノ酸番号97(メチオニン)をロイシンに、アミノ酸番号99(アラニン)をプロリンに、アミノ酸番号102(バリン)をフェニルアラニンに、アミノ酸番号104(スレオニン)をバリンに、アミノ酸番号120(アラニン)をグルタミンに、アミノ酸番号124(ロイシン)をバリンに、アミノ酸番号126(ロイシン)をイソロイシンに、置き換えることを伴い設計されたヒト化hA2-27D軽鎖を「ヒト化hA2-27D-L1タイプ軽鎖」(「hA2-27D-L1」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcA2-27Dの軽鎖のアミノ酸番号29(スレオニンをグリシンに、アミノ酸番号31(メチオニン)をロイシンに、アミノ酸番号32(アラニン)をセリンに、アミノ酸番号33(アラニン)をロイシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号39(バリン)をアラニンに、アミノ酸番号42(アスパラギン)をセリンに、アミノ酸番号59(セリン)をプロリンに、アミノ酸番号61(アラニン)をグルタミンに、アミノ酸番号64(リジン)をアルギニンに、アミノ酸番号79(アスパラギン)をアスパラギン酸に、アミノ酸番号89(セリン)をアスパラギン酸に、アミノ酸番号90(チロシン)をフェニルアラニンに、アミノ酸番号91(セリン)をスレオニンに、アミノ酸番号93(アラニン)をスレオニンに、アミノ酸番号96(セリン)をアルギニンに、アミノ酸番号97(メチオニン)をロイシンに、アミノ酸番号99(アラニン)をプロリンに、アミノ酸番号102(バリン)をフェニルアラニンに、アミノ酸番号104(スレオニン)をバリンに、アミノ酸番号120(アラニン)をグルタミンに、アミノ酸番号124(ロイシン)をバリンに、アミノ酸番号126(ロイシン)をイソロイシンに、置き換えることを伴い設計されたヒト化hA2-27D軽鎖を「ヒト化hA2-27D-L2タイプ軽鎖」(「hA2-27D-L2」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcA2-27Dの軽鎖のアミノ酸番号29(スレオニンをグリシンに、アミノ酸番号31(メチオニン)をロイシンに、アミノ酸番号32(アラニン)をセリンに、アミノ酸番号33(アラニン)をロイシンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号39(バリン)をアラニンに、アミノ酸番号42(アスパラギン)をセリンに、アミノ酸番号59(セリン)をプロリンに、アミノ酸番号64(リジン)をアルギニンに、アミノ酸番号79(アスパラギン)をアスパラギン酸に、アミノ酸番号89(セリン)をアスパラギン酸に、アミノ酸番号91(セリン)をスレオニンに、アミノ酸番号93(アラニン)をスレオニンに、アミノ酸番号96(セリン)をアルギニンに、アミノ酸番号97(メチオニン)をロイシンに、アミノ酸番号99(アラニン)をプロリンに、アミノ酸番号102(バリン)をフェニルアラニンに、アミノ酸番号124(ロイシン)をバリンに、アミノ酸番号126(ロイシン)をイソロイシンに、置き換えることを伴い設計されたヒト化hA2-27D軽鎖を「ヒト化hA2-27D-L3タイプ軽鎖」(「hA2-27D-L3」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcA2-27Dの軽鎖のアミノ酸番号29(スレオニンをグリシンに、アミノ酸番号32(アラニン)をセリンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号42(アスパラギン)をセリンに、アミノ酸番号59(セリン)をプロリンに、アミノ酸番号64(リジン)をアルギニンに、アミノ酸番号79(アスパラギン)をアスパラギン酸に、アミノ酸番号89(セリン)をアスパラギン酸に、アミノ酸番号91(セリン)をスレオニンに、アミノ酸番号93(アラニン)をスレオニンに、アミノ酸番号96(セリン)をアルギニンに、アミノ酸番号99(アラニン)をプロリンに、アミノ酸番号102(バリン)をフェニルアラニンに置き換えることを伴い設計されたヒト化hA2-27D軽鎖を「ヒト化hA2-27D-L4タイプ軽鎖」(「hA2-27D-L4」と呼ぶこともある)と命名した。
配列番号26に示されるキメラcA2-27Dの軽鎖のアミノ酸番号29(スレオニンをグリシンに、アミノ酸番号32(アラニン)をセリンに、アミノ酸番号38(リジン)をアルギニンに、アミノ酸番号91(セリン)をスレオニンに、アミノ酸番号93(アラニン)をスレオニンに、アミノ酸番号96(セリン)をアルギニンに、アミノ酸番号99(アラニン)をプロリンに、アミノ酸番号102(バリン)をフェニルアラニンに置き換えることを伴い設計されたヒト化hA2-27D軽鎖を「ヒト化hA2-27D-L5タイプ軽鎖」(「hA2-27D-L5」と呼ぶこともある)と命名した。
ヒト化hA2-27D-H1タイプ重鎖及びヒト化hA2-27D-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H1/L1」(「hA2-27D-H1/L1」と呼ぶこともある)と命名した。ヒト化hA2-27D-H1タイプ重鎖及びヒト化hA2-27D-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H1/L2」(「hA2-27D-H1/L2」と呼ぶこともある)と命名した。ヒト化hA2-27D-H1タイプ重鎖及びヒト化hA2-27D-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H1/L3」(「hA2-27D-H1/L3」と呼ぶこともある)と命名した。ヒト化hA2-27D-H2タイプ重鎖及びヒト化hA2-27D-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H2/L1」(「hA2-27D-H2/L1」と呼ぶこともある)と命名した。ヒト化hA2-27D-H2タイプ重鎖及びヒト化hA2-27D-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H2/L2」(「hA2-27D-H2/L2」と呼ぶこともある)と命名した。ヒト化hA2-27D-H2タイプ重鎖及びヒト化hA2-27D-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H2/L3」(「hA2-27D-H2/L3」と呼ぶこともある)と命名した。ヒト化hA2-27D-H3タイプ重鎖及びヒト化hA2-27D-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H3/L1」(「hA2-27D-H3/L1」と呼ぶこともある)と命名した。ヒト化hA2-27D-H3タイプ重鎖及びヒト化hA2-27D-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H3/L2」(「hA2-27D-H3/L2」と呼ぶこともある)と命名した。ヒト化hA2-27D-H3タイプ重鎖及びヒト化hA2-27D-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H3/L3」(「hA2-27D-H3/L3」と呼ぶこともある)と命名した。ヒト化hA2-27D-H3タイプ重鎖及びヒト化hA2-27D-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H3/L4」(「hA2-27D-H3/L4」と呼ぶこともある)と命名した。ヒト化hA2-27D-H4タイプ重鎖及びヒト化hA2-27D-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H4/L3」(「hA2-27D-H4/L3」と呼ぶこともある)と命名した。ヒト化hA2-27D-H4タイプ重鎖及びヒト化hA2-27D-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H4/L4」(「hA2-27D-H4/L4」と呼ぶこともある)と命名した。ヒト化hA2-27D-H4タイプ重鎖及びヒト化hA2-27D-L5タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H4/L5」(「hA2-27D-H4/L5」と呼ぶこともある)と命名した。ヒト化hA2-27D-H5タイプ重鎖及びヒト化hA2-27D-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-27D-H5/L4」(「hA2-27D-H5/L4」と呼ぶこともある)と命名した。以上により設計した抗体は、実施例8に準じて作製し、実施例2及び4に準じて評価することができる。
ヒト化A2-15A抗体、及びヒト化A2-27D抗体の発現ベクターの構築と抗体の調製
8)-1 ヒト化A2-15Aの重鎖発現ベクターの構築
8)-1-1 ヒト化hA2-15A-H1タイプ重鎖発現ベクターの構築
配列番号27に示すヒト化hA2-15A-H1のヌクレオチド配列のヌクレオチド番号36乃至443に示されるヒト化hA2-15A-H1の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。合成したDNA断片をテンプレートとして、KOD-Plus-(TOYOBO社、日本)と下記のプライマーセットでヒト化hA2-15A-H1の可変領域をコードするDNA配列を含むDNA断片を増幅し、キメラ及びヒト化抗体IgG1タイプ重鎖発現ベクターpCMA-G1を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することによりヒト化hA2-15A-H1発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-15A-H1」と命名した。
プライマーセット
5’-AGCTCCCAGATGGGTGCTGAGC-3’(EG-Inf-F;配列番号99)
5’-GGGCCCTTGGTGGAGGCTGAGC-3’(EG1-Inf-R;配列番号100)
配列番号29に示すヒト化hA2-15A-H4のヌクレオチド配列のヌクレオチド番号36乃至443に示されるヒト化hA2-15A-H4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-15A-H4発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-15A-H4」と命名した。
8)-2-1 ヒト化hA2-15A-L1タイプ軽鎖発現ベクターの構築
配列番号31に示すヒト化hA2-15A-L1をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。合成したDNA断片をテンプレートとして、KOD-Plus-(TOYOBO社)と下記のプライマーセットでヒト化hA2-15A-L1をコードする配列を含むDNA断片を増幅し、発現ベクターpCMA-LKを制限酵素XbaIおよびPmeIで消化してκ鎖分泌シグナルおよびヒトκ鎖定常領域を取り除いた箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することによりヒト化hA2-15A-L1発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-15A-L1」と命名した。
プライマーセット
5’-CCAGCCTCCGGACTCTAGAGCCACC-3’(CM-inf-F;配列番号101)
5’-AGTTAGCCTCCCCCGTTTAAACTC-3’(CM-inf-R;配列番号102)
配列番号33に示すヒト化hA2-15A-L4をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-15A-L4発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-15A-L4」と命名した。
配列番号35に示すヒト化hA2-15A-L6をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-15A-L6発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-15A-L6」と命名した。
配列番号37に示すヒト化hA2-15A-L7をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-15A-L7発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-15A-L7」と命名した。
8)-3-1 ヒト化hA2-27D-H1タイプ重鎖発現ベクターの構築
配列番号39に示すヒト化hA2-27D-H1のヌクレオチド配列のヌクレオチド番号36乃至437に示されるヒト化hA2-27D-H1の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-27D-H1発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-27D-H1」と命名した。
配列番号41に示すヒト化hA2-27D-H2のヌクレオチド配列のヌクレオチド番号36乃至437に示されるヒト化hA2-27D-H2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-27D-H2発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-27D-H2」と命名した。
配列番号43に示すヒト化hA2-27D-H3のヌクレオチド配列のヌクレオチド番号36乃至437に示されるヒト化hA2-27D-H3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-27D-H3発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-27D-H3」と命名した。
配列番号45に示すヒト化hA2-27D-H4のヌクレオチド配列のヌクレオチド番号36乃至437に示されるヒト化hA2-27D-H4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-27D-H4発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-27D-H4」と命名した。
配列番号47に示すヒト化hA2-27D-H5のヌクレオチド配列のヌクレオチド番号36乃至437に示されるヒト化hA2-27D-H5の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-27D-H5発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-27D-H5」と命名した。
8)-4-1 ヒト化hA2-27D-L1タイプ軽鎖発現ベクターの構築
配列番号49に示すヒト化hA2-27D-L1をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-27D-L1発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-27D-L1」と命名した。
配列番号51に示すヒト化hA2-27D-L2をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-27D-L2発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-27D-L2」と命名した。
配列番号53に示すヒト化hA2-27D-L3をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-27D-L3発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-27D-L3」と命名した。
配列番号55に示すヒト化hA2-27D-L4をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-27D-L4発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-27D-L4」と命名した。
配列番号57に示すヒト化hA2-27D-L5をコードする配列を含むDNA断片を合成した(GENEART社 遺伝子合成サービス)。実施例8)-2-1と同様の方法でヒト化hA2-27D-L5発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-27D-L5」と命名した。
8)-5-1 ヒト化A2-15A抗体(IgG1)、及びヒト化A2-27D抗体(IgG1)の生産
実施例5)-7と同様の方法で生産した。すなわち、実施例8)-1-2で構築したpCMA-G1/hA2-15A-H4と実施例8)-2-3で構築したpCMA/hA2-15A-L6との組合せによって、ヒト化hA2-15A-H4/L6を取得した。実施例8)-3-2で構築したpCMA-G1/hA2-27D-H2と実施例8)-4-2で構築したpCMA/hA2-27D-L2との組合せによって、ヒト化hA2-27D-H2/L2を取得した。実施例8)-3-3で構築したpCMA-G1/hA2-27D-H3と実施例8)-4-4で構築したpCMA/hA2-27D-L4の組合せによって、ヒト化hA2-27D-H3/L4を取得した。
実施例8)-5-1で得られた培養上清を、実施例5)-8と同様の方法で精製した。
ヒト化A2-15A抗体(IgG1)、及びヒト化A2-27D抗体(IgG1)のin vitro活性評価
9)-1 ルシフェラーゼ・レポーター・アッセイによる抗体評価
実施例8)-5で作製したヒト化hA2-15A-H4/L6、ヒト化hA2-27D-H2/L2、及びヒト化hA2-27D-H3/L4のALK2を介した細胞内シグナルの阻害活性は、BMP特異的なルシフェラーゼ・レポーターを用いて解析した。実施例6)-1と同様の方法でHEPG2細胞に対してpGL4.26/Id1WT4F-luc(Genes Cells,7,949(2002))を導入し、3時間後に培地を新鮮なFreeStyle293 expression medium (Invitrogen社)に交換した。その後、ヒト化抗体と10 ng/mLのBMP7(Milteney社製)を添加し、翌日にルシフェラーゼ活性を測定した。
ヒト化A2-15A抗体(IgG1)、及びヒト化A2-27D抗体(IgG1)のヒトALK2に対する結合性評価
実施例8)-5で作製したヒト化hA2-15A-H4/L6、ヒト化hA2-27D-H2/L2及びヒト化hA2-27D-H3/L4と抗原(Recombinant Human ALK2 Fc Chimera、Sino Biological Inc.)との解離定数測定は、Biacore T200(GEヘルスケアバイオサイエンス(株))を使用し、抗原をリガンドとして固定化し、抗体をアナライトとして測定した。抗原は、1.25μg/mLにて60秒間添加し、センサーチップCM5(GEヘルスケアバイオサイエンス(株))へ固定化させた。ランニングバッファーとしてHBS-EP+(10mM HEPES pH7.4、0.15M NaCl,3mM EDTA、0.05%Surfactant P20)を用いた。抗原を固定化したチップ上に、抗体の希釈系列溶液(0.2-50nM)を流速30μl/分で300秒間添加し、引き続き1800秒間の解離相をモニターした。再生溶液として、10mM グリシン塩酸溶液pH1.5を流速10μl/分で30秒間、2回添加した。データの解析には、分析ソフトウェア(BIAevaluation software, version 1.0)のBivalent結合モデルを用いて、結合速度定数ka、解離速度定数kd及び解離定数(KD;KD=kd/ka)を算出した。
ヒト化A2-15A抗体(IgG2)の調製
11)-1 ヒト化IgG2タイプ重鎖発現ベクターpCMA-G2の構築
実施例5)-1で構築したpCMA-LKをXbaI及びPmeIで消化してκ鎖分泌シグナル及びヒトκ鎖定常領域を取り除いたDNA断片と、ヒト重鎖分泌シグナル配列及びヒトIgG2定常領域のアミノ酸配列をコードするヌクレオチド配列を含むDNA断片(配列番号103)をIn-Fusion Advantage PCRクローニングキット(Clontech社)を用いて結合して、CMVプロモーターの下流にシグナル配列、クローニングサイト、ヒトIgG2重鎖定常領域をもつキメラ及びヒト化IgG2タイプ重鎖発現ベクターpCMA-G2を構築した。
実施例8)-1-2で構築したpCMA-G1/hA2-15A-H4をテンプレートとして、KOD-Plus-(TOYOBO社)と下記のプライマーセットで重鎖の可変領域をコードするcDNAを含むDNA断片を増幅し、ヒト化IgG2タイプ重鎖発現ベクターpCMA-G2を制限酵素BlpIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することにより、ヒト化hA2-15A-H4 IgG2タイプ発現ベクターを構築した。得られた発現ベクターを「pCMA-G2/hA2-15A-H4」と命名した。
ヒト化hA2-15A-H4 IgG2タイプ重鎖用プライマーセット
5’-CAGATGGGTGCTGAGCGAAGTGCAGCTGGTGGAATCTGGC-3’(15A-H4-F;配列番号130)
5’-CTTGGTGCTGGCTGAGCTGACGGTCACGAGGGTGCC-3’(15A-H4-R;配列番号131)
実施例5)-7と同様の方法で生産した。実施例11)-2で構築したpCMA-G2/hA2-15A-H4と実施例8)-2-3で構築したpCMA/hA2-15A-L6との組合せによって取得されたヒト化A2-15A抗体を「ヒト化hA2-15A-H4/L6(IgG2)」と命名した。
11)-4 ヒト化hA2-15A-H4/L6(IgG2)の二段階工程精製
実施例11)-3で得られた培養上清を、実施例5)-8と同様の方法で精製した。
ヒト化A2-27D抗体(IgG1 LALA)の調製
12)-1 ヒト化hA2-27D-H2-LALAタイプ重鎖発現ベクターの構築
実施例8)-3-2で構築したpCMA-G1/hA2-27D-H2をテンプレートとし、下記プライマーセットとKOD -Plus- Mutagenesis Kit(TOYOBO社)を用いて、変異を導入することによりhA2-27D-H2-LALAタイプ重鎖発現ベクターを構築した。構築した発現ベクターを「pCMA-G1/hA2-27D-H2-LALA」と命名した。
プライマーセット:
5’-GCGGGGGGACCCTCAGTCTTCCTCTTCCCC-3’(LALA-F;配列番号132)
5’-GGCTTCAGGTGCTGGGCAGGGTGGGCATGTG-3’(LALA-R;配列番号133)
実施例8)-3-3で構築したpCMA-G1/hA2-27D-H3をテンプレートとし、実施例12)-1と同様の方法でhA2-27D-H3-LALAタイプ重鎖発現ベクターを構築した。構築した発現ベクターを「pCMA-G1/hA2-27D-H3-LALA」と命名した。
実施例5)-7と同様の方法で生産した。実施例12)-1で構築したpCMA-G1/hA2-27D-H2-LALAと実施例8)-4-2で構築したpCMA/hA2-27D-L2の組合せによって取得されたヒト化A2-27D抗体を「ヒト化hA2-27D-H2/L2(IgG1 LALA)」と命名し、実施例12)-2で構築したpCMA-G1/hA2-27D-H3-LALAと実施例8)-4-4で構築したpCMA/hA2-27D-L4の組合せによって取得されたヒト化A2-27D抗体を「ヒト化hA2-27D-H3/L4(IgG1 LALA)」と命名した。
実施例12)-3で得られた培養上清を、実施例5)-8と同様の方法で精製した。
ヒト化A2-15A抗体(IgG2)、ヒト化A2-27D抗体(IgG1 LALA)のin vitro活性評価
13)-1 ルシフェラーゼ・レポーター・アッセイによる抗体評価
実施例11)-4で作製したヒト化A2-15A-H4/L6(IgG2)、実施例12)-4で得られたヒト化A2-27D-H2/L2(IgG1 LALA)のALK2を介した細胞内シグナルの阻害活性は、BMP特異的なルシフェラーゼ・レポーターを用いて解析した。実施例6)-1と同様の方法でHEPG2細胞に対してpGL4.26/Id1WT4F-luc(Genes Cells,7,949(2002))を導入し、3時間後に培地を新鮮なFreeStyle293 expression medium (Invitrogen社)に交換した。その後、ヒト化抗体と2.5 ng/mLのBMP9を添加し、実施例6)-1と同様に翌日にルシフェラーゼ活性を測定した。
ヒト化A2-15A抗体(IgG2)、ヒト化A2-27D抗体(IgG1 LALA)のヒトALK2に対する結合性評価
14)-1 ヒトALK2細胞外ドメインの発現精製
ヒトALK2細胞外ドメイン(NCBIの蛋白データベースのACCESSION番号NP_001096のアミノ酸配列の21乃至123番目のアミノ酸残基からなるポリペプチド)をコードするDNAをベクターpET-28b(+)(ノバジェン社、カタログ番号:69865)に組み込み、C末端側にHisタグ配列を連結した蛋白を発現させるプラスミドを構築した。このプラスミドを用いて、大腸菌SHuffle T7(ニューイングランドバイオラボ社、カタログ番号:C3029H)を形質転換し、TB培地(シグマアルドリッチ社、カタログ番号:T0918)で培養した。培養後、超音波破砕した菌体を遠心分離し、上清をHisTrap FF crudeカラム(GEヘルスケア社、カタログ番号:17-5286-01)で精製した。その後、HiLoad 26/600 Superdex 200カラム(GEヘルスケア社、カタログ番号:28-9893-36)を用いて、電気泳動で分子量12kDaの単一バンドになるまでヒトALK2細胞外ドメインを精製した。
実施例11)-4で作製したヒト化hA2-15A-H4/L6(IgG2)、実施例12)-4で作製したヒト化hA2-27D-H2/L2(IgG1 LALA) 及びヒト化hA2-27D-H3/L4(IgG1 LALA)と抗原(実施例14)-1にて調製したヒトALK2細胞外ドメイン)との解離定数測定は、Biacore T200(GEヘルスケアバイオサイエンス(株)、日本)を使用し、固定化した抗ヒトIgG(Fc)抗体に抗体をリガンドとして捕捉(キャプチャー)し、抗原をアナライトとして測定するキャプチャー法にて行った。抗ヒトIgG(Fc)抗体(Human Antibody Capture kit、GEヘルスケアバイオサイエンス(株))は、センサーチップCM5(GEヘルスケアバイオサイエンス(株))へアミンカップリング法にて約1000RU共有結合させた。リファレンスセルにも同様に固定化した。ランニングバッファーとしてHBS-EP+(10mM HEPES pH7.4、0.15M NaCl,3mM EDTA、0.05%Surfactant P20)を用いた。抗ヒトIgG(Fc)抗体を固定化したチップ上に、抗体を約1分間添加した後、抗原の希釈系列溶液(0.78-200nM)を流速30μl/分で300秒間添加し、引き続き600秒間の解離相をモニターした。再生溶液として、3M塩化マグネシウム溶液を流速10μl/分で30秒間添加した。データの解析には、分析ソフトウェア(BIAevaluation software, version 1.0)の1:1結合モデルを用いて、結合速度定数ka、解離速度定数kd及び解離定数(KD;KD=kd/ka)を算出した。
ヒト化A2-15A抗体(IgG2)、ヒト化A2-27D抗体(IgG1 LALA)のin vivo活性評価
実施例11)-4で作製したヒト化hA2-15A-H4/L6(IgG2)、及び実施例12)-4で作製したヒト化hA2-27D-H2/L2(IgG1 LALA)の異所性骨化に対する抑制活性はマウスを用いたBMP7の移植による異所性骨化モデルを用いて解析した。4mm径の円形に切り取ったCollaTape(Zimmer Dental社製)にBMP7(Milteney社製)を2.5マイクロG(μg)染み込ませたものを-80℃で一晩凍結させた後に真空乾燥させた。マウス(C57BL/6:8-9週齢)の大腿骨近傍の皮膚の毛を除毛し、イソフルラン吸引麻酔下で切開し、凍結乾燥させた濾紙を骨格筋内に移植した。移植してから2週間後に異所性骨化をマイクロCT(Comscan社製)にて石灰化した異所性骨の解析を行い、その後に骨格筋内の異所性骨を取り出し、重量を測定した。抗体の投与は1週間に1回(移植日をDay0としてDay-1, Day6)皮下投与にて実施した。投与抗体の濃度は1,3,10mg/kgとなるように溶媒(HBSor)で希釈を行った。コントロール群のマウスに対してはIgG(JACKSON IMMUNORESEARCH社製)を10mg/kgとなるように溶媒で調製して投与を行った。
A2-27D抗体のエピトープ解析
16)-1 ヒトキメラcA2-27D Fabフラグメントの作製
Pierce Fab Preparation Kitを使用して実施例5)-8で得られたヒトキメラcA2-27D抗体からFabフラグメントを作製した。
16)-1で得られたヒトキメラcA2-27D Fabフラグメントと実施例14に準じて調製したALK2-ECD複合体を2.4mg/mLに濃縮し、結晶化に用いた。結晶化には蒸気拡散法を用いた。タンパク質溶液0.5μLに沈殿剤溶液(2%(v/v)Tacsimate pH7.0,100mM HEPES pH7.5,20%(w/v)Polyethylene Glycol3,350)を等量加えた溶液を、50μLの沈殿剤溶液を入れた密閉容器に両溶液が触れ合わないように収め、20℃で静置した。3日後に0.1mm×0.1mm×0.1mmの単結晶が得られた。得られた結晶を20%(v/v)Glycerolを加えた沈殿剤溶液に浸し、続いて液化窒素で凍結した。高エネルギー加速器研究機構放射光科学研究施設のBL1Aにて95K窒素気流下でX線回折データを収集した。得られた回折像からソフトウェアXDS(Acta Cryst.(2010).D66,125-132)を用いて回折強度を数値化し、結晶構造因子を求めた。結晶は体心単斜晶系で空間群はC121、結晶の単位格子はa=c=119.39Å、b=37.32Å,β=92.54であった。得られた構造因子とFab(過去に結晶構造解析した抗体構造を利用)の三次元構造座標を用いて分子置換法を行い、位相を決定した。計算にはソフトウェアphaser (CCP4:Collaborative Computation Project No.4)を使用した。結晶は非対称単位に1つの複合体を含んでいた。ソフトウェアrefmac5(CCP4)を用いて構造の精密化を行い、ソフトウェアcootを用いてモデルの修正を行った。この操作を繰り返し行い、2.6Å分解能で最終のR値22.3%、freeR値26.7%を得た。モデルは1つの複合体から成り、A2-27D FabのL鎖アミノ酸残基1-211、H鎖アミノ酸残基1-134と141-223、ALK2-ECDのアミノ酸残基11-89、及び61個の水分子を含む。決定されたA2-27D Fabから4Å以内にあるALK2-ECDのアミノ酸残基は以下の通りである: Glu18,Gly19,Ile39,Asn40,Asp41,Gly42,Phe43,His44,Val45,Tyr46,Asn82,Thr84,Gln86,Leu87。図37に複合体全体のリボンモデルを示した。
ヒト化A2-11E抗体、及びヒト化A2-25C抗体のデザイン
17)-1 ヒト化hA2-11Eの設計
17)-1-1 A2-11Eの可変領域の分子モデリング
A2-11Eの可変領域の分子モデリングは、ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153,(1991))によって実行された。Protein Data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されるヒト免疫グロブリンの可変領域の1次配列(X線結晶構造から誘導される三次元構造が入手可能である)を、上で決定されたA2-11Eの可変領域と比較した。結果として、3BN9がA2-11Eの重鎖と軽鎖の可変領域に対して最も高い配列同一性を有するとして選択された。フレームワーク領域の三次元構造は、3BN9の座標を組み合わせて、「フレームワークモデル」を得ることによって作製された。次いで、それぞれのCDRについての代表的なコンホメーションがフレームワークモデルに組み込まれた。
ヒト化hA2-11Eの構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知の方法によって行った。アクセプター抗体は、フレームワーク領域内のアミノ酸同一性に基づいて選択された。
17)-2-1 ヒト化hA2-11E-H3タイプ重鎖
配列表の配列番号2に示されるA2-11E重鎖のアミノ酸番号7(スレオニン)をセリンに、アミノ酸番号16(アルギニン)をグリシンに、アミノ酸番号19(リジン)をアルギニンに、アミノ酸番号23(バリン)をアラニンに、アミノ酸番号48(イソロイシン)をバリンに、アミノ酸番号61(プロリン)をアラニンに、アミノ酸番号69(アラニン)をスレオニンに、アミノ酸番号75(アラニン)をセリンに、アミノ酸番号76(グルタミン酸)をリジンに、アミノ酸番号88(セリン)をアラニンに、アミノ酸番号93(スレオニン)をバリンに、置き換えることを伴い設計されたヒト化hA2-11E重鎖を「hA2-11E-H3タイプ重鎖」と命名した。
配列表の配列番号2に示されるA2-11E重鎖のアミノ酸番号7(スレオニン)をセリンに、アミノ酸番号16(アルギニン)をグリシンに、アミノ酸番号19(リジン)をアルギニンに、アミノ酸番号23(バリン)をアラニンに、アミノ酸番号69(アラニン)をスレオニンに、アミノ酸番号75(アラニン)をセリンに、アミノ酸番号76(グルタミン酸)をリジンに、アミノ酸番号88(セリン)をアラニンに、アミノ酸番号93(スレオニン)をバリンに、置き換えることを伴い設計されたヒト化hA2-11E重鎖を「hA2-11E-H4タイプ重鎖」と命名した。
17)-3-1 ヒト化hA2-11E-L2タイプ軽鎖
配列表の配列番号4に示されるA2-11E軽鎖のアミノ酸番号10(ロイシン)をセリンに、アミノ酸番号21(ロイシン)をイソロイシンに、アミノ酸番号22(セリン)をスレオニンに、アミノ酸番号40(ロイシン)をプロリンに、アミノ酸番号42(グルタミン酸)をリジンに、アミノ酸番号58(イソロイシン)をバリンに、アミノ酸番号83(バリン)をフェニルアラニンに、アミノ酸番号85(イソロイシン)をスレオニンに、アミノ酸番号87(フェニルアラニン)をチロシンに、アミノ酸番号99(プロリン)をグルタミンに、アミノ酸番号103(ロイシン)をバリンに、アミノ酸番号105(ロイシン)をイソロイシンに、アミノ酸番号108(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-11E軽鎖を「hA2-11E-L2タイプ軽鎖」と命名した。
配列表の配列番号4に示されるA2-11E軽鎖のアミノ酸番号10(ロイシン)をセリンに、アミノ酸番号21(ロイシン)をイソロイシンに、アミノ酸番号22(セリン)をスレオニンに、アミノ酸番号40(ロイシン)をプロリンに、アミノ酸番号42(グルタミン酸)をリジンに、アミノ酸番号83(バリン)をフェニルアラニンに、アミノ酸番号85(イソロイシン)をスレオニンに、アミノ酸番号87(フェニルアラニン)をチロシンに、アミノ酸番号99(プロリン)をグルタミンに、アミノ酸番号103(ロイシン)をバリンに、アミノ酸番号105(ロイシン)をイソロイシンに、アミノ酸番号108(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-11E軽鎖を「hA2-11E-L3タイプ軽鎖」と命名した。
配列表の配列番号4に示されるA2-11E軽鎖のアミノ酸番号10(ロイシン)をセリンに、アミノ酸番号21(ロイシン)をイソロイシンに、アミノ酸番号40(ロイシン)をプロリンに、アミノ酸番号83(バリン)をフェニルアラニンに、アミノ酸番号103(ロイシン)をバリンに、アミノ酸番号105(ロイシン)をイソロイシンに、アミノ酸番号108(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-11E軽鎖を「hA2-11E-L4タイプ軽鎖」と命名した。
ヒト化hA2-11E-H3タイプ重鎖及びヒト化hA2-11E-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H3/L2」(「hA2-11E-H3/L2」と呼ぶこともある)と命名した。ヒト化hA2-11E-H3タイプ重鎖及びヒト化hA2-11E-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H3/L3」(「hA2-11E-H3/L3」と呼ぶこともある)と命名した。ヒト化hA2-11E-H3タイプ重鎖及びヒト化hA2-11E-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H3/L4」(「hA2-11E-H3/L4」と呼ぶこともある)と命名した。ヒト化hA2-11E-H4タイプ重鎖及びヒト化hA2-11E-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H4/L2」(「hA2-11E-H4/L2」と呼ぶこともある)と命名した。ヒト化hA2-11E-H4タイプ重鎖及びヒト化hA2-11E-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H4/L3」(「hA2-11E-H4/L3」と呼ぶこともある)と命名した。ヒト化hA2-11E-H4タイプ重鎖及びヒト化hA2-11E-L4タイプ軽鎖からなる抗体を設計し「ヒト化hA2-11E-H4/L4」(「hA2-11E-H4/L4」と呼ぶこともある)と命名した。以上により設計した抗体は、実施例18に準じて作製し、実施例2及び4に準じて評価することができる。
17)-5-1 A2-25Cの可変領域の分子モデリング
A2-25Cの可変領域の分子モデリングは、ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153,(1991))によって実行された。Protein Data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されるヒト免疫グロブリンの可変領域の1次配列(X線結晶構造から誘導される三次元構造が入手可能である)を、上で決定されたAA2-25Cの可変領域と比較した。結果として、3BN9がA2-25Cの重鎖と軽鎖の可変領域に対して最も高い配列同一性を有するとして選択された。フレームワーク領域の三次元構造は、3BN9の座標を組み合わせて、「フレームワークモデル」を得ることによって作製された。次いで、それぞれのCDRについての代表的なコンホメーションがフレームワークモデルに組み込まれた。
ヒト化hA2-25Cの構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知の方法によって行った。アクセプター抗体は、フレームワーク領域内のアミノ酸同一性に基づいて選択された。
17)-6-1 ヒト化hA2-25C-H3タイプ重鎖
配列表の配列番号10に示されるA2-25C重鎖のアミノ酸番号19(リジン)をアルギニンに、アミノ酸番号38(システイン)をアルギニンに、アミノ酸番号42(スレオニン)をグリシンに、アミノ酸番号63(スレオニン)をセリンに、アミノ酸番号75(アラニン)をセリンに、アミノ酸番号84(アスパラギン酸)をアスパラギンに、アミノ酸番号88(セリン)をアラニンに、アミノ酸番号93(スレオニン)をバリンに、アミノ酸番号112(バリン)をスレオニンに、アミノ酸番号113(メチオニン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-25C重鎖を「hA2-25C-H3タイプ重鎖」と命名した。
配列表の配列番号10に示されるA2-25C重鎖のアミノ酸番号19(リジン)をアルギニンに、アミノ酸番号38(システイン)をアルギニンに、アミノ酸番号42(スレオニン)をグリシンに、アミノ酸番号63(スレオニン)をセリンに、アミノ酸番号75(アラニン)をセリンに、アミノ酸番号84(アスパラギン酸)をアスパラギンに、アミノ酸番号88(セリン)をアラニンに、アミノ酸番号113(メチオニン)をロイシンに、置き換えることを伴い設計されたヒト化hA2-25C重鎖を「hA2-25C-H4タイプ重鎖」と命名した。
17)-7-1 ヒト化hA2-25C-L1タイプ軽鎖
配列表の配列番号12に示されるA2-25C軽鎖のアミノ酸番号9(アラニン)をセリンに、アミノ酸番号15(ロイシン)をバリンに、アミノ酸番号16(グルタミン酸)をグリシンに、アミノ酸番号17(グルタミン酸)をアスパラギン酸に、アミノ酸番号18(イソロイシン)をアルギニンに、アミノ酸番号43(セリン)をアラニンに、アミノ酸番号45(グルタミン)をリジンに、アミノ酸番号66(アルギニン)をグリシンに、アミノ酸番号70(グルタミン)をアスパラギン酸に、アミノ酸番号71(チロシン)をフェニルアラニンに、アミノ酸番号72(セリン)をスレオニンに、アミノ酸番号74(リジン)をスレオニンに、アミノ酸番号77(アルギニン)をセリンに、アミノ酸番号79(アルギニン)をグルタミンに、アミノ酸番号80(バリン)をプロリンに、アミノ酸番号83(イソロイシン)をフェニルアラニンに、アミノ酸番号84(グリシン)をアラニンに、アミノ酸番号85(イソロイシン)をスレオニンに、アミノ酸番号100(セリン)をグルタミンに、アミノ酸番号104(ロイシン)をバリンに、アミノ酸番号109(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-25C軽鎖を「hA2-25C-L1タイプ軽鎖」と命名した。
配列表の配列番号12に示されるA2-25C軽鎖のアミノ酸番号9(アラニン)をセリンに、アミノ酸番号15(ロイシン)をバリンに、アミノ酸番号16(グルタミン酸)をグリシンに、アミノ酸番号17(グルタミン酸)をアスパラギン酸に、アミノ酸番号18(イソロイシン)をアルギニンに、アミノ酸番号43(セリン)をアラニンに、アミノ酸番号45(グルタミン)をリジンに、アミノ酸番号70(グルタミン)をアスパラギン酸に、アミノ酸番号72(セリン)をスレオニンに、アミノ酸番号74(リジン)をスレオニンに、アミノ酸番号77(アルギニン)をセリンに、アミノ酸番号79(アルギニン)をグルタミンに、アミノ酸番号80(バリン)をプロリンに、アミノ酸番号83(イソロイシン)をフェニルアラニンに、アミノ酸番号84(グリシン)をアラニンに、アミノ酸番号85(イソロイシン)をスレオニンに、アミノ酸番号100(セリン)をグルタミンに、アミノ酸番号104(ロイシン)をバリンに、アミノ酸番号109(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-25C軽鎖を「hA2-25C-L2タイプ軽鎖」と命名した。
配列表の配列番号12に示されるA2-25C軽鎖のアミノ酸番号9(アラニン)をセリンに、アミノ酸番号15(ロイシン)をバリンに、アミノ酸番号16(グルタミン酸)をグリシンに、アミノ酸番号17(グルタミン酸)をアスパラギン酸に、アミノ酸番号18(イソロイシン)をアルギニンに、アミノ酸番号45(グルタミン)をリジンに、アミノ酸番号72(セリン)をスレオニンに、アミノ酸番号74(リジン)をスレオニンに、アミノ酸番号77(アルギニン)をセリンに、アミノ酸番号79(アルギニン)をグルタミンに、アミノ酸番号80(バリン)をプロリンに、アミノ酸番号83(イソロイシン)をフェニルアラニンに、アミノ酸番号84(グリシン)をアラニンに、アミノ酸番号85(イソロイシン)をスレオニンに、アミノ酸番号104(ロイシン)をバリンに、アミノ酸番号109(アラニン)をスレオニンに、置き換えることを伴い設計されたヒト化hA2-25C軽鎖を「hA2-25C-L3タイプ軽鎖」と命名した。
ヒト化hA2-25C-H3タイプ重鎖及びヒト化hA2-25C-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H3/L1(「hA2-25C-H3/L1」と呼ぶこともある)と命名した。ヒト化hA2-25C-H3タイプ重鎖及びヒト化hA2-25C-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H3/L2」(「hA2-25C-H3/L2」と呼ぶこともある)と命名した。ヒト化hA2-125C-H3タイプ重鎖及びヒト化hA2-25C-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H3/L3」(「hA2-25C-H3/L3」と呼ぶこともある)と命名した。ヒト化hA2-25C-H4タイプ重鎖及びヒト化hA2-25C-L1タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H4/L1」(「hA2-25C-H4/L1」と呼ぶこともある)と命名した。ヒト化hA2-25C-H4タイプ重鎖及びヒト化hA2-25C-L2タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H4/L2」(「hA2-25C-H4/L2」と呼ぶこともある)と命名した。ヒト化hA2-25C-H4タイプ重鎖及びヒト化hA2-25C-L3タイプ軽鎖からなる抗体を設計し「ヒト化hA2-25C-H4/L3」(「hA2-25C-H4/L3」と呼ぶこともある)と命名した。以上により設計した抗体は、実施例18に準じて作製し、実施例2及び4に準じて評価することができる。
ヒト化A2-11E抗体(IgG1)、及びヒト化A2-25C抗体(IgG1)のベクターの構築と調製
18)-1 ヒト化A2-11Eの重鎖発現ベクターの構築
18)-1-1 ヒト化hA2-11E-H3タイプ重鎖発現ベクターの構築
配列番号110に示すヒト化hA2-11E-H3のヌクレオチド配列のヌクレオチド番号36乃至428に示されるヒト化hA2-11E-H3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-11E-H3発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-11E-H3」と命名した。
配列番号112に示すヒト化hA2-11E-H4のヌクレオチド配列のヌクレオチド番号36乃至428に示されるヒト化hA2-11E-H4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-11E-H4発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-11E-H4」と命名した。
18)-2-1 ヒト化hA2-11E-L2タイプ軽鎖発現ベクターの構築
配列番号114に示すヒト化hA2-11E-L2のヌクレオチド配列のヌクレオチド番号37乃至399に示されるヒト化hA2-11E-L2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。合成したDNA断片をテンプレートとして、KOD-Plus-(TOYOBO社)と下記のプライマーセットでヒト化hA2-11E-L2の可変領域をコードするDNA配列を含むDNA断片を増幅し、実施例5)-1で構築したキメラ及びヒト化抗体軽鎖発現ベクターpCMA-LKを制限酵素BsiWIで切断した箇所にIn-Fusion HD PCRクローニングキット(Clontech社)を用いて挿入することによりヒト化hA2-11E-L2発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-11E-L2」と命名した。
プライマーセット
5’-CTGTGGATCTCCGGCGCGTACGGC-3’(CM-LKF;配列番号134)
5’-GGAGGGGGCGGCCACCGTACG-3’(KCL-Inf-R;配列番号135)
配列番号116に示すヒト化hA2-11E-L3のヌクレオチド配列のヌクレオチド番号37乃至399に示されるヒト化hA2-11E-L3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例18)-2-1と同様の方法でヒト化hA2-11E-L3発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-11E-L3」と命名した。
配列番号118に示すヒト化hA2-11E-L4のヌクレオチド配列のヌクレオチド番号37乃至339に示されるヒト化hA2-11E-L4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例18)-2-1と同様の方法でヒト化hA2-11E-L4発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-11E-L4」と命名した。
18)-3-1 ヒト化hA2-25C-H3タイプ重鎖発現ベクターの構築
配列番号120に示すヒト化hA2-25C-H3のヌクレオチド配列のヌクレオチド番号36乃至428に示されるヒト化hA2-25C-H3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-25C-H3発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-25C-H3」と命名した。
配列番号122に示すヒト化hA2-25C-H4のヌクレオチド配列のヌクレオチド番号36乃至428に示されるヒト化hA2-25C-H4の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例8)-1-1と同様の方法でヒト化hA2-25C-H4発現ベクターを構築した。得られた発現ベクターを「pCMA-G1/hA2-25C-H4」と命名した。
18)-4-1 ヒト化hA2-25C-L1タイプ軽鎖発現ベクターの構築
配列番号124に示すヒト化hA2-25C-L1のヌクレオチド配列のヌクレオチド番号37乃至402に示されるヒト化hA2-25C-L1の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例18)-2-1と同様の方法でヒト化hA2-25C-L1発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-25C-L1」と命名した。
配列番号126に示すヒト化hA2-25C-L2のヌクレオチド配列のヌクレオチド番号37乃至402に示されるヒト化hA2-25C-L2の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例18)-2-1と同様の方法でヒト化hA2-25C-L2発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-25C-L2」と命名した。
配列番号128に示すヒト化hA2-25C-L3のヌクレオチド配列のヌクレオチド番号37乃至402に示されるヒト化hA2-25C-L3の可変領域をコードするDNA配列を含むDNA断片を合成した(GENEART社 人工遺伝子合成サービス)。実施例18)-2-1と同様の方法でヒト化hA2-25C-L3発現ベクターを構築した。得られた発現ベクターを「pCMA/hA2-25C-L3」と命名した。
FreeStyle 293F細胞(Invitrogen社)はマニュアルに従い、継代、培養をおこなった。
ヒト化A2-11E抗体(IgG1)、及びヒト化A2-25C抗体(IgG1)のin vitro活性評価
19)-1 BMPの骨芽細胞分化誘導アッセイによる抗体評価
実施例18)-5で作製したヒト化A2-11E抗体(IgG1)、及びヒト化A2-25C抗体(IgG1)の内在性ALK2を介した細胞内シグナルの阻害活性は、実施例6)-2と同様にBMPによるC2C12細胞の骨芽細胞への分化誘導活性に対する効果で解析した。分化誘導には2.5ng/mLのGDF2/BMP9(RD‐SYSTEMS社製)を用いた。
ヒト化A2-11E抗体(IgG1)、及びヒト化A2-25C抗体(IgG1)のヒトALK2に対する結合性評価
実施例18)-5で作製したヒト化A2-11E抗体(IgG1)、及びヒト化A2-25C抗体(IgG1)と抗原(実施例14)-1にて調製したヒトALK2細胞外ドメイン)との解離定数測定は、Biacore T200(GEヘルスケアバイオサイエンス(株))を使用し、固定化した抗ヒトIgG(Fc)抗体に抗体をリガンドとして捕捉(キャプチャー)し、抗原をアナライトとして測定するキャプチャー法にて行った。抗ヒトIgG(Fc)抗体(Human Antibody Capture kit、GEヘルスケアバイオサイエンス(株))は、センサーチップCM5(GEヘルスケアバイオサイエンス(株))へアミンカップリング法にて約1000RU共有結合させた。リファレンスセルにも同様に固定化した。ランニングバッファーとしてHBS-EP+(10mM HEPES pH7.4、0.15M NaCl,3mM EDTA、0.05%Surfactant P20)を用いた。抗ヒトIgG(Fc)抗体を固定化したチップ上に、抗体を含む培養上清を約1分間添加した後、抗原の希釈系列溶液(0.78-200nM)を流速30μl/分で300秒間添加し、引き続き600秒間の解離相をモニターした。再生溶液として、3M MgCl2を流速10μl/分で30秒間添加した。データの解析には、分析ソフトウェア(BIAevaluation software, version 1.0)の1:1結合モデルを用いて、結合速度定数ka、解離速度定数kd及び解離定数(KD;KD=kd/ka)を算出した。
A2-25C抗体のエピトープ解析
21)-1 ヒトキメラcA2-25C Fabフラグメントの作製
実施例5)-8と同様に調製したヒトキメラcA2-25Cを Papain(Sigma-Aldrich)を使用してFabフラグメントとFcフラグメントに切断し、これをHiTrap Protein A HPカラム(GE Healthcare)に添加した。フロースルー画分にて回収されたFabフラグメントを濃縮した。
実施例21)-1で得られたキメラA2-25C Fabフラグメントと実施例14に準じて調製したALK2-ECD複合体を3.8mg/mLに濃縮し、結晶化に用いた。結晶化には蒸気拡散法を用いた。タンパク質溶液0.5μLに沈殿剤溶液(0.15M Li2SO4,0.1M NaCitrate pH3.4,18%(w/v)PEG6,000,20%(v/v)Ethylene Glycol)を等量加えた溶液を、50μLの沈殿剤溶液を入れた密閉容器に両溶液が触れ合わないように収め、20℃で静置した。3日後に0.1mm×0.05mm×0.02mmの単結晶が得られた。得られた結晶を液化窒素で凍結し、SPring8のBL41XUにて95K窒素気流下でX線回折データを収集した。得られた回折像からソフトウェアmosflm(CCP4:Collaborative Computation Project No.4)を用いて回折強度を数値化し、結晶構造因子を求めた。結晶は直方晶系で空間群はP212121、結晶の単位格子はa=74.49Å,b=128.05Å、c=147.73Åであった。得られた構造因子とFab(過去に結晶構造解析した抗体構造を利用)の三次元構造座標を用いて分子置換法を行い、位相を決定した。計算にはソフトウェアphaser(CCP4:Collaborative Computation Project No.4)を使用した。結晶は非対称単位に2つの複合体を含んでいた。ソフトウェアrefmac5(CCP4)を用いて構造の精密化を行い、ソフトウェアcootを用いてモデルの修正を行った。この操作を繰り返し行い、2.1Å分解能で最終のR値22.4%、freeR値25.3%を得た。モデルは2つの複合体から成り、A2-25C FabのL鎖アミノ酸残基1-212、H鎖アミノ酸残基1-219、ALK2-ECDのアミノ酸残基12-52および66-88、及び411個の水分子を含む。決定された2つのA2-25C Fabから共通して4Å以内にあるALK2-ECDのアミノ酸残基は以下の通りである:Glu18,Gly19,Leu20,Ile39,Asp41,Gly42,Phe43,His44,Val45,Tyr46,Thr84。図49に複合体全体のリボンモデルを示した。
様々な変異ALK2に対するA2-27Dの阻害活性評価
これまでにFOP症例から同定された13種類の変異体(L196P、delP197_F198insL、R202I、R206H、Q207E、R258S、R258G、G325A、G328E、G328R、G328W、G356D、及びR375P)、および野生型ALK2に対するA2-27の阻害活性は、実施例2)-3と同様に、HEK293A細胞を用いたBMP特異的なId1WT4F-lucルシフェラーゼ・レポーターで解析した。遺伝子導入後、2.5時間後に培地を10ng/mLのBMP7(Milteney社製)と、3μg/mLのラットIgG1(R&D Systems社製)、またはA2-27Dを含む新鮮なOPTI-MEM I(LifeTechnologies社製)に交換して一晩培養した。翌日、Dual-Glo Luciferase Assay System(Promega社製)を用いてルシフェラーゼ活性を測定した。
配列番号2:A2-11Eの重鎖の可変領域のアミノ酸配列
配列番号3:A2-11Eの軽鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号4:A2-11Eの軽鎖の可変領域のアミノ酸配列
配列番号5:A2-15Aの重鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号6:A2-15Aの重鎖の可変領域のアミノ酸配列
配列番号7:A2-15Aの軽鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号8:A2-15Aの軽鎖の可変領域のアミノ酸配列
配列番号9:A2-25Cの重鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号10:A2-25Cの重鎖の可変領域のアミノ酸配列
配列番号11:A2-25Cの軽鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号12:A2-25Cの軽鎖の可変領域のアミノ酸配列
配列番号13:A2-27Dの重鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号14:A2-27Dの重鎖の可変領域のアミノ酸配列
配列番号15:A2-27Dの軽鎖の可変領域をコードするcDNAのヌクレオチド配列
配列番号16:A2-27Dの軽鎖の可変領域のアミノ酸配列
配列番号17:ヒトκ鎖分泌シグナル及びヒトκ鎖定常領域のアミノ酸をコードする配列を含むDNA断片のヌクレオチド配列
配列番号18:ヒト重鎖分泌シグナル及びヒトIgG1定常領域のアミノ酸をコードする配列を含むDNA断片のヌクレオチド配列
配列番号19:ヒトキメラcA2-15Aの重鎖のヌクレオチド配列
配列番号20:ヒトキメラcA2-15Aの重鎖のアミノ酸配列
配列番号21:ヒトキメラcA2-15Aの軽鎖のヌクレオチド配列
配列番号22:ヒトキメラcA2-15Aの軽鎖のアミノ酸配列
配列番号23:ヒトキメラcA2-27Dの重鎖のヌクレオチド配列
配列番号24:ヒトキメラcA2-27Dの重鎖のアミノ酸配列
配列番号25:ヒトキメラcA2-27Dの軽鎖のヌクレオチド配列
配列番号26:ヒトキメラcA2-27Dの軽鎖のアミノ酸配列
配列番号27:ヒト化hA2-15A-H1のヌクレオチド配列
配列番号28:ヒト化hA2-15A-H1のアミノ酸配列
配列番号29:ヒト化hA2-15A-H4のヌクレオチド配列
配列番号30:ヒト化hA2-15A-H4のアミノ酸配列
配列番号31:ヒト化hA2-15A-L1をコードする配列を含むDNA断片のヌクレオチド配列
配列番号32:ヒト化hA2-15A-L1のアミノ酸配列
配列番号33:ヒト化hA2-15A-L4をコードする配列を含むDNA断片のヌクレオチド配列
配列番号34:ヒト化hA2-15A-L4のアミノ酸配列
配列番号35:ヒト化hA2-15A-L6をコードする配列を含むDNA断片のヌクレオチド配列
配列番号36:ヒト化hA2-15A-L6のアミノ酸配列
配列番号37:ヒト化hA2-15A-L7をコードする配列を含むDNA断片のヌクレオチド配列
配列番号38:ヒト化hA2-15A-L7のアミノ酸配列
配列番号39:ヒト化hA2-27D-H1のヌクレオチド配列
配列番号40:ヒト化hA2-27D-H1のアミノ酸配列
配列番号41:ヒト化hA2-27D-H2のヌクレオチド配列
配列番号42:ヒト化hA2-27D-H2のアミノ酸配列
配列番号43:ヒト化hA2-27D-H3のヌクレオチド配列
配列番号44:ヒト化hA2-27D-H3のアミノ酸配列
配列番号45:ヒト化hA2-27D-H4のヌクレオチド配列
配列番号46:ヒト化hA2-27D-H4のアミノ酸配列
配列番号47:ヒト化hA2-27D-H5のヌクレオチド配列
配列番号48:ヒト化hA2-27D-H5のアミノ酸配列
配列番号49:ヒト化hA2-27D-L1をコードする配列を含むDNA断片のヌクレオチド配列
配列番号50:ヒト化hA2-27D-L1のアミノ酸配列
配列番号51:ヒト化hA2-27D-L2をコードする配列を含むDNA断片のヌクレオチド配列
配列番号52:ヒト化hA2-27D-L2のアミノ酸配列
配列番号53:ヒト化hA2-27D-L3をコードする配列を含むDNA断片のヌクレオチド配列
配列番号54:ヒト化hA2-27D-L3のアミノ酸配列
配列番号55:ヒト化hA2-27D-L4をコードする配列を含むDNA断片のヌクレオチド配列
配列番号56:ヒト化hA2-27D-L4のアミノ酸配列
配列番号57:ヒト化hA2-27D-L5をコードする配列を含むDNA断片のヌクレオチド配列
配列番号58:ヒト化hA2-27D-L5のアミノ酸配列
配列番号59:A2-15AのCDRH1のアミノ酸配列
配列番号60:A2-15AのCDRH2のアミノ酸配列
配列番号61:A2-15AのCDRH3のアミノ酸配列
配列番号62:A2-15AのCDRL1のアミノ酸配列
配列番号63:A2-15AのCDRL2のアミノ酸配列
配列番号64:A2-15AのCDRL3のアミノ酸配列
配列番号65:A2-27DのCDRH1のアミノ酸配列
配列番号66:A2-27DのCDRH2のアミノ酸配列
配列番号67:A2-27DのCDRH3のアミノ酸配列
配列番号68:A2-27DのCDRL1のアミノ酸配列
配列番号69:A2-27DのCDRL2のアミノ酸配列
配列番号70:A2-27DのCDRL3のアミノ酸配列
配列番号71:ヒト化hA2-15A-L6のCDRL2のアミノ酸配列
配列番号72:A2-11EのCDRH1のアミノ酸配列
配列番号73:A2-11EのCDRH2のアミノ酸配列
配列番号74:A2-11EのCDRH3のアミノ酸配列
配列番号75:A2-11EのCDRL1のアミノ酸配列
配列番号76:A2-11EのCDRL2のアミノ酸配列
配列番号77:A2-11EのCDRL3のアミノ酸配列
配列番号78:A2-25CのCDRH1のアミノ酸配列
配列番号79:A2-25CのCDRH2のアミノ酸配列
配列番号80:A2-25CのCDRH3のアミノ酸配列
配列番号81:A2-25CのCDRL1のアミノ酸配列
配列番号82:A2-25CのCDRL2のアミノ酸配列
配列番号83:A2-25CのCDRL3のアミノ酸配列
配列番号84:ヒトALK2のアミノ酸配列
配列番号85:ヒトALK2のヌクレオチド配列
配列番号86:マウスALK2のアミノ酸配列
配列番号87:マウスALK2のヌクレオチド配列
配列番号88~102:プライマー
配列番号103:ヒト重鎖シグナル配列及びヒトIgG2定常領域のアミノ酸をコードする配列を含むDNA断片のヌクレオチド配列
配列番号104:ヒト化hA2-15A-H4 IgG2タイプのヌクレオチド配列
配列番号105:ヒト化hA2-15A-H4 IgG2タイプのアミノ酸配列
配列番号106:ヒト化hA2-27D-H2-LALAのヌクレオチド配列
配列番号107:ヒト化hA2-27D-H2-LALAのアミノ配列
配列番号108:ヒト化hA2-27D-H3-LALAのヌクレオチド配列
配列番号109:ヒト化hA2-27D-H3-LALAのアミノ配列
配列番号110:ヒト化hA2-11E-H3のヌクレオチド配列
配列番号111:ヒト化hA2-11E-H3のアミノ酸配列
配列番号112:ヒト化hA2-11E-H4のヌクレオチド配列
配列番号113:ヒト化hA2-11E-H4のアミノ酸配列
配列番号114:ヒト化hA2-11E-L2のヌクレオチド配列
配列番号115:ヒト化hA2-11E-L2のアミノ酸配列
配列番号116:ヒト化hA2-11E-L3のヌクレオチド配列
配列番号117:ヒト化hA2-11E-L3のアミノ酸配列
配列番号118:ヒト化hA2-11E-L4のヌクレオチド配列
配列番号119:ヒト化hA2-11E-L4のアミノ酸配列
配列番号120:ヒト化hA2-25C-H3のヌクレオチド配列
配列番号121:ヒト化hA2-25C-H3のアミノ酸配列
配列番号122:ヒト化hA2-25C-H4のヌクレオチド配列
配列番号123:ヒト化hA2-25C-H4のアミノ酸配列
配列番号124:ヒト化hA2-25C-L1のヌクレオチド配列
配列番号125:ヒト化hA2-25C-L1のアミノ酸配列
配列番号126:ヒト化hA2-25C-L2のヌクレオチド配列
配列番号127:ヒト化hA2-25C-L2のアミノ酸配列
配列番号128:ヒト化hA2-25C-L3のヌクレオチド配列
配列番号129:ヒト化hA2-25C-L3のアミノ酸配列
配列番号130~135:プライマー
Claims (66)
- 以下の(a)乃至(e)のいずれか一つに記載のアミノ酸配列における少なくとも7アミノ酸からなるポリペプチド配列と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片。
(a)配列番号84に示されるアミノ酸配列
(b)配列番号84に示されるアミノ酸配列の21乃至123番目のアミノ酸残基からなるアミノ酸配列
(c)配列番号86に示されるアミノ酸配列
(d)配列番号86に示されるアミノ酸配列の21乃至123番目のアミノ酸残基からなるアミノ酸配列
(e)(a)乃至(d)のいずれか一つに記載のアミノ酸配列に1乃至数アミノ酸残基の置換、欠失又は付加を伴うアミノ酸配列 - 以下の(f)乃至(j)のいずれか一つに記載のヌクレオチド配列によってコードされるアミノ酸配列における少なくとも7アミノ酸からなるポリペプチド配列と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片。
(f)配列番号85に示されるヌクレオチド配列
(g)配列番号85に示されるヌクレオチド配列の728乃至1036番目のヌクレオチド残基からなるヌクレオチド配列
(h)配列番号87に示されるヌクレオチド配列
(i)配列番号87に示されるヌクレオチド配列の728乃至1036番目のヌクレオチド残基からなるヌクレオチド配列
(j)(f)乃至(i)のいずれか一つに記載のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドのヌクレオチド配列 - 前記ポリペプチド配列が、ALK2細胞外領域内の配列である、請求項1又は2に記載の抗体又は該抗体の抗原結合断片。
- 前記抗体が、野生型ALK2蛋白質及び変異型ALK2蛋白質に結合する、請求項1乃至3のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 前記抗体が、モノクローナル抗体又はポリクローナル抗体である、請求項1乃至4のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 前記抗体及び前記抗原結合断片が、キメラ抗体、ヒト化抗体、ヒト抗体、一本鎖抗体、二重特異性抗体、又は多重特異性抗体である、請求項1乃至5のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号2に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号4に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、配列番号6に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号8に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、配列番号10に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号12に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、並びに配列番号14に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号16に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体からなる群から選択される少なくともいずれか一つの抗体と前記ポリペプチドへの結合に対し交差競合することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号2に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号4に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、配列番号6に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号8に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、配列番号10に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号12に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体、並びに配列番号14に示されるアミノ酸配列からなる重鎖可変領域、及び配列番号16に示されるアミノ酸配列からなる軽鎖可変領域を含む抗体からなる群から選択される少なくともいずれか一つの抗体が結合するエピトープに結合することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号84に示されるアミノ酸配列中の18番目のグルタミン酸(Glu)、19番目のグリシン(Gly)、39番目のイソロイシン(Ile)、40番目のアスパラギン(Asn)、41番目のアスパラギン酸(Asp)、42番目のグリシン(Gly)、43番目のフェニルアラニン(Phe)、44番目のヒスチジン(His)、45番目のバリン(Val)、46番目のチロシン(Tyr)、82番目のアスパラギン(Asn)、84番目のトレオニン(Thr)、86番目のグルタミン(Gln)、87番目のロイシン(Leu)、88番目のプロリン(Pro)、及び89番目のトレオニン(Thr)の各残基を含むエピトープに結合することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号84に示されるアミノ酸配列中の18番目のグルタミン酸(Glu)、19番目のグリシン(Gly)、39番目のイソロイシン(Ile)、40番目のアスパラギン(Asn)、41番目のアスパラギン酸(Asp)、42番目のグリシン(Gly)、43番目のフェニルアラニン(Phe)、44番目のヒスチジン(His)、45番目のバリン(Val)、46番目のチロシン(Tyr)、82番目のアスパラギン(Asn)、84番目のトレオニン(Thr)、86番目のグルタミン(Gln)、87番目のロイシン(Leu)、88番目のプロリン(Pro)、及び89番目のトレオニン(Thr)の各残基との間で相互作用距離を有することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号84に示されるアミノ酸配列中の18番目のグルタミン酸(Glu)、19番目のグリシン(Gly)、20番目のロイシン(Leu)、39番目のイソロイシン(Ile)、40番目のアスパラギン(Asn)、41番目のアスパラギン酸(Asp)、42番目のグリシン(Gly)、43番目のフェニルアラニン(Phe)、44番目のヒスチジン(His)、45番目のバリン(Val)、46番目のチロシン(Tyr)、及び84番目のトレオニン(Thr)の各残基を含むエピトープに結合することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 配列番号84に示されるアミノ酸配列中の18番目のグルタミン酸(Glu)、19番目のグリシン(Gly)、20番目のロイシン(Leu)、39番目のイソロイシン(Ile)、40番目のアスパラギン(Asn)、41番目のアスパラギン酸(Asp)、42番目のグリシン(Gly)、43番目のフェニルアラニン(Phe)、44番目のヒスチジン(His)、45番目のバリン(Val)、46番目のチロシン(Tyr)、及び84番目のトレオニン(Thr)の各残基との間で相互作用距離を有することを特徴とする、請求項1乃至6のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 相互作用距離が6オングストローム以下である、請求項10又は12に記載の抗体又は該抗体の抗原結合断片。
- 相互作用距離が4オングストローム以下である、請求項10又は12に記載の抗体又は該抗体の抗原結合断片。
- 重鎖配列が、CDRH1、CDRH2、CDRH3を有する可変領域を含み、前記CDRH1は配列番号72に示されるアミノ酸配列からなり、前記CDRH2は配列番号73に示されるアミノ酸配列からなり、前記CDRH3は、配列番号74に示されるアミノ酸配列に示されるアミノ酸配列からなること;及び
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号75に示されるアミノ酸配列からなり、前記CDRL2は配列番号76に示されるアミノ酸配列からなり、前記CDRL3は、配列番号77に示されるアミノ酸配列からなること;
を特徴とする、請求項1乃至8のいずれか一項に記載の抗体又は該抗体の抗原結合断片。 - 配列番号2に示されるアミノ酸配列からなる重鎖可変領域配列及び配列番号4に示されるアミノ酸配列からなる軽鎖可変領域配列を含むことを特徴とする、請求項15に記載の抗体又は該抗体の抗原結合断片。
- 重鎖配列が、CDRH1、CDRH2、CDRH3を有する可変領域を含み、前記CDRH1は配列番号59に示されるアミノ酸配列からなり、前記CDRH2は配列番号60に示されるアミノ酸配列からなり、前記CDRH3は、配列番号61に示されるアミノ酸配列に示されるアミノ酸配列からなること;及び
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号62に示されるアミノ酸配列からなり、前記CDRL2は配列番号63又は配列番号71に示されるアミノ酸配列からなり、前記CDRL3は、配列番号64に示されるアミノ酸配列からなること;
を特徴とする、請求項1乃至8のいずれか一項に記載の抗体又は該抗体の抗原結合断片。 - 配列番号6に示されるアミノ酸配列からなる重鎖可変領域配列及び配列番号8に示されるアミノ酸配列又は配列番号36に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなる軽鎖可変領域配列を含むことを特徴とする請求項17に記載の抗体又は該抗体の抗原結合断片。
- 重鎖配列が、CDRH1、CDRH2、CDRH3を有する可変領域を含み、前記CDRH1は配列番号78に示されるアミノ酸配列からなり、前記CDRH2は配列番号79に示されるアミノ酸配列からなり、前記CDRH3は、配列番号80に示されるアミノ酸配列に示されるアミノ酸配列からなること;及び
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号81に示されるアミノ酸配列からなり、前記CDRL2は配列番号82に示されるアミノ酸配列からなり、前記CDRL3は、配列番号83に示されるアミノ酸配列からなること;
を特徴とする、請求項1乃至10、13乃至14のいずれか一項に記載の抗体又は該抗体の抗原結合断片。 - 配列番号10に示されるアミノ酸配列からなる重鎖可変領域配列及び配列番号12に示されるアミノ酸配列からなる軽鎖可変領域配列を含むことを特徴とする、請求項19に記載の抗体又は該抗体の抗原結合断片。
- 重鎖配列が、CDRH1、CDRH2、CDRH3を有する可変領域を含み、前記CDRH1は配列番号65に示されるアミノ酸配列からなり、前記CDRH2は配列番号66に示されるアミノ酸配列からなり、前記CDRH3は、配列番号67に示されるアミノ酸配列に示されるアミノ酸配列からなること;及び
軽鎖配列がCDRL1、CDRL2、CDRL3を有する可変領域を含み、前記CDRL1は配列番号68に示されるアミノ酸配列からなり、前記CDRL2は配列番号69に示されるアミノ酸配列からなり、前記CDRL3は、配列番号70に示されるアミノ酸配列からなること;
を特徴とする、請求項1乃至8、11乃至14のいずれか一項に記載の抗体又は該抗体の抗原結合断片。 - 配列番号14に示されるアミノ酸配列からなる重鎖可変領域配列及び配列番号16に示されるアミノ酸配列からなる軽鎖可変領域配列を含むことを特徴とする、請求項21に記載の抗体又は該抗体の抗原結合断片。
- Fab、F(ab’)2、Fab’及びFvからなる群から選択される、請求項1乃至22のいずれか一項に記載の抗体の抗原結合断片。
- scFvであることを特徴とする、請求項1乃至22のいずれか一項に記載の抗体。
- キメラ抗体であることを特徴とする、請求項1乃至22のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- ヒト化されていることを特徴とする、請求項1乃至22のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 重鎖がヒト免疫グロブリンG1重鎖、ヒト免疫グロブリンG2重鎖、又はヒト免疫グロブリンG4重鎖の定常領域を含み、軽鎖がヒト免疫グロブリンκ軽鎖の定常領域を含む、請求項1乃至24のいずれか一項に記載の抗体。
- 重鎖がヒト免疫グロブリンG1重鎖の定常領域を含む、請求項27に記載の抗体。
- ヒト免疫グロブリンG1重鎖の234番目のロイシン(Leu)がアラニン(Ala)により置換され、235番目のロイシン(Leu)がアラニン(Ala)により置換された、請求項28に記載の抗体。
- 重鎖がヒト免疫グロブリンG2重鎖の定常領域を含む、請求項27に記載の抗体。
- 重鎖がヒト免疫グロブリンG4重鎖の定常領域を含む、請求項27に記載の抗体。
- ヒト免疫グロブリンG4重鎖の241番目のセリン(Ser)がプロリン(Pro)により置換された、請求項31に記載の抗体。
- ALK2蛋白質の細胞外領域と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片であって、
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号28に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号30に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a3) 配列番号105に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなるアミノ酸配列;
a4) a1)乃至a3)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a5) a1)乃至a3)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a6) a1)乃至a3)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号32に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号34に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号36に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b4) 配列番号38に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなるアミノ酸配列;
b5) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b6) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b7) b1)乃至b4)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。 - 配列番号30に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号36に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体、又は配列番号105に示されるアミノ酸配列の20乃至142番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号36に示されるアミノ酸配列の21乃至133番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体である、請求項33に記載の抗体又は該抗体の抗原結合断片。
- 配列番号30に示されるアミノ酸配列の20乃至472番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号36に示されるアミノ酸配列の21乃至238番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体、又は配列番号105に示されるアミノ酸配列の20乃至468番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号36に示されるアミノ酸配列の21乃至238番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体である、請求項33に記載の抗体。
- 配列番号105に示されるアミノ酸配列の20乃至468番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号36に示されるアミノ酸配列の21乃至238番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体である、請求項33に記載の抗体。
- ALK2蛋白質の細胞外領域と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片であって、
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号40に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号42に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a3) 配列番号44に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a4) 配列番号46に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a5) 配列番号48に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a6) 配列番号107に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a7) 配列番号109に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなるアミノ酸配列;
a8) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a9) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a10) a1)乃至a7)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号50に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号52に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号54に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b4) 配列番号56に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b5) 配列番号58に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b6) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b7) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b8) b1)乃至b5)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。 - 配列番号42に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号52に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体、配列番号44に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号56に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体、配列番号107に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号52に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体、又は配列番号109に示されるアミノ酸配列の20乃至140番目のアミノ酸残基からなる重鎖可変領域配列を含む重鎖及び配列番号56に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなる軽鎖可変領域配列を含む軽鎖からなる抗体である、請求項37に記載の抗体又は該抗体の抗原結合断片。
- 配列番号42に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号52に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体、又は配列番号44に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号56に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体、配列番号107に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号52に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体、又は配列番号109に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号56に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体である、請求項37に記載の抗体。
- 配列番号107に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号52に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体、又は配列番号109に示されるアミノ酸配列の20乃至470番目のアミノ酸残基からなるアミノ酸配列を含む重鎖及び配列番号56に示されるアミノ酸配列の21乃至234番目のアミノ酸残基からなるアミノ酸配列を含む軽鎖からなる抗体である、請求項37に記載の抗体。
- ALK2蛋白質の細胞外領域と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片であって、
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号111に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号113に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a3) a1)又はa2)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a4) a1)又はa2)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a5) a1)又はa2)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号115に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号117に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号119に示されるアミノ酸配列の21乃至128番目のアミノ酸残基からなるアミノ酸配列;
b4) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b5) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b6) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。 - ALK2蛋白質の細胞外領域と特異的に結合し、かつALK2を介するBMPシグナル伝達を抑制する抗体又は該抗体の抗原結合断片であって、
(a)以下のアミノ酸配列からなる群から選択される重鎖可変領域配列:
a1) 配列番号121に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a2) 配列番号123に示されるアミノ酸配列の20乃至137番目のアミノ酸残基からなるアミノ酸配列;
a3) a1)又はa2)のアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
a4) a1)又はa2)のアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
a5) a1)又はa2)のアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;及び
(b)以下のアミノ酸配列からなる群から選択される軽鎖可変領域配列:
b1) 配列番号125に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b2) 配列番号127に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b3) 配列番号129に示されるアミノ酸配列の21乃至129番目のアミノ酸残基からなるアミノ酸配列;
b4) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも95%の同一性を持つアミノ酸配列;
b5) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列と少なくとも99%の同一性を持つアミノ酸配列;
b6) b1)乃至b3)から選択されるいずれか一つのアミノ酸配列に1乃至数個のアミノ酸残基が置換、欠失又は付加されたアミノ酸配列;
を含むことを特徴とする、抗体又は該抗体の抗原結合断片。 - カルボキシル末端の1乃至数個のアミノ酸が欠失した重鎖を含む抗体である、請求項1乃至42のいずれか一項に記載の抗体。
- 重鎖又は軽鎖のアミノ末端のアミノ酸残基がピログルタミル化されている抗体である、請求項1乃至43のいずれか一項に記載の抗体又は該抗体の抗原結合断片。
- 請求項1乃至44のいずれか一項に記載の抗体又は該抗体の抗原結合断片の少なくともいずれか一つを含有することを特徴とする、医薬組成物。
- 異所性骨化の治療及び/又は予防剤であることを特徴とする、請求項45に記載の医薬組成物。
- 請求項1乃至44のいずれか一項に記載の抗体又は該抗体の抗原結合断片の少なくともいずれか一つ、並びに、抗炎症剤、ステロイド剤、ビスフォスフォネート、筋弛緩剤、レチノイン酸受容体(RAR)γアゴニストからなる群から選択される少なくともいずれか一つを含有することを特徴とする、異所性骨化の治療及び/又は予防用医薬組成物。
- 異所性骨化が、進行性骨化性線維形成異常症(FOP)、進行性骨異形成(POH)、外傷性の異所性骨化、又は人工関節置換術後の異所性骨化であることを特徴とする、請求項46又は47に記載の医薬組成物。
- 異所性骨化が、進行性骨化性線維形成異常症(FOP)であることを特徴とする、請求項46又は47に記載の医薬組成物。
- 貧血の治療及び/又は予防剤であることを特徴とする、請求項45に記載の医薬組成物。
- びまん性橋膠腫(DIPG)の治療及び/又は予防剤であることを特徴とする、請求項45に記載の医薬組成物。
- 請求項1乃至44のいずれか一項に記載の抗体、該抗体の抗原結合断片、又は請求項45乃至49のいずれか一項に記載の医薬組成物の少なくともいずれか一つを投与することを特徴とする、異所性骨化の治療及び/又は予防方法。
- 請求項1乃至44のいずれか一項に記載の抗体、該抗体の抗原結合断片、又は請求項45乃至49のいずれか一項に記載の医薬組成物の少なくともいずれか一つ、並びに、抗炎症剤、ステロイド剤、ビスフォスフォネート、筋弛緩剤、レチノイン酸受容体(RAR)γアゴニストからなる群から選択される少なくともいずれか一つを同時又は相前後して投与することを特徴とする、異所性骨化の治療及び/又は予防方法。
- 異所性骨化が、進行性骨化性線維形成異常症(FOP)、進行性骨異形成(POH)、外傷性の異所性骨化、又は人工関節置換術後の異所性骨化であることを特徴とする、請求項52又は53に記載の治療及び/又は予防方法。
- 異所性骨化が、進行性骨化性線維形成異常症(FOP)であることを特徴とする請求項52又は53に記載の治療及び/又は予防方法。
- 請求項1乃至44のいずれか一項に記載の抗体、該抗体の抗原結合断片、或いは請求項45又は50に記載の医薬組成物の少なくともいずれか一つを投与することを特徴とする、貧血の治療及び/又は予防方法。
- 請求項1乃至44のいずれか一項に記載の抗体、該抗体の抗原結合断片、或いは請求項45又は51に記載の医薬組成物の少なくともいずれか一つを投与することを特徴とする、びまん性橋膠腫(DIPG)の治療及び/又は予防方法。
- 請求項1乃至44のいずれか一項に記載の抗体をコードするポリヌクレオチド。
- (a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号27に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号29に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号104に示されるヌクレオチド配列の58乃至426番目のヌクレオチドからなるヌクレオチド配列;
a4) a1)乃至a3)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a5) a1)乃至a3)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a6) a1)乃至a3)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a7) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号31に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号33に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号35に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号37に示されるヌクレオチド配列の86乃至424番目のヌクレオチドからなるヌクレオチド配列;
b5) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b6) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b7) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b8) b1)乃至b4)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。 - (a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号39に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号41に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a3) 配列番号43に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a4) 配列番号45に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a5) 配列番号47に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a6) 配列番号106に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a7) 配列番号108に示されるヌクレオチド配列の58乃至420番目のヌクレオチドからなるヌクレオチド配列;
a8) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a9) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a10) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a11) a1)乃至a7)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号49に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号51に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号53に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b4) 配列番号55に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b5) 配列番号57に示されるヌクレオチド配列の86乃至412番目のヌクレオチドからなるヌクレオチド配列;
b6) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b7) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b8) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b9) b1)乃至b5)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。 - (a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号110に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号112に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号114に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号116に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号118に示されるヌクレオチド配列の61乃至384番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。 - (a)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
a1) 配列番号120に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a2) 配列番号122に示されるヌクレオチド配列の58乃至411番目のヌクレオチドからなるヌクレオチド配列;
a3) a1)又はa2)のヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
a4) a1)又はa2)のヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
a5) a1)又はa2)のヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
a6) a1)又はa2)のヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;及び/或いは
(b)以下のヌクレオチド配列からなる群から選択されるポリヌクレオチド:
b1) 配列番号124に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b2) 配列番号126に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b3) 配列番号128に示されるヌクレオチド配列の61乃至387番目のヌクレオチドからなるヌクレオチド配列;
b4) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも95%の同一性を持つヌクレオチド配列;
b5) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と少なくとも99%の同一性を持つヌクレオチド配列;
b6) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列と相補的なヌクレオチド配列からなるポリヌクレオチドとストリンジェントな条件でハイブリダイズするポリヌクレオチドが保有するヌクレオチド配列;
b7) b1)乃至b3)から選択されるいずれか一つのヌクレオチド配列に1乃至数個のヌクレオチドが置換、欠失又は付加されたヌクレオチド配列;
を含むことを特徴とするポリヌクレオチド。 - 請求項58乃至62のいずれか一項に記載のいずれか一つのポリヌクレオチドを含むベクター。
- 請求項58乃至62のいずれか一項に記載のいずれか一つのポリヌクレオチドを含む形質転換宿主細胞。
- 請求項63に記載のベクターを含む形質転換宿主細胞。
- 請求項64又は65に記載の宿主細胞を培養し、培養産物から抗体を精製する工程を含む請求項1乃至44のいずれか一項に記載の抗体の生産方法。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177022490A KR20170105558A (ko) | 2015-01-30 | 2016-01-29 | 항 alk2 항체 |
BR112017015661-0A BR112017015661A2 (ja) | 2015-01-30 | 2016-01-29 | Anti-ALK2 antibody |
US15/547,231 US10428148B2 (en) | 2015-01-30 | 2016-01-29 | Anti-ALK2 antibody |
CN201680007605.0A CN107207604B (zh) | 2015-01-30 | 2016-01-29 | 抗alk2抗体 |
CA2975376A CA2975376A1 (en) | 2015-01-30 | 2016-01-29 | Anti-alk2 antibody |
JP2016572167A JP6763783B2 (ja) | 2015-01-30 | 2016-01-29 | 抗alk2抗体 |
EP16743511.4A EP3252074A4 (en) | 2015-01-30 | 2016-01-29 | Anti-alk2 antibody |
US16/543,991 US11312776B2 (en) | 2015-01-30 | 2019-08-19 | Anti-ALK2 antibody |
US17/511,357 US11447554B2 (en) | 2015-01-30 | 2021-10-26 | Anti-ALK2 antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-017882 | 2015-01-30 | ||
JP2015017882 | 2015-01-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/547,231 A-371-Of-International US10428148B2 (en) | 2015-01-30 | 2016-01-29 | Anti-ALK2 antibody |
US16/543,991 Division US11312776B2 (en) | 2015-01-30 | 2019-08-19 | Anti-ALK2 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016121908A1 true WO2016121908A1 (ja) | 2016-08-04 |
Family
ID=56543512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/052602 WO2016121908A1 (ja) | 2015-01-30 | 2016-01-29 | 抗alk2抗体 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10428148B2 (ja) |
EP (1) | EP3252074A4 (ja) |
JP (2) | JP6763783B2 (ja) |
KR (1) | KR20170105558A (ja) |
CN (2) | CN107207604B (ja) |
BR (1) | BR112017015661A2 (ja) |
CA (1) | CA2975376A1 (ja) |
TW (2) | TWI774028B (ja) |
WO (1) | WO2016121908A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmpシグナル阻害化合物 |
CN109906272A (zh) * | 2016-10-31 | 2019-06-18 | 国立大学法人鸟取大学 | 产生人抗体的非人动物和使用该非人动物的人抗体制作方法 |
WO2019172165A1 (ja) | 2018-03-05 | 2019-09-12 | 学校法人埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
WO2021015029A1 (ja) * | 2019-07-19 | 2021-01-28 | 国立大学法人京都大学 | Alk2の変異を有する疾患の治療または予防用医薬組成物 |
WO2021020282A1 (ja) | 2019-07-26 | 2021-02-04 | 学校法人埼玉医科大学 | Alk2/acvr1の細胞外領域を認識する抗体 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016121908A1 (ja) * | 2015-01-30 | 2016-08-04 | 学校法人埼玉医科大学 | 抗alk2抗体 |
GB201510758D0 (en) * | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
CN109438572A (zh) * | 2018-10-15 | 2019-03-08 | 上海药明生物技术有限公司 | 连续应用亲和层析和陶瓷羟基磷灰石层析分离抗体药物的方法 |
EP3870613A4 (en) * | 2018-10-23 | 2022-08-03 | Keros Therapeutics, Inc. | ALK2 ANTIBODIES AND METHODS OF USE THEREOF |
WO2020118011A1 (en) * | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2021163170A1 (en) * | 2020-02-11 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and uses thereof |
IL295980A (en) * | 2020-02-28 | 2022-10-01 | Brigham & Womens Hospital Inc | Selective modulation of transforming growth factor beta superfamily signaling using multispecific antibodies |
EP4047955A1 (en) | 2021-02-17 | 2022-08-24 | Oticon A/s | A hearing aid comprising a feedback control system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012531922A (ja) * | 2009-07-06 | 2012-12-13 | オプソナ セラピューティクス リミテッド | Toll受容体2へのヒト化抗体およびその使用 |
JP2013513361A (ja) * | 2009-12-10 | 2013-04-22 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 中和プロラクチン受容体抗体およびそれらの治療的使用 |
WO2014078306A1 (en) * | 2012-11-13 | 2014-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007123896A2 (en) | 2006-04-18 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop) |
US20110182904A1 (en) | 2006-09-05 | 2011-07-28 | Deborah Zimmerman | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
WO2011112671A2 (en) * | 2010-03-09 | 2011-09-15 | President And Fellows Of Harvard College | Conversion of vascular endothelial cells into multipotent stem-like cells |
TR201802772T4 (tr) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
JPWO2014051109A1 (ja) * | 2012-09-28 | 2016-08-25 | 協和発酵キリン株式会社 | 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
WO2016121908A1 (ja) * | 2015-01-30 | 2016-08-04 | 学校法人埼玉医科大学 | 抗alk2抗体 |
CN107488625B (zh) | 2017-08-31 | 2018-12-21 | 广州蕊特生物科技有限公司 | 一种胎牛血清替代物及其制备方法和应用 |
US11859006B2 (en) | 2018-03-05 | 2024-01-02 | Saitama Medical University | Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody |
-
2016
- 2016-01-29 WO PCT/JP2016/052602 patent/WO2016121908A1/ja active Application Filing
- 2016-01-29 CN CN201680007605.0A patent/CN107207604B/zh active Active
- 2016-01-29 KR KR1020177022490A patent/KR20170105558A/ko not_active Application Discontinuation
- 2016-01-29 TW TW109125515A patent/TWI774028B/zh active
- 2016-01-29 US US15/547,231 patent/US10428148B2/en active Active
- 2016-01-29 EP EP16743511.4A patent/EP3252074A4/en active Pending
- 2016-01-29 CN CN202111192884.1A patent/CN113980131A/zh active Pending
- 2016-01-29 CA CA2975376A patent/CA2975376A1/en active Pending
- 2016-01-29 TW TW105102791A patent/TWI703156B/zh active
- 2016-01-29 JP JP2016572167A patent/JP6763783B2/ja active Active
- 2016-01-29 BR BR112017015661-0A patent/BR112017015661A2/ja active Search and Examination
-
2019
- 2019-08-19 US US16/543,991 patent/US11312776B2/en active Active
-
2020
- 2020-09-10 JP JP2020151717A patent/JP7101732B2/ja active Active
-
2021
- 2021-10-26 US US17/511,357 patent/US11447554B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012531922A (ja) * | 2009-07-06 | 2012-12-13 | オプソナ セラピューティクス リミテッド | Toll受容体2へのヒト化抗体およびその使用 |
JP2013513361A (ja) * | 2009-12-10 | 2013-04-22 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 中和プロラクチン受容体抗体およびそれらの治療的使用 |
WO2014078306A1 (en) * | 2012-11-13 | 2014-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
Non-Patent Citations (4)
Title |
---|
KATAGIRI TAKENOBU. ET AL.: "The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway", BIOLOGICAL CHEMISTRY, vol. 394, no. 6, 2013, pages 703 - 714, XP055472098 * |
KATAGIRI TAKENOBU: "Heterotopic Bone Formation Induced by Bone Morphogenetic Protein Signaling: Fibrodysplasia Ossificans Progressiva", JOURNAL OF ORAL BIOSCIENCES, vol. 52, no. 1, 2010, pages 33 - 41, XP055472094 * |
KATAGIRI TAKENOBU: "Recent topics infibrodysplasia ossificans progressiva", JOURNAL OF ORAL BIOSCIENCES, vol. 54, no. 3, 2012, pages 119 - 123, XP055472097 * |
See also references of EP3252074A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109906272A (zh) * | 2016-10-31 | 2019-06-18 | 国立大学法人鸟取大学 | 产生人抗体的非人动物和使用该非人动物的人抗体制作方法 |
WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmpシグナル阻害化合物 |
US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
WO2019172165A1 (ja) | 2018-03-05 | 2019-09-12 | 学校法人埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
KR20200128017A (ko) | 2018-03-05 | 2020-11-11 | 각코우호우징 사이타마이카다이가쿠 | 이소성 골화의 치료 또는 예방을 위한 의약 조성물 |
JPWO2019172165A1 (ja) * | 2018-03-05 | 2021-03-04 | 学校法人 埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
JP7125979B2 (ja) | 2018-03-05 | 2022-08-25 | 学校法人 埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
US11859006B2 (en) | 2018-03-05 | 2024-01-02 | Saitama Medical University | Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody |
WO2021015029A1 (ja) * | 2019-07-19 | 2021-01-28 | 国立大学法人京都大学 | Alk2の変異を有する疾患の治療または予防用医薬組成物 |
WO2021020282A1 (ja) | 2019-07-26 | 2021-02-04 | 学校法人埼玉医科大学 | Alk2/acvr1の細胞外領域を認識する抗体 |
EP4008350A4 (en) * | 2019-07-26 | 2023-06-14 | Saitama Medical University | ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1 |
Also Published As
Publication number | Publication date |
---|---|
JP7101732B2 (ja) | 2022-07-15 |
JP2021006535A (ja) | 2021-01-21 |
US20180118835A1 (en) | 2018-05-03 |
BR112017015661A2 (ja) | 2018-03-20 |
TWI703156B (zh) | 2020-09-01 |
CA2975376A1 (en) | 2016-08-04 |
CN107207604A (zh) | 2017-09-26 |
EP3252074A4 (en) | 2018-07-11 |
CN113980131A (zh) | 2022-01-28 |
TW202110894A (zh) | 2021-03-16 |
US10428148B2 (en) | 2019-10-01 |
JP6763783B2 (ja) | 2020-09-30 |
US11312776B2 (en) | 2022-04-26 |
JPWO2016121908A1 (ja) | 2017-11-09 |
CN107207604B (zh) | 2021-10-26 |
US20220041738A1 (en) | 2022-02-10 |
US11447554B2 (en) | 2022-09-20 |
EP3252074A1 (en) | 2017-12-06 |
TW201636368A (zh) | 2016-10-16 |
TWI774028B (zh) | 2022-08-11 |
US20200002427A1 (en) | 2020-01-02 |
KR20170105558A (ko) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7101732B2 (ja) | 抗alk2抗体 | |
JP6210966B2 (ja) | 抗Siglec−15抗体 | |
WO2013147212A1 (ja) | 新規抗Siglec-15抗体 | |
JP6059205B2 (ja) | CDR改変抗Siglec−15抗体 | |
EP3725802A2 (en) | Antibodies to alpha-synuclein and uses thereof | |
US11859006B2 (en) | Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody | |
KR102444797B1 (ko) | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 | |
CA2762446A1 (en) | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16743511 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016572167 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122020024321 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2975376 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15547231 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017015661 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20177022490 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2016743511 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112017015661 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170721 |